US20050250707A1 - HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis - Google Patents

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis Download PDF

Info

Publication number
US20050250707A1
US20050250707A1 US11/155,568 US15556805A US2005250707A1 US 20050250707 A1 US20050250707 A1 US 20050250707A1 US 15556805 A US15556805 A US 15556805A US 2005250707 A1 US2005250707 A1 US 2005250707A1
Authority
US
United States
Prior art keywords
substituted
group
methyl
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/155,568
Inventor
Stacie Canan Koch
Therese Alexander
Benjamin Burke
Tanya Jewell
David Kucera
Maria Linton
Lennert Mitchell
Siegfried Reich
Donald Skalitzky
John Tatlock
Michael Varney
Scott Virgil
Stephen Webber
Stephen Worland
Mark Barvian
Gary Bolton
Frederick Boyer
Jeffrey Machak
Tod Holler
Sean Murphy
Michael Melnick
Vara Josyula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/155,568 priority Critical patent/US20050250707A1/en
Publication of US20050250707A1 publication Critical patent/US20050250707A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Definitions

  • This invention relates to novel compounds as useful as HIV protease inhibitors and to the use of such compounds as antiviral agents for treatment of HIV infected individuals.
  • This invention also relates to methods of preparation of these compounds and to intermediates that are useful in the preparation thereof.
  • AIDS Acquired Immune Deficiency Syndrome
  • HTLV-III human T-lymphotropic retrovirus III
  • HIV is a member of the class of viruses known as retroviruses.
  • the retroviral genome is composed of RNA, which is converted to DNA by reverse transcription.
  • This retroviral DNA is then stably integrated into a host cell's chromosome and, employing the replicative processes of the host cells, produces new retroviral particles and advances the infection to other cells.
  • HIV appears to have a particular affinity for the human T-4 lymphocyte cell, which plays a vital role in the body's immune system. HIV infection of these white blood cells depletes this white cell population.
  • the immune system is rendered inoperative and ineffective against various opportunistic diseases such as, among others, pneumocystic carini pneumonia, Kaposi's sarcoma, and cancer of the lymph system.
  • the drug azidothymidine has been found effective for inhibiting the reverse transcription of the retroviral genome of the HIV virus, thus giving a measure of control, though not a cure, for patients afflicted with AIDS.
  • the search continues for drugs that can cure or at least provide an improved measure of control of the deadly HIV virus.
  • Retroviral replication routinely features post-translational processing of polyproteins. This processing is accomplished by virally encoded HIV protease enzyme. This yields mature polypeptides that will subsequently aid in the formation and function of infectious virus. If this molecular processing is stifled, then the normal production of HIV is terminated. Therefore, inhibitors of HIV protease may function as anti-HIV viral agents.
  • HIV protease is one of the translated products from the HIV structural protein pol gene. This retroviral protease specifically cleaves other structural polypeptides at discrete sites to release these newly activated structural proteins and enzymes, thereby rendering the virion replication-competent. As such, inhibition of the HIV protease by potent compounds may prevent proviral integration of infected T-lymphocytes during the early phase of the HIV-1 life cycle, as well as inhibit viral proteolytic processing during its late stage. Additionally, the protease inhibitors may have the advantages of being more readily available, longer lived in virus, and less toxic than currently available drugs, possibly due to their specificity for the retroviral protease.
  • HIV proteases Related inhibitors of HIV proteases have been described in, e.g., U.S. Pat. No. 5,962,640, U.S. Pat. No. 5,932,550, Australian Patent No. 705193, Canadian Patent Application No. 2,179,935, European Patent Application No. 0 751 145, and Japanese Patent Application No. 100867489.
  • Other related HIV protease inhibitors have been described in K. Yoshimura, et al., Proct. Natl. Acad. Sci. USA, 96, 8675-8680 (1999) and T. Mimoto, et al., J. Med. Chem., 42, 1789-1802 (1999).
  • This invention relates to compounds useful for inhibiting the activity of HIV-protease of Formula I: wherein:
  • the present invention relates to compounds of Formula I below, and prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts and solvates thereof that inhibit the protease encoded by human immunodeficiency virus (HIV) type 1 (HIV-1) or type 2 (HIV-2), as well as mutant strains thereof.
  • HIV human immunodeficiency virus
  • the compounds, their pharmaceutically acceptable salts, and the pharmaceutical compositions of the present invention can be used alone or in combination with other antivirals, immunomodulators, antibiotics or vaccines.
  • Compounds of the present invention can also be converted to prodrugs, by derivatization, according to conventional techniques. Methods of treating AIDS, methods of treating HIV infection and methods of inhibiting HIV protease are disclosed.
  • aliphatic represents a saturated or unsaturated, straight- or branched-chain hydrocarbon, containing 1 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below.
  • the term “aliphatic” is intended to encompass alkyl, alkenyl and alkynyl groups.
  • alkyl represents a straight- or branched-chain saturated or unsaturated hydrocarbon, containing 1 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below.
  • exemplary alkyl substituents include, but are not limited to methyl (Me), ethyl (Et), propyl, isopropyl, butyl, isobutyl, t-butyl, and the like.
  • lower alkyl refers to an alkyl group containing from 1 to 6 carbon atoms
  • alkenyl represents a straight- or branched-chain hydrocarbon, containing one or more carbon-carbon double bonds and having 2 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below.
  • alkenyl substituents include, but are not limited to ethenyl, propenyl, butenyl, allyl, pentenyl and the like.
  • alkynyl represents a straight- or branched-chain hydrocarbon, containing one or more carbon-carbon triple bonds and having 2 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below.
  • An alkynyl moiety may also contain one or more carbon-carbon double bonds.
  • Exemplary alkynyl substituents include, but are not limited to ethynyl, butynyl, propynyl (propargyl) isopropynyl, pentynyl, hexynyl and the like.
  • carrier represents a saturated, partially saturated, or fully unsaturated (aromatic) cyclic hydrocarbon group containing from 3 to 14 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described herein below.
  • the term “carbocyclic” is intended to encompass mono-, bi- and tri-cyclic saturated, partially saturated, or fully unsaturated hydrocarbon groups; for example, cycloalkyl, cycloalkenyl and aryl groups.
  • carrier is also intended to encompass bi- and tri-cyclic hydrocarbon groups which contain any-combination of ring moieties that are saturated, partially saturated, or fully unsaturated (aromatic).
  • Partially saturated carbocycles include, for example, dihydro-arenes (e.g., indanyl) or tetrahydro-arenes (e.g. tetrahydronaphthalene), wherein any one or more points of saturation may occur in any ring moiety of the carbocycle.
  • dihydro-arenes e.g., indanyl
  • tetrahydro-arenes e.g. tetrahydronaphthalene
  • bonding between any bi- or tri-cyclic carbocyclic group and any other substituent or variable group may be made at any suitable position of the carbocycle.
  • carbocyclic-aliphatic group is intended to encompass aliphatic groups having a carbocyclic substituent (e.g., phenylmethyl-(benzyl), phenylethyl-, cyclopropylmethyl-, etc.), wherein the carbocyclic moiety and the aliphatic moiety thereof may be independently substituted by one or more suitable substituents.
  • a carbocyclic substituent e.g., phenylmethyl-(benzyl), phenylethyl-, cyclopropylmethyl-, etc.
  • Cycloalkyl represents a group comprising a non-aromatic monocyclic, bicyclic, or tricyclic hydrocarbon containing from 3 to 14 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below.
  • Exemplary cycloalkyls include monocyclic rings having from 3-8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • Illustrative examples of cycloalkyl groups include the following:
  • Cycloalkenyl represents a group comprising a non-aromatic monocyclic, bicyclic, or tricyclic hydrocarbon containing from 4 to 14 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below and contains at least one carbon-carbon double bond.
  • Exemplary monocyclic cycloalkenyls include groups having from 4-8, preferably 5-6, carbon atoms, such as cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl and the like.
  • Illustrative examples of cycloalkenyl groups include the following:
  • Aryl represents a group comprising an aromatic, monovalent monocyclic, bicyclic, or tricyclic radical containing from 6 to 18 carbon ring atoms, which may be unsubstituted or substituted by one or more of the substituents described below.
  • Illustrative examples of aryl groups include the following:
  • Carbocyclic also to encompasses mixed bi- and tri-cyclic cycloalkyl/cycloalkenyl/aryl groups, which may be unsubstituted or substituted by one or more of the substituents described below.
  • Illustrative examples of such mixed bi- and tri-cyclic groups include the following:
  • bonding or substitution of any bi-cyclic or tri-cyclic carbocyclic or heterocyclic group described herein may be at any suitable position on any ring.
  • heterocyclic represents a saturated, partially saturated, or fully unsaturated (aromatic) cyclic group containing from 3 to 18 ring atoms, which includes 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents described herein below.
  • heterocyclic is intended to encompass mono-, bi- and tri-cyclic saturated, partially saturated, or fully unsaturated heteroatom-containing cyclic groups; for example, heterocycloalkyl, heterocycloalkenyl and heteroaryl groups.
  • heterocyclic is also intended to encompass bi- and tri-cyclic groups which contain any combination of ring moieties that are saturated, partially saturated, or fully unsaturated (aromatic).
  • Partially saturated heterocycles include, for example, dihydroheteroarenes (e.g., dihydroindole) or tetrahydro-heteroarenes (e.g. tetrahydroquinoline), wherein any one or more points of saturation may occur in any ring moiety of the heterocycle.
  • heterocyclic-aliphatic group is intended to encompass aliphatic groups having a heterocyclic substituent (e.g., pyridylmethyl-, thiazolylmethyl-, tetrahydrofuranylmethyl-, etc.) wherein the heterocyclic moiety and the aliphatic moiety thereof may be independently substituted by one or more suitable substituents.
  • Heterocycloalkyl represents a group comprising a saturated monovalent monocyclic, bicyclic, or tricyclic radical, containing 3 to 18 ring atoms, which includes 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents described below.
  • heterocycloalkyl groups include, but are not limited to, azetidinyl, pyrrolidyl, piperidyl, piperazinyl, morpholinyl, tetrahydro-2H-1,4-thiazinyl, tetrahydrofuryl, tetrahydropyranyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxathiolanyl, 1,3-oxathianyl, 1,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]nonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1]heptyl, 1,5,9-triazacyclododecyl, and the like.
  • heterocycloalkyl groups include the following:
  • heterocycloalkenyl is used herein to represent a non-aromatic, monovalent monocyclic, bicyclic, or tricyclic radical, containing 4 to 18 ring atoms, which may include from 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents described below and which contains at least one carbon-carbon or carbon-heteroatom double bond.
  • exemplary monocyclic heterocycloalkenyls include groups having from 4-8, preferably 5-6, ring atoms.
  • heterocycloalkenyl groups include, but are not limited to, dihydrofuryl, dihydropyranyl, isoxazolinyl, dihydropyridyl, tetrahydropyridyl, and the like.
  • heterocycloalkenyl groups include the following:
  • Heteroaryl represents a group comprising an aromatic monovalent monocyclic, bicyclic, or tricyclic radical, containing 5 to 18 ring atoms, including 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more of the substituents described below.
  • the term “heteroaryl” is also intended to encompass the N-oxide derivative (or N-oxide derivatives, if the heteroaryl group contains more than one nitrogen such that more than one N-oxide derivative may be formed) of the nitrogen-containing heteroaryl groups described herein.
  • heteroaryl groups include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, thiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, benzo[b]thienyl, naphtho[2,3-b]thianthrenyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathienyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxyalinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, te
  • N-oxide derivatives of heteroaryl groups include, but are not limited to, pyridyl N-oxide, pyrazinyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, triazinyl N-oxide, isoquinolyl N-oxide, and quinolyl N-oxide.
  • heteroaryl groups include the following moieties: wherein R is H, alkyl, hydroxyl or represents a compound according to Formula I.
  • heterocyclic also to encompasses mixed bi- and tri-cyclic heterocycloalkyl/heterocycloalkenyl/heteroaryl groups, which may be unsubstituted or substituted by one or more of the substituents described below.
  • Illustrative examples of such mixed bi- and tri-cyclic heterocyclic groups include the following:
  • the alkyl, alkenyl and alkynyl groups may be optionally substituted by one or more suitable substituents independently selected from phenyl, nitro, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, cycloalkyloxy, cycloalkylalkyloxy, cycloalkenyloxy, cycloalkenylalkyloxy, heterocycloalkoxy, heterocycloalkylalkyloxy, heterocycloalkenyloxy, heterocycloalkenylalkyloxy, heteroaryloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy,
  • alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl moieties of any of the above substituents may be optionally substituted by one or more groups independently selected from alkyl (except for alkyl), haloalkyl, aryl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, mercapto, alkylthio, haloalkylthio or arylthio groups.
  • the substituted carbocyclic or heterocyclic groups may be optionally substituted by one or more suitable substituents independently selected from alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, nitro, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, alkylenedioxy, aryloxy, cycloalkyloxy, cycloalkylalkyloxy, cycloalkenyloxy, cycloalkenylalkyloxy, heterocycloalkoxy, heterocycloalkylalkyloxy, heterocycloalkenyloxy, heterocycloalkenylalkyloxy, heteroaryloxy, alkylcarbonyl, alkyloxycarbonyl, alkyloxycarbonyl, alkylcarbony
  • Preferred “suitable substituents” include alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, halogen, hydroxyl, alkoxy, alkylenedioxy, aryloxy, cycloalkoxy, heteroaryloxy, alkylthio, haloalkylthio and carboxyl.
  • alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of any of the above substituents may be optionally substituted by one or more groups independently selected from: alkyl, haloalkyl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, mercapto, alkylthio, haloalkylthio or arylthio groups.
  • the substituted phenyl or phenyl moiety of R 2 may comprise at least one substituent (other than halo or methyl) selected from haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkoxyalkyl, alkylcarbonylalkyl, haloalkoxyalkyl, aryloxyalkyl, alkylthioalkyl, haloalkylthioalkyl, arylthioalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, nitro, amino, cyano, hydroxyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, alkylenedioxy, aryloxy, cycl
  • Preferred “suitable substituents” include alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, halogen, hydroxyl, alkoxy, alkylenedioxy, aryloxy, cycloalkoxy, heteroaryloxy, alkylthio, haloalkylthio and carboxyl.
  • alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of any of the above substituents may be optionally substituted by one or more groups independently selected from: alkyl, haloalkyl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, mercapto, alkylthio, haloalkylthio or arylthio groups.
  • the substituent may be protected with a suitable protecting group that is stable to the reaction conditions used in these methods.
  • the protecting group may be removed at a suitable point in the reaction sequence of the method to provide a desired intermediate or target compound.
  • suitable protecting groups and the methods for protecting and de-protecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which may be found in T. Greene and P. Wuts, Protecting Groups in Chemical Synthesis (3 rd ed.), John Wiley & Sons, NY (1999), which is incorporated herein by reference in its entirety.
  • a substituent may be specifically selected to be reactive under the reaction conditions used in the methods of this invention. Under these circumstances, the reaction conditions convert the selected substituent into another substituent that is either useful in an intermediate compound in the methods of this invention or is a desired substituent in a target compound.
  • R 2 and R 2′ may be a suitable nitrogen protecting group.
  • nitrogen protecting groups are well known in the art and any nitrogen protecting group that is useful in the methods of preparing the compounds of this invention or may be useful in the HIV protease inhibitory compounds of this invention may be used.
  • Exemplary nitrogen protecting groups include alkyl, substituted alkyl, carbamate, urea, amide, imide, enamine, sulfenyl, sulfonyl, nitro, nitroso, oxide, phosphinyl, phosphoryl, silyl, organometallic, borinic acid and boronic acid groups.
  • R 2 and/or R 2′ are independently suitable nitrogen protecting groups
  • suitable R 2 and R 2′ substituents include, but are not limited to, carbamate protecting groups such as alkyloxycarbonyl (e.g., Boc: t-butyloxycarbonyl) and aryloxycarbonyl (e.g., Cbz: benzyloxycarbonyl, or FMOC: fluorene-9-methyloxycarbonyl), alkyloxycarbonyls (e.g., methyloxycarbonyl), alkyl or arylcarbonyl, substituted alkyl, especially arylalkyl (e.g., trityl (triphenylmethyl), benzyl and substituted benzyl), and the like.
  • arylalkyl e.g., trityl (triphenylmethyl), benzyl and substituted benzyl
  • halogen and halo represent chloro, fluoro, bromo or iodo substituents.
  • Heterocycle is intended to mean a heteroaryl or heterocycloalkyl group.
  • Acyl is intended to mean a —C(O)—R radical, where R is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.
  • Acyloxy is intended to mean an —OC(O)—R radical, where R is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.
  • Thioacyl is intended to mean a —C(S)—R radical, where R is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.
  • Sulfonyl is intended to mean an —SO 2 — biradical.
  • Sulfenyl is intended to mean an —SO— biradical.
  • Sulfo is intended to mean an —SO 2 H radical.
  • Hydroxy is intended to mean the radical —OH.
  • Amine or “amino” is intended to mean the radical —NH 2 .
  • Alkylamino is intended to mean the radical —NHR a , where R a is an alkyl group.
  • Dialkylamino is intended to mean the radical —NR a R b , where R a and R b are each independently an alkyl group, and is intended to include heterocycloalkyl groups, wherein R a and R b , taken together, form a heterocyclic ring that includes the amine nitrogen.
  • Alkoxy is intended to mean the radical —OR a , where R a is an alkyl group. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, and the like.
  • “Lower alkoxy” groups have alkyl moieties having from 1 to 4 carbons.
  • “Alkoxycarbonyl” is intended to mean the radical —C(O)OR a , where R a is an alkyl group.
  • “Alkylsulfonyl” is intended to mean the radical —SO 2 R a , where R a is an alkyl group.
  • “Alkylenedioxy” is intended to mean the divalent radical —OR a O— which is bonded to adjacent atoms (e.g., adjacent atoms on a phenyl or naphthyl ring), wherein R a is a lower alkyl group.
  • Alkylaminocarbonyl is intended to mean the radical —C(O)NHR a , where R a is an alkyl group.
  • Dialkylaminocarbonyl is intended to mean the radical —C(O)NR a R b , where R a and R b are each independently an alkyl group.
  • Mercapto is intended to mean the radical —SH.
  • Alkylthio is intended to mean the radical —SR a , where R a is an alkyl group.
  • Carboxy is intended to mean the radical —C(O)OH.
  • Keto or “oxo” is intended to mean the diradical ⁇ O.
  • “Thioketo” is intended to mean the diradical ⁇ S.
  • Carbamoyl is intended to mean the radical —C(O)NH 2 .
  • “Cycloalkylalkyl” is intended to mean the radical -alkyl-cloalkyl, wherein alkyl and cycloalkyl are defined as above, and is represented by the bonding arrangement present in the groups —CH 2 -cyclohexane or —CH 2 -cyclohexene.
  • “Arylalkyl” is intended to mean the radical -alkylaryl, wherein alkyl and aryl are defined as above, and is represented by the bonding arrangement present in a benzyl group.
  • “Aminocarbonylalkyl” is intended to mean the radical -alkylC(O)NH 2 and is represented by the bonding arrangement present in the group —CH 2 CH 2 C(O)NH 2 .
  • “Alkylaminocarbonylalkyl” is intended to mean the radical -alkylC(O)NHR a , where R a is an alkyl group and is represented by the bonding arrangement present in the group —CH 2 CH 2 C(O)NHCH 3 .
  • “Alkylcarbonylaminoalkyl is intended to mean the radical -alkylNHC(O)-alkyl and is represented by the bonding arrangement present in the group —CH 2 NHC(O)CH 3 .
  • Dialkylaminocarbonylalkyl is intended to mean the radical -alkylC(O)NR a R b , where R a and R b are each independently an alkyl group.
  • Aryloxy is intended to mean the radical —OR c , where R c is an aryl group.
  • Heteroaryloxy is intended to mean the radical —OR d , where R d is a heteroaryl group.
  • Arylthio is intended to mean the radical —SR c , where R c is an aryl group.
  • Heteroarylthio is intended to mean the radical —SR d , where R d is a heteroaryl group.
  • a desired salt may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid, such as glucuronic acid or galacturonic acid, alpha-hydroxy acid, such as citric acid or tartaric acid, amino acid, such as aspartic acid or glutamic acid, aromatic acid, such as benzoic acid or cinnamic acid, sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid,
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • this invention relates to compounds of Formula I, above, wherein:
  • this invention relates to compounds of Formula I, above, wherein:
  • this invention relates to compounds useful for inhibiting the activity of HIV-protease of Formula I, above, wherein:
  • this invention relates to compounds useful for inhibiting the activity of HIV-protease of Formula I, above, wherein:
  • this invention relates to compounds of Formula I, above, wherein:
  • R 1 is phenyl, where said phenyl is substituted with one or more substituents independently selected from methyl, halogen or hydroxyl;
  • All compounds of this invention contain at least one chiral center and may exist as single stereoisomers (e.g., single enantiomers or single diastereomers), any mixture of stereosisomers (e.g., any mixture of enantiomers or diastereomers) or racemic mixtures thereof. All such single stereoisomers, mixtures and racemates are intended to be encompassed within the broad scope of the present invention.
  • Compounds identified herein as single stereoisomers are meant to describe compounds that are present in a form that contains at least 90% of a single stereoisomer of each chiral center present in the compounds.
  • the chemical structure is intended to encompass compounds containing either stereoisomer of each chiral center present in the compound.
  • the inventive compounds are used in optically pure, that is, stereoisomerically pure, form or substantially optically pure (substantially stereoisomerically pure) form.
  • stereoisomeric purity refers to the “enantiomeric” purity and/or “diastereomeric” purity of a compound.
  • Compounds that are substantially enantiomerically pure contain at least 90% of a single isomer and preferably contain at least 95% of a single isomer of each chiral center present in the enantiomer.
  • Compounds that are substantially diastereomerically pure contain at least 90% of a single isomer of each chiral center present in the diastereomer, and preferably contain at least 95% of a single isomer of each chiral center. More preferably, the substantially enantiomerically and diastereomerically pure compounds in this invention contain at least 97.5% of a single isomer and most preferably contain at least 99% of a single isomer of each chiral center in the compound.
  • racemic or “racemic mixture” refers to a mixture of equal amounts of enantiomeric compounds, which encompasses mixtures of enantiomers and mixtures of enantiomeric diastereomers.
  • the compounds of this invention may be obtained in stereoisomerically pure (i.e., enantiomerically and/or diastereomerically pure) or substantially stereoisomerically pure (i.e., substantially enantiomerically and/or diastereomerically pure) form.
  • Such compounds may be obtained synthetically, according to the procedures described herein using optically pure or substantially optically pure materials. Alternatively, these compounds may be obtained by resolution/separation of a mixture of stereoisomers, including racemic mixtures, using conventional procedures.
  • Exemplary methods that may be useful for the resolution/separation of stereoisomeric mixtures include chromatography and crystallization/re-crystallization. Other useful methods may be found in “ Enantiomers, Racemates, and Resolutions ,” J. Jacques et al., 1981, John Wiley and Sons, New York, N.Y., the disclosure of which is incorporated herein by reference. Preferred stereoisomers of the compounds of this invention are described herein.
  • Especially preferred embodiments of this invention comprise compounds, wherein the stereogenic centers (chiral carbons) have the following designated stereochemistry:
  • stereogenic centers More preferably, at least two of the stereogenic centers have the following designated stereochemistry:
  • stereogenic centers Even more preferably, at least three of the stereogenic centers have the following designated stereochemistry:
  • Exemplary compounds of this invention include:
  • the invention is also directed to the intermediates of Formula II, which are useful in the synthesis of certain compounds of Formula I:
  • the HIV protease inhibitor compounds of this invention include prodrugs, the pharmaceutically active metabolites, and the pharmaceutically acceptable salts and solvates thereof.
  • the compounds of Formula I, prodrugs, pharmaceutically acceptable salts, and pharmaceutically active metabolites and solvates thereof demonstrate an HIV-protease inhibitory activity, corresponding to K i of at least 100 nM, an EC 50 of at least 10 mM or an IC 50 of at least 10 mM.
  • the compounds of this invention demonstrate an HIV-protease inhibitory activity, corresponding to a K i of at least 10 nM, an EC 50 of at least 1 mM or an IC 50 of at least 1 mM.
  • the compounds of this invention demonstrate an HIV-protease inhibitory activity against mutant strains of HIV, corresponding to a K i of at least 100 nM, an EC 50 of at least 10 mM or an IC 50 of at least 10 mM. Even more preferably, the compounds of this invention demonstrate protease inhibitory activity against mutant strains corresponding to a K i of at least 10 nM, an EC 50 of at least 1 mM or an IC 50 of at least 1 mM.
  • a “prodrug” is intended to mean a compound that is converted under physiological conditions or by solvolysis or metabolically to a specified compound that is pharmaceutically active.
  • a prodrug may be a derivative of one of the compounds of this invention that contains a moiety, such as for example —CO 2 R, —PO(OR) 2 or —C ⁇ NR, that may be cleaved under physiological conditions or by solvolysis. Any suitable R substituent may be used that provides a pharmaceutically acceptable solvolysis or cleavage product.
  • a prodrug containing such a moiety may be prepared according to conventional procedures by treatment of a compound of this invention containing, for example, an amido, carboxylic acid, or hydroxyl moiety with a suitable reagent.
  • a “pharmaceutically active metabolite” is intended to mean a pharmacologically active compound produced through metabolism in the body of a specified compound.
  • Prodrugs and active metabolites of compounds of this invention of the above-described Formulas may be determined using techniques known in the art, for example, through metabolic studies. See, e.g., “Design of Prodrugs,” (Bundgaard, ed.), 1985, Elsevier Publishers B.V., Amsterdam, The Netherlands. The following is an example of a prodrug that can be converted to the compound of this invention under physiological conditions, by solvolysis or metabolically:
  • a “pharmaceutically acceptable salt” is intended to mean a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable.
  • pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates,
  • a “solvate” is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound.
  • solvates include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
  • inventive compounds, salts, and solvates may exist in different crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.
  • the present invention is also directed to a method of inhibiting HIV protease activity, comprising contacting the protease with an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
  • HIV protease activity may be inhibited in mammalian tissue by administering a compound of Formula I or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof. More preferably, the present method is directed at inhibiting HIV-protease activity.
  • Treating” or “treatment” is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, that is alleviated by the inhibition of the activity of HIV proteases.
  • the methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example, as a prophylactic.
  • the activity of the inventive compounds as inhibitors of HIV protease activity may be measured by any of the suitable methods known to those skilled in the art, including in vivo and in vitro assays. Examples of suitable assays for activity measurements are escribed herein.
  • Administration of the compounds of the Formula I and their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates may be performed according to any of the generally accepted modes of administration available to those skilled in the art.
  • suitable modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal.
  • An inventive compound of Formula I or a pharmaceutically acceptable salt, prodrug, active metabolite, or solvate thereof may be administered as a pharmaceutical composition in any pharmaceutical form recognizable to the skilled artisan as being suitable.
  • Suitable pharmaceutical forms include solid, semisolid, liquid, or lyophilized formulations, such as tablets, powders, capsules, suppositories, suspensions, liposomes, and aerosols.
  • Pharmaceutical compositions of the invention may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use or mode of administration. Acceptable methods of preparing suitable pharmaceutical forms of the pharmaceutical compositions may be routinely determined by those skilled in the art.
  • pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.
  • the present invention includes pharmaceutical compositions useful for inhibiting HIV protease, comprising an effective amount of a compound of this invention, and a pharmaceutically acceptable carrier.
  • Pharmaceutical compositions useful for treating infection by HIV, or for treating AIDS or ARC are also encompassed by the present invention, as well as a method of inhibiting HIV protease, and a method of treating infection by HIV, or of treating AIDS or ARC.
  • the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of an HIV infection/AIDS treatment agent selected from:
  • the present invention also includes the use of a compound of the present invention as described above in the preparation of a medicament for (a) inhibiting HIV protease, (b) preventing or treating infection by HIV, or (c) treating AIDS or ARC.
  • the present invention further includes the use of any of the HIV protease inhibiting compounds of the present invention as described above in combination with one or more HIV infection/AIDS treatment agents selected from an HIV/AIDS antiviral agent, an anti-infective agent, and an immunomodulator for the manufacture of a medicament for (a) inhibiting HIV protease, (b) preventing or treating infection by HIV, or (c) treating AIDS or ARC, said medicament comprising an effective amount of the HIV protease inhibitor compound and an effective amount of the one or more treatment agents.
  • HIV infection/AIDS treatment agents selected from an HIV/AIDS antiviral agent, an anti-infective agent, and an immunomodulator for the manufacture of a medicament for (a) inhibiting HIV protease, (b) preventing or treating infection by HIV, or (c) treating AIDS or ARC, said medicament comprising an effective amount of the HIV protease inhibitor compound and an effective amount of the one or more treatment agents.
  • Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions.
  • Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid.
  • Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water.
  • the carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension.
  • a dose of the pharmaceutical composition contains at least a therapeutically effective amount of the active compound (i.e., a compound of Formula I or a pharmaceutically acceptable salt, prodrug, active metabolite, or solvate thereof), and preferably is made up of one or more pharmaceutical dosage units.
  • the selected dose may be administered to a mammal, for example, a human patient, in need of treatment mediated by inhibition of HIV protease activity, by any known or suitable method of administering the dose, including: topically (for example, as an ointment or cream), orally, rectally (for example, as a suppository), parenterally (by injection) or continuously by intravaginal, intranasal, intrabronchial, intraaural, or intraocular infusion.
  • a “therapeutically effective amount” is intended to mean the amount of an inventive agent that, when administered to a mammal in need thereof, is sufficient to effect treatment for disease conditions alleviated by the inhibition of the activity of one or more variant of the HIV protease.
  • the amount of a given compound of the invention that will be therapeutically effective will vary depending upon factors such as the particular compound, the disease condition and the severity thereof, the identity of the mammal in need thereof, which amount may be routinely determined by artisans.
  • the compounds of this invention are also useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for isolating enzyme mutants that are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV protease, e.g., by competitive inhibition.
  • the compounds of this invention are commercial products to be sold for these purposes.
  • the inventive compounds are prepared by the methods of the present invention, including the General Methods shown below.
  • stereochemistry is not specified in chemical structures, either stereocenter may be utilized.
  • the following abbreviations also apply: Boc (tert-butoxycarbonyl), Ac (acetyl), Cbz (benzyloxycarbonyl), DMB (2,4-dimethoxybenzyl), TBS (tert-butyldimethylsilyl), TBDPS (tert-butyldiphenylsilyl), Ms (methanesulfonate), Ts (toluenesulfonate), Bn (benzyl), and Tr (triphenylmethyl)
  • Tiglic acid (1) (20.0 g, 0.200 mol) was dissolved in ether (80 ml) and added dropwise over 30 min to a suspension of LiAlH 4 (15.0 g, 0.417 mol) in ether (80 ml) at 0° C. and the reaction mixture was allowed to warm to room temperature. After 3 h the mixture was re-cooled to 0° C. and quenched slowly by the addition of H 2 O (15 ml), 15% NaOH (15 ml) and H 2 O (15 ml). The reaction mixture was filtered to remove the granular precipitate and washed thoroughly with ether. The filtrate was washed successively with 1N HCl, NaHCO 3 (saturated aqueous), and brine.
  • 3-Hydroxybenzylalcohol (1) (0.500 g 4.03 mmol) was dissolved in DMF (2 mL) at ambient temperature.
  • Ethyl bromide (0.900 mL, 12.1 mmol) and finely crushed K 2 CO 3 (2.78 g, 20.1 mmol) were added and the reaction mixture was stirred for 5 h.
  • the DMF was then removed in vacuo and the residue was partitioned between EtOAc and H 2 O, and extracted with EtOAc (3 ⁇ 10 mL). The organic layers were washed with brine (10 mL) and passed over a short plug of Na 2 SO 4 .
  • Cis-2-penten-1-ol (1) (1.00 g, 11.6 mmol) and carbon tetrabromide (3.85 g, 13.9 mmol) were dissolved in CH 2 Cl 2 (75 mL). The mixture was cooled to 0° C. and triphenylphosphine (3.65 mL, 13.9 mmol) dissolved in CH 2 Cl 2 (50 mL) was added dropwise. The mixture was allowed to warm to room temperature and was stirred overnight. The CH 2 Cl 2 was removed in vacuo and the crude residue was loaded directly onto a flash silica gel column and eluted quickly with 20% EtOAc/hexanes.
  • Amine was generated by alkylation of 3-hydroxybenzyl alcohol with ethyl bromide as describe in method C above followed by conversion of the alcohol to the amine as described in method D above provided desired amine.
  • Amine was generated from displacement of bromide in 3-nitrobenzylbromide with di BOC amine as described in method F above. Reduction of the nitro moiety to the aniline (method G above) followed by acetylation (method H above) and BOC removal (method F above) provided desired amine.
  • Amines were generated from conversion of the corresponding primary alcohols as described in method E above. Displacement of the bromide with di BOC amine and deprotection with TFA (method F above) provided the desired amines.
  • Amine was generated from 3-dimethylaminobenzyl alcohol as described in method D above.
  • Amine was generated from 3-benzyloxybenzyl alcohol. Conversion to the azide and reduction of both the azide and benzyl protecting group were accomplished using method D as described above with longer hydrogenation time.
  • Amine was generated by LiAlH 4 reduction of 2-cyanophenol (Ludeman, S. M., et. al. J. Med. Chem. 1975, 18, 1252-3.).
  • Amine was generated from the condensation of o-tolualdehyde with 2-aminoethanol followed by reduction with sodium borohydride ( Tetrahedron Assym. 1997, 8, 2367-74.).
  • Amine was generated from the corresponding aldehyde by the reductive amination procedure described in method I above.
  • Amine was generated by a reductive amination with the corresponding aldehyde ( Arch. Pharm. 1987, 320, 647-54.).
  • the above amine was prepared according to Weinheim, G. Arch. Pharm. 1987, 320, 647-654.
  • the synthesis of compounds with the general structure 5 is as follows.
  • the boc-protected thiazolidine carboxylic acid 1 is coupled to the requisite amines 2 to yield amino amides 3 using a two step process.
  • the process includes treatment of 1 with 2 in the presence of either diphenylchlorophosphate or HATU, followed by exposure to methane sulfonic acid.
  • Final compounds 5 are obtained by a DCC-mediated coupling of 3 and 4 followed by deprotection of the P2 phenol.
  • Final compounds were purified either by flash chromatography or preparative HPLC.
  • An alternative approach to the general structure 5 is as follows.
  • the thiazolidine ester 6 is coupled to acid 7 under carbodiimide reaction conditions, resulting in product 8 which is converted to acid 9 by mild base hydrolysis.
  • Acid 9 is combined with various amines, using diphenylphosphoryl azide, followed by cleavage of the P2 acetate to yield final compounds 5.
  • the products were purified by either flash chromatography or preparative HPLC.
  • Amides of the general structure 3 are coupled to boc-protected acid 15, and exposed to methane sulfonic acid to yield amines 16. Subjecting amines 16 to the reaction conditions depicted yielded a series of amides 17 and ureas 19.
  • Nicotinic acid 3-[(1S,2S)-3-((R)-4-allylcarbamoyl-5,5-dimethyl-thiazolidin-3-yl)-1-benzyl-2-hydroxy-3-oxo-propylcarbamoyl]-2-methyl-phenyl ester
  • the synthesis of compounds with the general structure 24 is as follows.
  • the boc-protected carboxylic acids 20a-f are coupled to the requisite amines 2 to yield amino amides 23 using a two step process.
  • the process includes treatment of 20 with 2 in the presence of either diphenyl chlorophosphate or EDCI, followed by exposure to HCl or methane sulfonic acid.
  • Final compounds 24 are obtained by a DCC-mediated coupling of 23 and 4 followed by deprotection of the P2 phenol.
  • Final compounds were purified either by flash chromatography or preparative HPLC.
  • DCC coupling A solution of acid, amine and HOBT was prepared in ethyl acetate. To the solution was then added DCC in an EtOAc solution at 0° C. and the mixture was stirred overnight at room temperature. The mixture was filtered and the filtrate was concentrated in vacuo. The residue dissolved in ethyl acetate washed with saturated NH 4 Cl (1 ⁇ ), saturated NaHCO 3 (1 ⁇ ), brine (1 ⁇ ), dried over Na 2 SO 4 and concentrated in vacuo. The crude was used without further purification unless otherwise noted.
  • Boc-acids 20a and 20b were prepared following the procedure of Demange, L.; Menez, A.; Dugave, C. Tet. Lett. 1998, 39, 1169.
  • Boc-acids 20c, 20d, 20e and 20f were prepared following the procedure of Karanewsky, D.; et al. J. Med. Chem. 1990, 33, 1459.
  • the title compound was prepared according to general methods using the corresponding Boc-protected pyrrolidinic acid (0.96 g, 3.8 mmol), o-methylbenzyl amine (0.57 mL, 4.6 mmol), HOBT (0.62 g, 4.6 mmol), EDCI (0.88 g, 4.6 mmol), CH 2 Cl 2 (50 mL).
  • the Boc was removed using the general 4N HCl Boc deprotection. 4N HCl in 1,4-dioxane (5 mL), 1,4-dioxane (5 mL).
  • Amino amide 23 (100 mg, 0.34 mmol) was coupled to carboxylic acid 4 (140 mg, 0.38 mmol) using the general DCC coupling method outlined above. HOBT (51 mg, 0.38 mmol), DCC (78 mg, 0.38 mmol), TEA (50 ⁇ L, 0.36 mmol), CH 2 Cl 2 (10 mL). The crude was purified by chromatography eluted with 10% acetone in CH 2 Cl 2 . Isolated yield: 0.13 g (63%). MS-APCI (m/z+): 608.
  • the grignard reagent, 3-butenylmagnesium bromide (7.7 mL, 3.80 mmol) was added dropwise over 10 min. The result was stirred at ⁇ 78° C. for 1 h then at ⁇ 55° C. for 30 min. The reaction was quenched at ⁇ 55° C. with sat NH 4 Cl soln. (3 mL) and then poured into H 2 O (50 mL). The mixture was extracted with EtOAc (2 ⁇ 50 mL). The combined organics were washed with brine (1 ⁇ 100 mL), dried over Na 2 SO 4 , filtered, and concentrated. The result was the amino ketone 26 that was sufficiently pure to use in the subsequent step.
  • the clear oil 26 (0.24 g, 1.15 mmol) was dissolved in EtOAc (10 mL).
  • AMB-AHPBA 4 (0.40 g, 1.09 mmol) was added followed by HOBt (0.15 g, 1.09 mmol).
  • the mixture was stirred at room temperature 1 h, then cooled to 0° C.
  • DCC (0.24 g, 1.15 mmol) was slowly added as solution in EtOAc (6 mL). The mixture was warmed to room temperature and stirred overnight. The mixture was filtered and the filtrate was washed with 1N HCl (10 mL), saturated NaHCO 3 (10 mL), brine (10 mL), dried over Na 2 SO 4 and concentrated to give a crude white solid (contaminated with DCU).
  • the DCU was removed by flash chromatography (30% to 50% EtOAc in hexanes) to provide a white solid, which was dissolved in MeOH (2 mL) and treated with 4N HCl in 1,4-dioxane (0.26 mL, 1.1 mmol). The reaction was stirred at room temperature overnight then partitioned between 1N HCl (10 mL) and EtOAc (10 mL). The organic layer was washed with saturated sat.
  • the combinatorial building block, 8, is prepared using the following method.
  • the boc-protected thiazolidine carboxylic acid, 1, is treated with allyl bromide in the presence of NaHCO 3 to yield the boc-protected thiazolidine allyl ester, 2.
  • Deprotection of boc-protected allyl ester, 2, with HCl (g) in EtOAc gives the HCl salt of the thiazolidine allyl ester amine, 3, which is treated with TEA and coupled to 4 in the presence of HOBT and DCC to give the building block precursor, 5.
  • Deprotection of the building block, 5, with 4N HCl yields the phenol, 6.
  • Loading the building block, 6, on to activated cross-linked trityl chloride polystyrene beads, 7, was accomplished in the following manner.
  • the polystyrene cross-linked trityl alcohol was activated to the trityl chloride, 7, by treatment with 20% acetyl chloride in anhydrous CH 2 Cl 2 at room temperature.
  • the trityl chloride beads were combined with the phenol 6 in the presence of Hunig's base in anhydrous CH 2 Cl 2 to yield the substrate loaded polystyrene beads 8.
  • Intermediates were purified either by flash chromatography or preparative HPLC.
  • the synthesis of the HIV protease combinatorial library was carried out in the following fashion.
  • the allyl ester was removed by treatment with Pd[PPh 3 ] 4 and NMM in anhydrous THF to give carboxylate 9, which was treated with pentafluorophenol, pentafluorophenol trifluoromethyl acetate and pyridine in DMF to yield the pentafluoro ester, 10.
  • the pentafluoro ester 10 was treated with various primary amines in a 96-well plate format to give amides 12.
  • the final products were cleaved from the polystyrene crowns with TFA to give products 13. Each product was analyzed by LCMS and HPLC.
  • DCM 3 mL/MiniKan
  • the appropriate primary P 2 ′ amine (3 eq), sodium triacetoxyborohydride (5 eq), and acetic acid (3 eq) were added, and the mixtures were placed under argon, agitated with periodic venting at room temperature for 1-2 hours, and allowed to react overnight.
  • the filtrates were poured off and the MiniKans were washed with DCM, MeOH (2 ⁇ ), DCM (2 ⁇ ), Et 3 N/DCM (1:3, 3 ⁇ ), DCM (2 ⁇ ), MeOH (3 ⁇ ), and DCM (4 ⁇ ).
  • a container of MiniKans in DMF and piperidine (25%) with a total reaction volume of 3 mL/MiniKan was agitated under argon at room temperature for 45 minutes. The filtrate was removed, and the reaction procedure was repeated. The MiniKans were filtered and washed with DMF (3 ⁇ ), MeOH (2 ⁇ ), DCM (3 ⁇ ), and DMF, and taken directly on to Step D.
  • FMOC-Allophenylnorstatine (APNS) (3 eq) was added to the flask of MiniKans in DMF (3 mL/MiniKan). After dissolution, HOAT (3.5 eq) and DIC (3.5 eq) were added. The mixture was placed under argon and agitated at room temperature overnight. The reaction was filtered and the MiniKans were washed with DMF (3 ⁇ ), MeOH (3 ⁇ ), DCM (3 ⁇ ), and DMF. FMOC deprotection was carried out as in Step C, and the MiniKans were washed with DMF (3 ⁇ ), MeOH (2 ⁇ ), DCM (3 ⁇ ), dried under vacuum and taken on to Step E or F.
  • APNS FMOC-Allophenylnorstatine
  • DCM 3 mL/MiniKan
  • the appropriate primary P 2 ′ amine (3 eq), sodium triacetoxyborohydride (5 eq), and acetic acid (3 eq) were added, and the mixtures were placed under argon, agitated with periodic venting at room temperature for 1-2 hours, and allowed to react overnight.
  • the filtrates were poured off and the MiniKans were washed with DCM, MeOH (2 ⁇ ), DCM (2 ⁇ ), Et 3 N/DCM (1:3, 3 ⁇ ), DCM (2 ⁇ ), MeOH (3 ⁇ ), and DCM (4 ⁇ ).
  • a container of MiniKans in DMF and piperidine (25%) with a total reaction volume of 3 mL/MiniKan was agitated under argon at room temperature for 45 minutes. The filtrate was removed, and the reaction procedure was repeated. The MiniKans were filtered and washed with DMF (3 ⁇ ), MeOH (2 ⁇ ), DCM (3 ⁇ ), and DMF, and taken directly on to Step D.
  • FMOC-Allophenylnorstatine (APNS) (3 eq) was added to the flask of MiniKans in DMF (3 mL/MiniKan). After dissolution, HOAT (3.5 eq) and DIC (3.5 eq) were added. The mixture was placed under argon and agitated at room temperature overnight. The reaction was filtered and the MiniKans were washed with DMF (3 ⁇ ), MeOH (3 ⁇ ), DCM (3 ⁇ ), and DMF. FMOC deprotection was carried out as in Step C, and the MiniKans were washed with DMF (3 ⁇ ), MeOH (2 ⁇ ), DCM (3 ⁇ ), dried under vacuum and taken on to Step E or F.
  • APNS FMOC-Allophenylnorstatine
  • HIV-1 NL4-3 (184V/L90M) was derived from a clinical isolate that exhibited the protease inhibitor-resistance associated substitutions 184V and L90M, by cloning of an reverse transcriptase-polymerase chain reaction amplified fragment into the unique Age I and Spe I restriction sites of pNL4-3.
  • CPE Cytopathic Effect
  • Viability as determined by the amount of XTT formazan produced, was quantified spectrophotometrically by absorbance at 450 nm. Data from CPE assays were expressed as the percent of formazan produced in compound-treated cells compared to formazan produced in wells of uninfected, compound-free cells.
  • the fifty percent effective concentration (EC 50 ) was calculated as the concentration of compound that effected an increase in the percentage of formazan production in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells.
  • the 50% cytotoxicity concentration (CC 50 ) was calculated as the concentration of compound that decreased the percentage of formazan produced in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.
  • the therapeutic index was calculated by dividing the cytotoxicity (CC 50 ) by the antiviral activity (EC 50 ).
  • MT-2 cells were infected with either HIV-1 NL4-3 or HIV-1 NL4-3(184V/L90M) and incubated in the presence of serial 0.5 log dilutions of test compounds. Three days later, culture supernatants were collected and virus production, as determined by p24 ELISA, was assayed. Percent inhibition was calculated as p24 concentration in compound-treated samples as compared to infected, compound-free controls. Inhibition of viral replication is determined by measuring reduction in HIV p24 present in the culture supernatant, using a Beckman-Coulter p24 HIV-1 Ag EIA kit and following the supplied protocol. Absorbance is read on a MRX microplate reader (Dynex Technologies). The EC 50 was calculated as the concentration of compound that effected a decrease in the p24 production by infected, compound-treated cells to 50% of that produced by infected, compound-free cells.
  • Ki's for the inhibitors of HIV-1 protease were determined using a resonance energy transfer (RET) assay.
  • RET resonance energy transfer
  • a mutant form of this enzyme (Q7S) is used for this assay because it is more stable against auto-proteolysis than the wild-type protein.
  • This enzyme is first partially purified as inclusion bodies from cell lysate. It is then solublized in 8M urea and passed through a Q-Sepharose column (Pharmacia) for further purification. To refold this protein, samples containing Q7S is dialyzed into 50 mM sodium phosphate pH 7.0, 50 mM NaCl, 10 mM DTT, and 10% glycerol.
  • the commercially available peptide substrate (Molecular Probes Cat. # H-2930) RE(EDANS)SQNYPIVQK(DABCYL)R is used to assess activity and Ki's.
  • This peptide is cleaved quantitatively by HIV-1 Pr at the Tyr-Pro bond.
  • the EDANS fluorophore absorbs at 340 nm and emits at 490 nm.
  • the reaction is carried out in a 96 well plate in a total volume of 100 ⁇ L and is run for 12 minutes at 37 C under steady-state conditions with 5 ⁇ M substrate and 2 nM active dimer enzyme concentration.
  • the literature value Km for this substrate and enzyme is 103+/ ⁇ 8 ⁇ M (See Matayoshi, et al., “Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer,” Science 247, 954 (1990)).
  • the buffer for this reaction is 0.1M sodium acetate pH 4.8, 1M NaCl, 1 mM EDTA, 5 mM dithiothreitol, 10% dimethyl sulfoxide and 1 mg/ml bovine serum albumin. Inhibition curves are fit using the Morrison tight binding equation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of the formula:
Figure US20050250707A1-20051110-C00001
 where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

Description

  • This application claims the benefit of U.S. Provisional Application No. 60/297,460, filed on Jun. 11, 2001, and U.S. Provisional Application No. 60/297,729, filed on Jun. 11, 2001.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention relates to novel compounds as useful as HIV protease inhibitors and to the use of such compounds as antiviral agents for treatment of HIV infected individuals. This invention also relates to methods of preparation of these compounds and to intermediates that are useful in the preparation thereof.
  • 2. Related Background Art
  • Acquired Immune Deficiency Syndrome (AIDS) causes a gradual breakdown of the body's immune system as well as progressive deterioration of the central and peripheral nervous systems. Since its initial recognition in the early 1980's, AIDS has spread rapidly and has now reached epidemic proportions within a relatively limited segment of the population. Intensive research has led to the discovery of the responsible agent, human T-lymphotropic retrovirus III (HTLV-III), now more commonly referred to as the human immunodeficiency virus or HIV.
  • HIV is a member of the class of viruses known as retroviruses. The retroviral genome is composed of RNA, which is converted to DNA by reverse transcription. This retroviral DNA is then stably integrated into a host cell's chromosome and, employing the replicative processes of the host cells, produces new retroviral particles and advances the infection to other cells. HIV appears to have a particular affinity for the human T-4 lymphocyte cell, which plays a vital role in the body's immune system. HIV infection of these white blood cells depletes this white cell population. Eventually, the immune system is rendered inoperative and ineffective against various opportunistic diseases such as, among others, pneumocystic carini pneumonia, Kaposi's sarcoma, and cancer of the lymph system.
  • Although the exact mechanism of the formation and working of the HIV virus is not understood, identification of the virus has led to some progress in controlling the disease. For example, the drug azidothymidine (AZT) has been found effective for inhibiting the reverse transcription of the retroviral genome of the HIV virus, thus giving a measure of control, though not a cure, for patients afflicted with AIDS. The search continues for drugs that can cure or at least provide an improved measure of control of the deadly HIV virus.
  • Retroviral replication routinely features post-translational processing of polyproteins. This processing is accomplished by virally encoded HIV protease enzyme. This yields mature polypeptides that will subsequently aid in the formation and function of infectious virus. If this molecular processing is stifled, then the normal production of HIV is terminated. Therefore, inhibitors of HIV protease may function as anti-HIV viral agents.
  • HIV protease is one of the translated products from the HIV structural protein pol gene. This retroviral protease specifically cleaves other structural polypeptides at discrete sites to release these newly activated structural proteins and enzymes, thereby rendering the virion replication-competent. As such, inhibition of the HIV protease by potent compounds may prevent proviral integration of infected T-lymphocytes during the early phase of the HIV-1 life cycle, as well as inhibit viral proteolytic processing during its late stage. Additionally, the protease inhibitors may have the advantages of being more readily available, longer lived in virus, and less toxic than currently available drugs, possibly due to their specificity for the retroviral protease.
  • Related inhibitors of HIV proteases have been described in, e.g., U.S. Pat. No. 5,962,640, U.S. Pat. No. 5,932,550, Australian Patent No. 705193, Canadian Patent Application No. 2,179,935, European Patent Application No. 0 751 145, and Japanese Patent Application No. 100867489. Other related HIV protease inhibitors have been described in K. Yoshimura, et al., Proct. Natl. Acad. Sci. USA, 96, 8675-8680 (1999) and T. Mimoto, et al., J. Med. Chem., 42, 1789-1802 (1999).
  • On-going treatment of HIV-infected individuals with compounds that inhibit HIV protease has led to the development of mutant viruses that possess protesases that are resistant to the inhibitory effect of these compounds. Thus, to be effective, new HIV protease inhibitors must be effective not only against wild-type strains of HIV, but must also demonstrate efficacy against the newly emerging mutant strains that are resistant to the commercially available protease inhibitors. Accordingly, there continues to be a need for new inhibitors targeting the HIV protease in both wild type and mutant strains of HIV.
    • SUMMARY OF THE INVENTION
  • This invention relates to compounds useful for inhibiting the activity of HIV-protease of Formula I:
    Figure US20050250707A1-20051110-C00002
    wherein:
      • R1 is a 5- or 6-membered mono-cyclic carbocyclic or heterocyclic group, wherein said carbocyclic or heterocyclic group is saturated, partially unsaturated or fully unsaturated and is unsubstituted or substituted by one or more suitable substituents;
      • R2 is a substituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted phenyl group, a substituted phenylalkyl group, a substituted or unsubstituted phenylalkenyl group or a substituted or unsubstituted phenylalkynyl group,
      • R2′ is H or a substituted or unsubstituted C1-C4 alkyl group;
      • X is
        Figure US20050250707A1-20051110-C00003
      •  wherein Rx is H or one or more suitable substituents;
      • Z is S, O, SO, SO2, CH2 or CFH;
      • R3 is H or a substituted or unsubstituted C1-C4 alkyl group;
      • R4, R5, R6 and R7 are independently selected from H or a C1-C6 alkyl group; and
      • R8 and R8′ are independently selected from H, halo, a C1-C4 aliphatic group or a C1-C4 halo-substituted aliphatic group;
      • where any of said substituted alkyl, alkenyl or alkynyl groups are substituted by one or more suitable substituents
      • provided that said 5- or 6-membered mono-cyclic heterocycloalkyl, heterocycloalkenyl or heteroaryl group contains at least two heteroatoms when R2 is a substituted phenyl group, a substituted phenylalkyl group, a substituted or unsubstituted phenylalkenyl group or a substituted or unsubstituted phenylalkynyl group; or
      • provided that said alkyl, alkenyl or alkynyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more substituents selected from halo or keto; or
      • provided that said substituted phenyl group or phenyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more suitable substituents other than halo or methyl.
  • The present invention relates to compounds of Formula I below, and prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts and solvates thereof that inhibit the protease encoded by human immunodeficiency virus (HIV) type 1 (HIV-1) or type 2 (HIV-2), as well as mutant strains thereof. These compounds are useful in the treatment of infection by HIV and the treatment of the acquired immune deficiency syndrome (AIDS). The compounds, their pharmaceutically acceptable salts, and the pharmaceutical compositions of the present invention can be used alone or in combination with other antivirals, immunomodulators, antibiotics or vaccines. Compounds of the present invention can also be converted to prodrugs, by derivatization, according to conventional techniques. Methods of treating AIDS, methods of treating HIV infection and methods of inhibiting HIV protease are disclosed.
    • DETAILED DESCRIPTION OF INVENTION AND PREFERRED EMBODIMENTS
  • In accordance with a convention used in the art,
    Figure US20050250707A1-20051110-C00004
    is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.
  • As used herein, the term “aliphatic” represents a saturated or unsaturated, straight- or branched-chain hydrocarbon, containing 1 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below. The term “aliphatic” is intended to encompass alkyl, alkenyl and alkynyl groups.
  • As used herein, the term “alkyl” represents a straight- or branched-chain saturated or unsaturated hydrocarbon, containing 1 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below. Exemplary alkyl substituents include, but are not limited to methyl (Me), ethyl (Et), propyl, isopropyl, butyl, isobutyl, t-butyl, and the like. The term “lower alkyl” refers to an alkyl group containing from 1 to 6 carbon atoms
  • The term “alkenyl” represents a straight- or branched-chain hydrocarbon, containing one or more carbon-carbon double bonds and having 2 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below. Exemplary alkenyl substituents include, but are not limited to ethenyl, propenyl, butenyl, allyl, pentenyl and the like.
  • The term “alkynyl” represents a straight- or branched-chain hydrocarbon, containing one or more carbon-carbon triple bonds and having 2 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below. An alkynyl moiety may also contain one or more carbon-carbon double bonds. Exemplary alkynyl substituents include, but are not limited to ethynyl, butynyl, propynyl (propargyl) isopropynyl, pentynyl, hexynyl and the like.
  • The term “carbocyclic” represents a saturated, partially saturated, or fully unsaturated (aromatic) cyclic hydrocarbon group containing from 3 to 14 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described herein below. The term “carbocyclic” is intended to encompass mono-, bi- and tri-cyclic saturated, partially saturated, or fully unsaturated hydrocarbon groups; for example, cycloalkyl, cycloalkenyl and aryl groups. The term “carbocyclic” is also intended to encompass bi- and tri-cyclic hydrocarbon groups which contain any-combination of ring moieties that are saturated, partially saturated, or fully unsaturated (aromatic). Partially saturated carbocycles include, for example, dihydro-arenes (e.g., indanyl) or tetrahydro-arenes (e.g. tetrahydronaphthalene), wherein any one or more points of saturation may occur in any ring moiety of the carbocycle. In addition, it is understood that bonding between any bi- or tri-cyclic carbocyclic group and any other substituent or variable group may be made at any suitable position of the carbocycle. The term “carbocyclic-aliphatic” group is intended to encompass aliphatic groups having a carbocyclic substituent (e.g., phenylmethyl-(benzyl), phenylethyl-, cyclopropylmethyl-, etc.), wherein the carbocyclic moiety and the aliphatic moiety thereof may be independently substituted by one or more suitable substituents.
  • “Cycloalkyl” represents a group comprising a non-aromatic monocyclic, bicyclic, or tricyclic hydrocarbon containing from 3 to 14 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below. Exemplary cycloalkyls include monocyclic rings having from 3-8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Illustrative examples of cycloalkyl groups include the following:
    Figure US20050250707A1-20051110-C00005
  • “Cycloalkenyl” represents a group comprising a non-aromatic monocyclic, bicyclic, or tricyclic hydrocarbon containing from 4 to 14 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below and contains at least one carbon-carbon double bond. Exemplary monocyclic cycloalkenyls include groups having from 4-8, preferably 5-6, carbon atoms, such as cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl and the like. Illustrative examples of cycloalkenyl groups include the following:
    Figure US20050250707A1-20051110-C00006
  • “Aryl” represents a group comprising an aromatic, monovalent monocyclic, bicyclic, or tricyclic radical containing from 6 to 18 carbon ring atoms, which may be unsubstituted or substituted by one or more of the substituents described below. Illustrative examples of aryl groups include the following:
    Figure US20050250707A1-20051110-C00007
  • The term “carbocyclic” also to encompasses mixed bi- and tri-cyclic cycloalkyl/cycloalkenyl/aryl groups, which may be unsubstituted or substituted by one or more of the substituents described below. Illustrative examples of such mixed bi- and tri-cyclic groups include the following:
    Figure US20050250707A1-20051110-C00008
  • It is understood that bonding or substitution of any bi-cyclic or tri-cyclic carbocyclic or heterocyclic group described herein may be at any suitable position on any ring.
  • Illustrative examples of such bonding in mixed bi- and tri-cyclic carbocyclic groups include the following:
    Figure US20050250707A1-20051110-C00009
    wherein R′ is any suitable substituent.
  • The term “heterocyclic” represents a saturated, partially saturated, or fully unsaturated (aromatic) cyclic group containing from 3 to 18 ring atoms, which includes 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents described herein below. The term “heterocyclic” is intended to encompass mono-, bi- and tri-cyclic saturated, partially saturated, or fully unsaturated heteroatom-containing cyclic groups; for example, heterocycloalkyl, heterocycloalkenyl and heteroaryl groups. The term “heterocyclic” is also intended to encompass bi- and tri-cyclic groups which contain any combination of ring moieties that are saturated, partially saturated, or fully unsaturated (aromatic). Partially saturated heterocycles include, for example, dihydroheteroarenes (e.g., dihydroindole) or tetrahydro-heteroarenes (e.g. tetrahydroquinoline), wherein any one or more points of saturation may occur in any ring moiety of the heterocycle. In addition, it is understood that bonding between any bi- or tri-cyclic heterocyclic group and any other substituent or variable group may be made at any suitable position of the heterocycle (i.e., there is no restriction that a substituent or variable group must be bonded to the heteroatom-containing moiety of a bi- or tri-cyclic heterocyclic group). The term “heterocyclic-aliphatic” group is intended to encompass aliphatic groups having a heterocyclic substituent (e.g., pyridylmethyl-, thiazolylmethyl-, tetrahydrofuranylmethyl-, etc.) wherein the heterocyclic moiety and the aliphatic moiety thereof may be independently substituted by one or more suitable substituents.
  • “Heterocycloalkyl” represents a group comprising a saturated monovalent monocyclic, bicyclic, or tricyclic radical, containing 3 to 18 ring atoms, which includes 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents described below. Illustrative examples of heterocycloalkyl groups include, but are not limited to, azetidinyl, pyrrolidyl, piperidyl, piperazinyl, morpholinyl, tetrahydro-2H-1,4-thiazinyl, tetrahydrofuryl, tetrahydropyranyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxathiolanyl, 1,3-oxathianyl, 1,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]nonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1]heptyl, 1,5,9-triazacyclododecyl, and the like. Illustrative examples of heterocycloalkyl groups include the following:
    Figure US20050250707A1-20051110-C00010
      • wherein R is H, alkyl, hydroxyl or represents a compound according to Formula I, and the bond depicted as
        Figure US20050250707A1-20051110-C00011
        represents bonding to either face of the bi-cyclic moiety (i.e., endo or exo).
  • The term “heterocycloalkenyl” is used herein to represent a non-aromatic, monovalent monocyclic, bicyclic, or tricyclic radical, containing 4 to 18 ring atoms, which may include from 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, and which may be unsubstituted or substituted by one or more of the substituents described below and which contains at least one carbon-carbon or carbon-heteroatom double bond. Exemplary monocyclic heterocycloalkenyls include groups having from 4-8, preferably 5-6, ring atoms. Illustrative examples of heterocycloalkenyl groups include, but are not limited to, dihydrofuryl, dihydropyranyl, isoxazolinyl, dihydropyridyl, tetrahydropyridyl, and the like. Illustrative examples of heterocycloalkenyl groups include the following:
    Figure US20050250707A1-20051110-C00012
      • wherein R is H, alkyl, hydroxyl or represents a compound according to Formula I.
  • “Heteroaryl” represents a group comprising an aromatic monovalent monocyclic, bicyclic, or tricyclic radical, containing 5 to 18 ring atoms, including 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more of the substituents described below. As used herein, the term “heteroaryl” is also intended to encompass the N-oxide derivative (or N-oxide derivatives, if the heteroaryl group contains more than one nitrogen such that more than one N-oxide derivative may be formed) of the nitrogen-containing heteroaryl groups described herein. Illustrative examples of heteroaryl groups include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, thiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, benzo[b]thienyl, naphtho[2,3-b]thianthrenyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathienyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxyalinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl, carbazolyl, beta-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, and phenoxazinyl. Illustrative examples of N-oxide derivatives of heteroaryl groups include, but are not limited to, pyridyl N-oxide, pyrazinyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, triazinyl N-oxide, isoquinolyl N-oxide, and quinolyl N-oxide. Further examples of heteroaryl groups include the following moieties:
    Figure US20050250707A1-20051110-C00013
    wherein R is H, alkyl, hydroxyl or represents a compound according to Formula I.
  • The term “heterocyclic” also to encompasses mixed bi- and tri-cyclic heterocycloalkyl/heterocycloalkenyl/heteroaryl groups, which may be unsubstituted or substituted by one or more of the substituents described below. Illustrative examples of such mixed bi- and tri-cyclic heterocyclic groups include the following:
    Figure US20050250707A1-20051110-C00014
  • Illustrative examples of such bonding in mixed bi- and tri-cyclic heterocyclic groups include the following:
    Figure US20050250707A1-20051110-C00015
    wherein R′ is any suitable substituent.
  • In the compounds of this invention, the alkyl, alkenyl and alkynyl groups may be optionally substituted by one or more suitable substituents independently selected from phenyl, nitro, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, cycloalkyloxy, cycloalkylalkyloxy, cycloalkenyloxy, cycloalkenylalkyloxy, heterocycloalkoxy, heterocycloalkylalkyloxy, heterocycloalkenyloxy, heterocycloalkenylalkyloxy, heteroaryloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyl, arylcarbonyloxy, aryloxycarbonyl, cycloalkylcarbonyl, cycloalkylcarbonyloxy, cycloalkyoxycarbonyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heterocycloalkylcarbonyl, heterocycloalkylcarbonyloxy, heterocycloalkyoxycarbonyl, carboxyl, carbamoyl, formyl, keto (oxo), thioketo, sulfo, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocycloalkylamino, heterocycloalkenylamino, heteroarylamino, dialkylamino, alkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, cycloalkylaminocarbonyl, cycloalkenylamino, arylaminocarbonyl, heterocycloalkylaminocarbonyl, heterocycloalkenylcarbonyl, heteroarylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, cycloalkylaminothiocarbonyl, arylaminothiocarbonyl, heterocycloalkylaminothiocarbonyl, heteroarylaminothiocarbonyl, dialkylaminothiocarbonyl, alkylsulfonyl, arylsulfonyl, alkylsulfenyl, arylsulfenyl, alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heterocycloalkylcarbonylamino, heteroarylcarbonylamino, alkylthiocarbonylamino, cycloalkylthiocarbonylamino, arylthiocarbonylamino, heterocycloalkylthiocarbonylamino, heteroarylthiocarbonylamino, alkylsulfonyloxy, arylsulfonyloxy, alkylsulfonylamino, arylsulfonylamino, mercapto, alkylthio, haloalkylthio, arylthio and heteroarylthio groups, wherein any of the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl moieties present in the above substituents may be further substituted. The alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl moieties of any of the above substituents may be optionally substituted by one or more groups independently selected from alkyl (except for alkyl), haloalkyl, aryl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, mercapto, alkylthio, haloalkylthio or arylthio groups.
  • In the compounds of this invention the substituted carbocyclic or heterocyclic groups may be optionally substituted by one or more suitable substituents independently selected from alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, nitro, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, alkylenedioxy, aryloxy, cycloalkyloxy, cycloalkylalkyloxy, cycloalkenyloxy, cycloalkenylalkyloxy, heterocycloalkoxy, heterocycloalkylalkyloxy, heterocycloalkenyloxy, heterocycloalkenylalkyloxy, heteroaryloxy, alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, arylcarbonyl, arylcarbonyloxy, aryloxycarbonyl, cycloalkylcarbonyl, cycloalkylcarbonyloxy, cycloalkyoxycarbonyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heterocycloalkylcarbonyl, heterocycloalkylcarbonyloxy, heterocycloalkyoxycarbonyl, carboxyl, carbamoyl, formyl, keto (oxo), thioketo, sulfo, alkylamino, cycloalkylamino, arylamino, heterocycloalkylamino, heteroarylamino, dialkylamino, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocycloalkylaminocarbonyl, heteroarylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, cycloalkylaminothiocarbonyl, arylaminothiocarbonyl, heterocycloalkylaminothiocarbonyl, heteroarylaminothiocarbonyl, dialkylaminothiocarbonyl, alkylsulfonyl, arylsulfonyl, alkylsulfenyl, arylsulfenyl, alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heterocycloalkylcarbonylamino, heteroarylcarbonylamino, alkylthiocarbonylamino, cycloalkylthiocarbonylamino, arylthiocarbonylamino, heterocycloalkylthiocarbonylamino, heteroarylthiocarbonylamino, alkylsulfonyloxy, arylsulfonyloxy, alkylsulfonylamino, arylsulfonylamino, mercapto, alkylthio, haloalkylthio, arylthio and heteroarylthio groups, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, heteroaryl moieties present in the above substituents may be further substituted. Preferred “suitable substituents” include alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, halogen, hydroxyl, alkoxy, alkylenedioxy, aryloxy, cycloalkoxy, heteroaryloxy, alkylthio, haloalkylthio and carboxyl. The alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of any of the above substituents may be optionally substituted by one or more groups independently selected from: alkyl, haloalkyl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, mercapto, alkylthio, haloalkylthio or arylthio groups.
  • For example, in the compounds of this invention, the substituted phenyl or phenyl moiety of R2 may comprise at least one substituent (other than halo or methyl) selected from haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkoxyalkyl, alkylcarbonylalkyl, haloalkoxyalkyl, aryloxyalkyl, alkylthioalkyl, haloalkylthioalkyl, arylthioalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, nitro, amino, cyano, hydroxyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, alkylenedioxy, aryloxy, cycloalkyloxy, cycloalkylalkyloxy, cycloalkenyloxy, cycloalkenylalkyloxy, heterocycloalkoxy, heterocycloalkylalkyloxy, heterocycloalkenyloxy, heterocycloalkenylalkyloxy, heteroaryloxy, alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, arylcarbonyl, arylcarbonyloxy, aryloxycarbonyl, cycloalkylcarbonyl, cycloalkylcarbonyloxy, cycloalkyoxycarbonyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heterocycloalkylcarbonyl, heterocycloalkylcarbonyloxy, heterocycloalkyoxycarbonyl, carboxyl, carbamoyl, formyl, keto (oxo), thioketo, sulfo, alkylamino, cycloalkylamino, arylamino, heterocycloalkylamino, heteroarylamino, dialkylamino, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocycloalkylaminocarbonyl, heteroarylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, cycloalkylaminothiocarbonyl, arylaminothiocarbonyl, heterocycloalkylaminothiocarbonyl, heteroarylaminothiocarbonyl, dialkylaminothiocarbonyl, alkylsulfonyl, arylsulfonyl, alkylsulfenyl, arylsulfenyl, alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heterocycloalkylcarbonylamino, heteroarylcarbonylamino, alkylthiocarbonylamino, cycloalkylthiocarbonylamino, arylthiocarbonylamino, heterocycloalkylthiocarbonylamino, heteroarylthiocarbonylamino, alkylsulfonyloxy, arylsulfonyloxy, alkylsulfonylamino, arylsulfonylamino, mercapto, alkylthio, haloalkylthio, arylthio and heteroarylthio groups, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, heteroaryl moieties present in the above substituents may be further substituted. Preferred “suitable substituents” include alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, halogen, hydroxyl, alkoxy, alkylenedioxy, aryloxy, cycloalkoxy, heteroaryloxy, alkylthio, haloalkylthio and carboxyl. The alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of any of the above substituents may be optionally substituted by one or more groups independently selected from: alkyl, haloalkyl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, mercapto, alkylthio, haloalkylthio or arylthio groups.
  • If the substituents themselves are not compatible with the synthetic methods of this invention, the substituent may be protected with a suitable protecting group that is stable to the reaction conditions used in these methods. The protecting group may be removed at a suitable point in the reaction sequence of the method to provide a desired intermediate or target compound. Suitable protecting groups and the methods for protecting and de-protecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which may be found in T. Greene and P. Wuts, Protecting Groups in Chemical Synthesis (3rd ed.), John Wiley & Sons, NY (1999), which is incorporated herein by reference in its entirety. In some instances, a substituent may be specifically selected to be reactive under the reaction conditions used in the methods of this invention. Under these circumstances, the reaction conditions convert the selected substituent into another substituent that is either useful in an intermediate compound in the methods of this invention or is a desired substituent in a target compound.
  • In the compounds of this invention, R2 and R2′, independently or taken together, may be a suitable nitrogen protecting group. As indicated above, nitrogen protecting groups are well known in the art and any nitrogen protecting group that is useful in the methods of preparing the compounds of this invention or may be useful in the HIV protease inhibitory compounds of this invention may be used. Exemplary nitrogen protecting groups include alkyl, substituted alkyl, carbamate, urea, amide, imide, enamine, sulfenyl, sulfonyl, nitro, nitroso, oxide, phosphinyl, phosphoryl, silyl, organometallic, borinic acid and boronic acid groups. Examples of each of these groups, methods for protecting nitrogen moieties using these groups and methods for removing these groups from nitrogen moieties are disclosed in T. Greene and P. Wuts, supra. Preferably, when R2 and/or R2′ are independently suitable nitrogen protecting groups, suitable R2 and R2′ substituents include, but are not limited to, carbamate protecting groups such as alkyloxycarbonyl (e.g., Boc: t-butyloxycarbonyl) and aryloxycarbonyl (e.g., Cbz: benzyloxycarbonyl, or FMOC: fluorene-9-methyloxycarbonyl), alkyloxycarbonyls (e.g., methyloxycarbonyl), alkyl or arylcarbonyl, substituted alkyl, especially arylalkyl (e.g., trityl (triphenylmethyl), benzyl and substituted benzyl), and the like. When R2 and R2′ taken together are a suitable nitrogen protecting group, suitable R2/R2′ substituents include phthalimido and a stabase (1,2-bis (dialkylsilyl))ethylene).
  • The terms “halogen” and “halo” represent chloro, fluoro, bromo or iodo substituents. “Heterocycle” is intended to mean a heteroaryl or heterocycloalkyl group. “Acyl” is intended to mean a —C(O)—R radical, where R is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group. “Acyloxy” is intended to mean an —OC(O)—R radical, where R is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group. “Thioacyl” is intended to mean a —C(S)—R radical, where R is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group. “Sulfonyl” is intended to mean an —SO2— biradical. “Sulfenyl” is intended to mean an —SO— biradical. “Sulfo” is intended to mean an —SO2H radical. “Hydroxy” is intended to mean the radical —OH. “Amine” or “amino” is intended to mean the radical —NH2. “Alkylamino” is intended to mean the radical —NHRa, where Ra is an alkyl group. “Dialkylamino” is intended to mean the radical —NRaRb, where Ra and Rb are each independently an alkyl group, and is intended to include heterocycloalkyl groups, wherein Ra and Rb, taken together, form a heterocyclic ring that includes the amine nitrogen. “Alkoxy” is intended to mean the radical —ORa, where Ra is an alkyl group. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, and the like. “Lower alkoxy” groups have alkyl moieties having from 1 to 4 carbons. “Alkoxycarbonyl” is intended to mean the radical —C(O)ORa, where Ra is an alkyl group. “Alkylsulfonyl” is intended to mean the radical —SO2Ra, where Ra is an alkyl group. “Alkylenedioxy” is intended to mean the divalent radical —ORaO— which is bonded to adjacent atoms (e.g., adjacent atoms on a phenyl or naphthyl ring), wherein Ra is a lower alkyl group. “Alkylaminocarbonyl” is intended to mean the radical —C(O)NHRa, where Ra is an alkyl group. “Dialkylaminocarbonyl” is intended to mean the radical —C(O)NRaRb, where Ra and Rb are each independently an alkyl group. “Mercapto” is intended to mean the radical —SH. “Alkylthio” is intended to mean the radical —SRa, where Ra is an alkyl group. “Carboxy” is intended to mean the radical —C(O)OH. “Keto” or “oxo” is intended to mean the diradical ═O. “Thioketo” is intended to mean the diradical ═S. “Carbamoyl” is intended to mean the radical —C(O)NH2. “Cycloalkylalkyl” is intended to mean the radical -alkyl-cloalkyl, wherein alkyl and cycloalkyl are defined as above, and is represented by the bonding arrangement present in the groups —CH2-cyclohexane or —CH2-cyclohexene. “Arylalkyl” is intended to mean the radical -alkylaryl, wherein alkyl and aryl are defined as above, and is represented by the bonding arrangement present in a benzyl group. “Aminocarbonylalkyl” is intended to mean the radical -alkylC(O)NH2 and is represented by the bonding arrangement present in the group —CH2CH2C(O)NH2. “Alkylaminocarbonylalkyl” is intended to mean the radical -alkylC(O)NHRa, where Ra is an alkyl group and is represented by the bonding arrangement present in the group —CH2CH2C(O)NHCH3. “Alkylcarbonylaminoalkyl is intended to mean the radical -alkylNHC(O)-alkyl and is represented by the bonding arrangement present in the group —CH2NHC(O)CH3. “Dialkylaminocarbonylalkyl” is intended to mean the radical -alkylC(O)NRaRb, where Ra and Rb are each independently an alkyl group. “Aryloxy” is intended to mean the radical —ORc, where Rc is an aryl group. “Heteroaryloxy” is intended to mean the radical —ORd, where Rd is a heteroaryl group. “Arylthio” is intended to mean the radical —SRc, where Rc is an aryl group. “Heteroarylthio” is intended to mean the radical —SRd, where Rd is a heteroaryl group.
  • If an inventive compound is a base, a desired salt may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid, such as glucuronic acid or galacturonic acid, alpha-hydroxy acid, such as citric acid or tartaric acid, amino acid, such as aspartic acid or glutamic acid, aromatic acid, such as benzoic acid or cinnamic acid, sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
  • If an inventive compound is an acid, a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • Specific embodiments of the compounds of this invention comprising the compounds depicted by Formula I may also be described. For example, this invention relates to compounds useful for inhibiting the activity of HIV-protease of Formula I, above, wherein:
      • R1 is a 5- or 6-membered monocyclic cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group, where said cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, alkylenedioxy, di-haloalkylenedioxy, aryloxy, cycloalkoxy, cycloalkylalkoxy, cycloalkenyloxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenyloxy, heterocycloalkenylalkoxy, heteroaryloxy, alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, alkylamino, dialkylamino, keto, alkylsulfonyl, arylsulfonyl, alkylcarbonylamino, alkylthio, haloalkylthio and arylthio, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, heteroaryl moieties present in the above substituents may be further substituted by one or more groups independently selected from alkyl, haloalkyl, aryl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, mercapto, alkylthio, haloalkylthio and arylthio groups;
      • R2 is a substituted alkyl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group, wherein said alkyl, alkenyl or alkynyl group is a straight or branched chained group, and
      • where said substituted alkyl, alkenyl or alkynyl group is substituted by one or more substituents independently selected from amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, cycloalkoxy, cycloalkylalkoxy, cycloalkenyloxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenyloxy, heterocycloalkenlalkoxy, heteroaryloxy, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylsulfenyl, arylsulfenyl, alkylthio, haloalkylthio, arylthio and heteroarylthio groups, wherein any of the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl moieties present in the above substituents may be further substituted by one or more groups independently selected from alkyl, haloalkyl, halogen, hydroxyl, alkoxy, haloalkoxy, alkylthio and haloalkylthio groups;
      • R2′ is H, methyl, ethyl or propyl, where said methyl, ethyl or propyl is unsubstituted or substituted by halo or hydroxyl;
      • X is
        Figure US20050250707A1-20051110-C00016
      •  wherein Rx is H or one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyl, alkylenedioxy, di-haloalkylenedioxy, alkylamino, dialkylamino, alkylthio and haloalkylthio;
      • Z is S, O, SO, SO2, CH2 or CFH;
      • R3 is H;
      • R4, R5, R6 and R7 are independently selected from H or methyl; and
      • R8 and R8′ are independently selected from H, halogen, methyl, monohalo-methyl, dihalo-methyl and tri-halomethyl;
      • or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
  • In more specific embodiments, this invention relates to compounds of Formula I, above, wherein:
      • R1 is phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl, where said phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, halogen, and hydroxyl;
      • R2 is a substituted alkyl group, a substituted or unsubstituted C1-C6 alkenyl group, or a substituted or unsubstituted C1-C6 alkynyl group, wherein said alkyl, alkenyl or alkynyl group is a straight or branched chained group, and
      • where said substituted alkyl, alkenyl or alkynyl group is substituted by one or more substituents independently selected from cyano, halogen and alkylamino;
      • R2′ is H, methyl or ethyl;
      • X is
        Figure US20050250707A1-20051110-C00017
      •  wherein Rx is H, halogen, or alkoxy;
      • Z is S, O, CH2 or CFH;
      • R3, R4, R5, R8 and R8′ are each H; and
      • R6 and R7 are independently selected from H or methyl;
      • or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
  • In preferred specific embodiments, this invention relates to compounds of Formula I, above, wherein:
      • R1 is phenyl, where said phenyl is substituted with one or more substituents independently selected from alkyl, halogen or hydroxyl;
      • R2 is a C1-C6 alkenyl group or a C1-C6 alkynyl group, wherein said alkenyl or alkynyl group is a straight or branched chained group, and
      • where said alkenyl or alkynyl group is unsubstituted or is substituted by one or more halogen substituents;
      • R2′ is H;
      • X is
        Figure US20050250707A1-20051110-C00018
      •  wherein Rx is H;
      • Z is S;
      • R3, R4, R5, R8 and R8′ are each H; and
      • R6 and R7 are each methyl;
      • or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
  • More specifically, this invention relates to compounds useful for inhibiting the activity of HIV-protease of Formula I, above, wherein:
      • R1 is a 5- or 6-membered mono-cyclic cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group, where said cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, alkylenedioxy, dihaloalkylenedioxy, aryloxy, cycloalkoxy, cycloalkylalkoxy, cycloalkenyloxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenyloxy, heterocycloalkenylalkoxy, heteroaryloxy, alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarbonylamino, alkylthio, haloalkylthio and arylthio, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, heteroaryl moieties present in the above substituents are substituted by one or more groups independently selected from alkyl, haloalkyl, aryl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, mercapto, alkylthio, haloalkylthio and arylthio groups;
      • R2 is a substituted phenyl group, a substituted phenylalkyl group, a substituted or unsubstituted phenylalkenyl group or a substituted or unsubstituted phenylalkynyl group;
      • where said alkyl, alkenyl or alkynyl moiety of said phenylalkyl, phenylalkenyl or phenylalkynyl group is a straight or branched chain moiety;
      • R2′ is H, methyl, ethyl or propyl, where said methyl, ethyl or propyl is unsubstituted or substituted with halo or hydroxyl;
      • X is
        Figure US20050250707A1-20051110-C00019
      •  wherein Rx is H or one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyl, alkylenedioxy, di-haloalkylenedioxy, alkylamino, dialkylamino, alkylthio and haloalkylthio;
      • Z is S, O, SO, SO2, CH2 or CFH;
      • R3 is H;
      • R4, R5, R6 and R7 are independently selected from H or methyl; and
      • R8 and R8′ are independently selected from H, halogen, methyl, monohalo-methyl, dihalo-methyl and tri-halomethyl;
      • provided that said 5- or 6-membered mono-cyclic heterocycloalkyl, heterocycloalkenyl or heteroaryl group contains at least two heteroatoms; or provided that said alkyl, alkenyl or alkynyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more substituents selected from halo or keto; or
      • provided that said substituted phenyl group or phenyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more substituents other than halo or methyl, where said one or more substituents is independently selected from haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkoxyalkyl, alkylcarbonylalkyl, haloalkoxyalkyl, aryloxyalkyl, alkylthioalkyl, haloalkylthioalkyl, arylthioalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, nitro, amino, cyano, hydroxyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, alkylenedioxy, aryloxy, cycloalkoxy, cycloalkylalkoxy, cycloalkenyloxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenoxy, heterocycloalkenylalkoxy, heteroaryloxy, alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, arylcarbonyl, arylcarbonyloxy, aryloxycarbonyl, cycloalkylcarbonyl, cycloalkylcarbonyloxy, cycloalkyoxycarbonyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heterocycloalkylcarbonyl, heterocycloalkylcarbonyloxy, heterocycloalkyoxycarbonyl, carboxyl, carbamoyl, formyl, keto, thioketo, sulfo, alkylamino, cycloalkylamino, arylamino, heterocycloalkylamino, heteroarylamino, dialkylamino, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocycloalkylaminocarbonyl, heteroarylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, cycloalkylaminothiocarbonyl, arylaminothiocarbonyl, heterocycloalkylaminothiocarbonyl, heteroarylaminothiocarbonyl, dialkylaminothiocarbonyl, alkylsulfonyl, arylsulfonyl, alkylsulfenyl, arylsulfenyl, alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heterocycloalkylcarbonylamino, heteroarylcarbonylamino, alkylthiocarbonylamino, cycloalkylthiocarbonylamino, arylthiocarbonylamino, heterocycloalkylthiocarbonylamino, heteroarylthiocarbonylamino, alkylsulfonyloxy, arylsulfonyloxy, alkylsulfonylamino, arylsulfonylamino, mercapto, alkylthio, haloalkylthio, arylthio and heteroarylthio groups, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl moieties present in the above substituents are unsubstituted or substituted by one or more groups independently selected from alkyl, haloalkyl, halogen, hydroxyl, alkoxy, haloalkoxy, alkylthio and haloalkylthio groups;
      • or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof. If the phenyl group or phenyl moiety of R2 contains more than one substituent, the substituents may be the same or different, and may be independently selected from the above-described substituents.
  • More specifically, this invention relates to compounds useful for inhibiting the activity of HIV-protease of Formula I, above, wherein:
      • R1 is phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl, where said phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, halogen, and hydroxyl;
      • R2 is a substituted phenylalkyl group, where said alkyl moiety of said substituted phenylalkyl group is a straight or branched chain alkyl moiety;
      • R2′ is H, methyl, ethyl or propyl, where said methyl, ethyl or propyl is unsubstituted or substituted with hydroxyl;
      • X is
        Figure US20050250707A1-20051110-C00020
      •  wherein Rx is H, halogen, or alkoxy;
      • Z is S, O, CH2 or CFH;
      • R3, R4, R5, R8 and R8′ are each H; and
      • R6 and R7 are independently selected from H or methyl;
      • provided that R1 is selected from isoxazolyl, pyrazolyl, thiazolyl or tetrahydropyridazinyl, where said is isoxazolyl, pyrazolyl, thiazolyl or tetrahydropyridazinyl is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, halogen, and hydroxyl when R2 is a substituted or unsubstituted phenylalkyl group or
      • provided that R1 is selected from phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl when R2 is a substituted phenylalkyl group and said phenyl moiety of said substituted phenylalkyl group comprises one or more substituents other than halo or methyl, where said one or more substituents is independently selected from haloalkyl, amino, hydroxyl, alkoxy, haloalkoxy, alkylenedioxy, di-haloalkylenedioxy, cycloalkylalkyloxy, dialkylamino, alkylsulfonyl and alkylthio;
      • or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
  • In preferred embodiments, this invention relates to compounds of Formula I, above, wherein:
  • R1 is phenyl, where said phenyl is substituted with one or more substituents independently selected from methyl, halogen or hydroxyl;
      • R2 is a substituted phenylalkyl group, where said alkyl moiety of said substituted phenylalkyl group is a straight or branched chain alky moiety;
      • where said phenyl moiety of said substituted phenylalkyl group comprises one or more substituents other than halo or methyl, where said one or more substituents is independently selected from trifluoromethyl, amino, hydroxyl, C1-C4alkoxy, alkylenedioxy, di-fluoro-alkylenedioxy, cyclopropylmethoxy, di-methyl-amino, methanesulfonyl and methylthio;
      • R2′ is H, methyl or ethyl;
      • X is
        Figure US20050250707A1-20051110-C00021
      •  wherein Rx is H;
      • Z is S or O; and
      • R3, R4, R5, R6, R7, R8 and R8′ are each H;
      • or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
  • All compounds of this invention contain at least one chiral center and may exist as single stereoisomers (e.g., single enantiomers or single diastereomers), any mixture of stereosisomers (e.g., any mixture of enantiomers or diastereomers) or racemic mixtures thereof. All such single stereoisomers, mixtures and racemates are intended to be encompassed within the broad scope of the present invention. Compounds identified herein as single stereoisomers are meant to describe compounds that are present in a form that contains at least 90% of a single stereoisomer of each chiral center present in the compounds. Where the stereochemistry of the chiral carbons present in the chemical structures illustrated herein is not specified, the chemical structure is intended to encompass compounds containing either stereoisomer of each chiral center present in the compound. Preferably, however, the inventive compounds are used in optically pure, that is, stereoisomerically pure, form or substantially optically pure (substantially stereoisomerically pure) form. As used herein, the term “stereoisomeric” purity (or “optical” purity) refers to the “enantiomeric” purity and/or “diastereomeric” purity of a compound. Compounds that are substantially enantiomerically pure contain at least 90% of a single isomer and preferably contain at least 95% of a single isomer of each chiral center present in the enantiomer. Compounds that are substantially diastereomerically pure contain at least 90% of a single isomer of each chiral center present in the diastereomer, and preferably contain at least 95% of a single isomer of each chiral center. More preferably, the substantially enantiomerically and diastereomerically pure compounds in this invention contain at least 97.5% of a single isomer and most preferably contain at least 99% of a single isomer of each chiral center in the compound. The term “racemic” or “racemic mixture” refers to a mixture of equal amounts of enantiomeric compounds, which encompasses mixtures of enantiomers and mixtures of enantiomeric diastereomers. The compounds of this invention may be obtained in stereoisomerically pure (i.e., enantiomerically and/or diastereomerically pure) or substantially stereoisomerically pure (i.e., substantially enantiomerically and/or diastereomerically pure) form. Such compounds may be obtained synthetically, according to the procedures described herein using optically pure or substantially optically pure materials. Alternatively, these compounds may be obtained by resolution/separation of a mixture of stereoisomers, including racemic mixtures, using conventional procedures. Exemplary methods that may be useful for the resolution/separation of stereoisomeric mixtures include chromatography and crystallization/re-crystallization. Other useful methods may be found in “Enantiomers, Racemates, and Resolutions,” J. Jacques et al., 1981, John Wiley and Sons, New York, N.Y., the disclosure of which is incorporated herein by reference. Preferred stereoisomers of the compounds of this invention are described herein.
  • Especially preferred embodiments of this invention comprise compounds, wherein the stereogenic centers (chiral carbons) have the following designated stereochemistry:
    Figure US20050250707A1-20051110-C00022
  • More preferably, at least two of the stereogenic centers have the following designated stereochemistry:
    Figure US20050250707A1-20051110-C00023
  • Even more preferably, at least three of the stereogenic centers have the following designated stereochemistry:
    Figure US20050250707A1-20051110-C00024
  • Exemplary compounds of this invention include:
    Figure US20050250707A1-20051110-C00025
    Figure US20050250707A1-20051110-C00026
    Figure US20050250707A1-20051110-C00027
    Figure US20050250707A1-20051110-C00028
    Figure US20050250707A1-20051110-C00029
    Figure US20050250707A1-20051110-C00030
    Figure US20050250707A1-20051110-C00031
    Figure US20050250707A1-20051110-C00032
    Figure US20050250707A1-20051110-C00033
    Figure US20050250707A1-20051110-C00034
    Figure US20050250707A1-20051110-C00035
      • and the prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts and solvates thereof.
  • The invention is also directed to the intermediates of Formula II, which are useful in the synthesis of certain compounds of Formula I:
    Figure US20050250707A1-20051110-C00036
  • The HIV protease inhibitor compounds of this invention include prodrugs, the pharmaceutically active metabolites, and the pharmaceutically acceptable salts and solvates thereof. In preferred embodiments, the compounds of Formula I, prodrugs, pharmaceutically acceptable salts, and pharmaceutically active metabolites and solvates thereof demonstrate an HIV-protease inhibitory activity, corresponding to Ki of at least 100 nM, an EC50 of at least 10 mM or an IC50 of at least 10 mM. Preferably, the compounds of this invention demonstrate an HIV-protease inhibitory activity, corresponding to a Ki of at least 10 nM, an EC50 of at least 1 mM or an IC50 of at least 1 mM. More preferably, the compounds of this invention demonstrate an HIV-protease inhibitory activity against mutant strains of HIV, corresponding to a Ki of at least 100 nM, an EC50 of at least 10 mM or an IC50 of at least 10 mM. Even more preferably, the compounds of this invention demonstrate protease inhibitory activity against mutant strains corresponding to a Ki of at least 10 nM, an EC50 of at least 1 mM or an IC50 of at least 1 mM.
  • A “prodrug” is intended to mean a compound that is converted under physiological conditions or by solvolysis or metabolically to a specified compound that is pharmaceutically active. A prodrug may be a derivative of one of the compounds of this invention that contains a moiety, such as for example —CO2R, —PO(OR)2 or —C═NR, that may be cleaved under physiological conditions or by solvolysis. Any suitable R substituent may be used that provides a pharmaceutically acceptable solvolysis or cleavage product. A prodrug containing such a moiety may be prepared according to conventional procedures by treatment of a compound of this invention containing, for example, an amido, carboxylic acid, or hydroxyl moiety with a suitable reagent. A “pharmaceutically active metabolite” is intended to mean a pharmacologically active compound produced through metabolism in the body of a specified compound. Prodrugs and active metabolites of compounds of this invention of the above-described Formulas may be determined using techniques known in the art, for example, through metabolic studies. See, e.g., “Design of Prodrugs,” (Bundgaard, ed.), 1985, Elsevier Publishers B.V., Amsterdam, The Netherlands. The following is an example of a prodrug that can be converted to the compound of this invention under physiological conditions, by solvolysis or metabolically:
    Figure US20050250707A1-20051110-C00037
  • A “pharmaceutically acceptable salt” is intended to mean a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycollates, tartrates, methane-sulfonates (mesylates), propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates. A “solvate” is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound. Examples of solvates include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine. In the case of compounds, salts, or solvates that are solids, it is understood by those skilled in the art that the inventive compounds, salts, and solvates may exist in different crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.
  • The present invention is also directed to a method of inhibiting HIV protease activity, comprising contacting the protease with an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof. For example, HIV protease activity may be inhibited in mammalian tissue by administering a compound of Formula I or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof. More preferably, the present method is directed at inhibiting HIV-protease activity. “Treating” or “treatment” is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, that is alleviated by the inhibition of the activity of HIV proteases. The methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example, as a prophylactic. The activity of the inventive compounds as inhibitors of HIV protease activity may be measured by any of the suitable methods known to those skilled in the art, including in vivo and in vitro assays. Examples of suitable assays for activity measurements are escribed herein. Administration of the compounds of the Formula I and their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates may be performed according to any of the generally accepted modes of administration available to those skilled in the art. Illustrative examples of suitable modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal.
  • An inventive compound of Formula I or a pharmaceutically acceptable salt, prodrug, active metabolite, or solvate thereof may be administered as a pharmaceutical composition in any pharmaceutical form recognizable to the skilled artisan as being suitable. Suitable pharmaceutical forms include solid, semisolid, liquid, or lyophilized formulations, such as tablets, powders, capsules, suppositories, suspensions, liposomes, and aerosols. Pharmaceutical compositions of the invention may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use or mode of administration. Acceptable methods of preparing suitable pharmaceutical forms of the pharmaceutical compositions may be routinely determined by those skilled in the art. For example, pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.
  • The present invention includes pharmaceutical compositions useful for inhibiting HIV protease, comprising an effective amount of a compound of this invention, and a pharmaceutically acceptable carrier. Pharmaceutical compositions useful for treating infection by HIV, or for treating AIDS or ARC, are also encompassed by the present invention, as well as a method of inhibiting HIV protease, and a method of treating infection by HIV, or of treating AIDS or ARC. Additionally, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of an HIV infection/AIDS treatment agent selected from:
      • 1) an HIV/AIDS antiviral agent,
      • 2) an anti-infective agent, and
      • 3) an immunomodulator.
  • The present invention also includes the use of a compound of the present invention as described above in the preparation of a medicament for (a) inhibiting HIV protease, (b) preventing or treating infection by HIV, or (c) treating AIDS or ARC.
  • The present invention further includes the use of any of the HIV protease inhibiting compounds of the present invention as described above in combination with one or more HIV infection/AIDS treatment agents selected from an HIV/AIDS antiviral agent, an anti-infective agent, and an immunomodulator for the manufacture of a medicament for (a) inhibiting HIV protease, (b) preventing or treating infection by HIV, or (c) treating AIDS or ARC, said medicament comprising an effective amount of the HIV protease inhibitor compound and an effective amount of the one or more treatment agents.
  • Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions. Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid. Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water. The carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension. A dose of the pharmaceutical composition contains at least a therapeutically effective amount of the active compound (i.e., a compound of Formula I or a pharmaceutically acceptable salt, prodrug, active metabolite, or solvate thereof), and preferably is made up of one or more pharmaceutical dosage units. The selected dose may be administered to a mammal, for example, a human patient, in need of treatment mediated by inhibition of HIV protease activity, by any known or suitable method of administering the dose, including: topically (for example, as an ointment or cream), orally, rectally (for example, as a suppository), parenterally (by injection) or continuously by intravaginal, intranasal, intrabronchial, intraaural, or intraocular infusion. A “therapeutically effective amount” is intended to mean the amount of an inventive agent that, when administered to a mammal in need thereof, is sufficient to effect treatment for disease conditions alleviated by the inhibition of the activity of one or more variant of the HIV protease. The amount of a given compound of the invention that will be therapeutically effective will vary depending upon factors such as the particular compound, the disease condition and the severity thereof, the identity of the mammal in need thereof, which amount may be routinely determined by artisans.
  • The compounds of this invention are also useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants that are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV protease, e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these purposes.
    • General Synthetic Methods
  • Preferably, the inventive compounds are prepared by the methods of the present invention, including the General Methods shown below. When stereochemistry is not specified in chemical structures, either stereocenter may be utilized. The following abbreviations also apply: Boc (tert-butoxycarbonyl), Ac (acetyl), Cbz (benzyloxycarbonyl), DMB (2,4-dimethoxybenzyl), TBS (tert-butyldimethylsilyl), TBDPS (tert-butyldiphenylsilyl), Ms (methanesulfonate), Ts (toluenesulfonate), Bn (benzyl), and Tr (triphenylmethyl)
  • All reactions were performed in septum-sealed flasks under a slight positive pressure of argon unless otherwise noted. All commercial reagents and solvents were used as received from their respective suppliers with the following exceptions: Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl prior to use. Dichloromethane (CH2Cl2) was distilled from calcium hydride prior to use. Flash chromatography was performed using silica gel 60 (Merck art. 9385). 1H NMR spectra were recorded at 300 MHz utilizing a Varian UNITYplus 300 spectrometer. Chemical shifts are reported in ppm (δ) downfield relative to internal tetramethylsilane, and coupling constants are given in Hertz. Infrared absorption spectra were recorded using a Perkin-Elmer 1600 series FTIR spectrometer. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, Ga. Melting points are uncorrected.
  • All P2′ amine variants mentioned in General Methods A-E described hereinbelow were either purchased and used directly or synthesized as follows.
    Method A: Representative Procedure for Reduction of Ketones to Alcohols.
    Figure US20050250707A1-20051110-C00038
  • 6,7-Dihydro-4-(5H)-benzofuranone (1) (1.00 g 7.34 mmol) was dissolved in methanol (55 mL). The mixture was cooled to 0° C. and NaBH (0.31 g, 8.08 mmol) was added in portions. The reaction was stirred for 2 h at 0° C. at which time the methanol was evaporated. The residue was dissolved in EtOAc and poured into NaHCO3 (saturated aqueous) and extracted with EtOAc (3×10 mL). The combined organic extracts were washed with brine (10 mL), passed over a short plug of Na2SO4, and concentrated in vacuo to give 2 (1.01 g, 99%, as a mixture of isomers) as a pale yellow, thick oil, which was of sufficient quality to be advanced to the next step without further purification. Rf (50% EtOAc/hexanes): 0.53.
    Method B: Representative Procedure for Reduction of Acids to Alcohols.
    Figure US20050250707A1-20051110-C00039
  • Tiglic acid (1) (20.0 g, 0.200 mol) was dissolved in ether (80 ml) and added dropwise over 30 min to a suspension of LiAlH4 (15.0 g, 0.417 mol) in ether (80 ml) at 0° C. and the reaction mixture was allowed to warm to room temperature. After 3 h the mixture was re-cooled to 0° C. and quenched slowly by the addition of H2O (15 ml), 15% NaOH (15 ml) and H2O (15 ml). The reaction mixture was filtered to remove the granular precipitate and washed thoroughly with ether. The filtrate was washed successively with 1N HCl, NaHCO3 (saturated aqueous), and brine. The combined organic layers were dried over MgSO4 and concentrated in vacuo to give (E)-2-methyl-but-2-en-1-ol (2) as a clear oil (12.8 g, 74%).
    Method C: Representative Procedure for Alkylation of Phenols Alcohols.
    Figure US20050250707A1-20051110-C00040
  • 3-Hydroxybenzylalcohol (1) (0.500 g 4.03 mmol) was dissolved in DMF (2 mL) at ambient temperature. Ethyl bromide (0.900 mL, 12.1 mmol) and finely crushed K2CO3 (2.78 g, 20.1 mmol) were added and the reaction mixture was stirred for 5 h. The DMF was then removed in vacuo and the residue was partitioned between EtOAc and H2O, and extracted with EtOAc (3×10 mL). The organic layers were washed with brine (10 mL) and passed over a short plug of Na2SO4. The solvents were removed in vacuo to give alcohol 2 (0.55 g, 90%) as a pale yellow, thick oil, which was of sufficient quality to be advanced to the next step without further purification. Rf (40% EtOAC/hexanes): 0.69.
    Method D: Representative Procedure for Conversion of Alcohols to Amines.
    Figure US20050250707A1-20051110-C00041
  • 3-Ethoxy-phenyl-methanol (1) (1.23 g 8.08 mmol) was dissolved in CH2Cl2 (10 mL) at ambient temperature and diphenylphosphoryl azide (2.67 g, 9.70 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (1.45 mL, 9.70 mmol) were added. The mixture was stirred for 5 h at which time the CH2Cl2 was removed in vacuo and the crude residue was partitioned between EtOAc and H2O and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), passed over a short plug of Na2SO4, and concentrated in vacuo to give a yellow oil that was loaded directly onto a flash silica gel column and was quickly eluted with 10% EtOAc/hexanes. The solvents were removed in vacuo to give azide 2 (1.43 g, 84%) as a colorless oil Rf (30% EtOAc/hexanes): 0.79.
  • 1-Azidomethyl-3-ethoxy-benzene (2) (1.19 g 6.71 mmol) was dissolved in MeOH (15 mL) and palladium 10% on activated carbon, wet (20% in weight) was added. The reaction was hydrogenated for 30 min at 40 PSI in a Parr Hydrogenator. The black suspension was then filtered through compacted celite and the methanol was removed in vacuo to give amine 3 (0.88 g, 88%) as a pale yellow, thick oil, which was of sufficient quality to be advanced to the coupling reactions without further purification.
    Method E: Representative Procedure for Conversion of Alcohols to Bromides.
    Figure US20050250707A1-20051110-C00042
  • Cis-2-penten-1-ol (1) (1.00 g, 11.6 mmol) and carbon tetrabromide (3.85 g, 13.9 mmol) were dissolved in CH2Cl2 (75 mL). The mixture was cooled to 0° C. and triphenylphosphine (3.65 mL, 13.9 mmol) dissolved in CH2Cl2 (50 mL) was added dropwise. The mixture was allowed to warm to room temperature and was stirred overnight. The CH2Cl2 was removed in vacuo and the crude residue was loaded directly onto a flash silica gel column and eluted quickly with 20% EtOAc/hexanes. The solvents were removed in vacuo to give bromide 2 (1.53 g, 88%) as a colorless volatile oil. Rf (30% EtOAC/hexanes): 0.89.
    Method F: Representative Procedure for Conversion of Bromides to Amines.
    Figure US20050250707A1-20051110-C00043
  • A mixture of bromide 1 (3.00 g, 20.1 mmol), di-tert-butyl-iminodicarboxylate (4.8 g, 22 mmol), and K2CO3 (3.10 g, 80.4 mmol) in DMF (30 ml) was stirred at ambient temperature overnight. The mixture was partitioned between 1N HCl and EtOAc. The organic layer was washed with H2O and brine, then dried over NaSO4. Concentration in vacuo affored a yellow oil which upon purification by flash column chromatography (hexanes to 5% EtOAc/Hexane gradient) yielded protected amine 2 as a clear oil (2.0 g, 35%).
  • A mixture of the diBOC amine 2 (2.0 g, 7.0 mmol), trifluoroacetic acid (2.7 ml, 35 mmol) and CH2Cl2 (40 ml) was stirred at ambient temperature overnight. The reaction mixture was concentrated in vacuo to give the TFA salt of (E)-2-methyl-but-2-enylamine (3).
    Method G: Representative Procedure for Reduction of Aromatic Nitro Groups by Hydrogenation.
    Figure US20050250707A1-20051110-C00044
  • Compound 1 (2.04, 5.79 mmol) was dissolved in EtOAc (20 mL) and palladium 10% on activated carbon, wet (20% in weight) was added. The reaction was hydrogenated for 4 h at 45 PSI in a Parr Hydrogenator. The black suspension was then filtered through compacted celite and the methanol was removed in vacuo to give aniline 2 (1.65 g, 88%) as a pale yellow, thick oil, which was of sufficient quality to be advanced to the acetylation reaction without further purification.
    Method H: Representative Procedure for Acetylation of Anilines.
    Figure US20050250707A1-20051110-C00045
  • Aniline 1 (1.65 g, 5.12 mmol) was dissolved in CH2Cl2 (25 mL) at ambient temperature. Acetyl chloride (0.48 g, 6.14 mmol) and N,N-Diisopropylethylamine (0.79 g, 6.14 mmol) were added, and the reaction was stirred overnight. The CH2Cl2 was removed in vacuo and the crude residue was partitioned between EtOAc and 5% KHSO4 and extracted with EtOAc (3×10 mL). The combined organic extracts were washed with NaHCO3 (saturated aqueous, 10 mL), brine (10 mL), and dried over Na2SO4. The solvents were removed in vacuo to give an orange oil which was of sufficient quality to be advanced to the next step without further purification. Rf (50% EtOAC/hexanes): 0.42.
    Method I: Representative Procedure for Reduction of Aldehydes to Amines.
    Figure US20050250707A1-20051110-C00046
  • Hydroxylamine hydrochloride (758 mg, 10.7 mmol) and pyridine (2.16 mL) was added to a solution of 2,2-difluoro-5-formyl benzodioxole (1) (2.00 g, 10.7 mmol) in MeOH (10 mL). After 18 hours the MeOH was removed in vacuo. The reaction mixture was diluted with EtOAc and was washed sequentially with H2O, 10% W/V CuSO4, and brine and then dried over MgSO4. The solution was concentrated in vacuo. The hydroxy imine was purified by column chromatography using 20% EtOAc/Hexanes to give 1.37 g (64% yield) of a white solid. Imine was then subjected to LAH reduction as described above to provide amine 3.
  • The following amines were synthesized for the corresponding example numbers:
    • EXAMPLE A26
  • Figure US20050250707A1-20051110-C00047
  • Amine was generated by alkylation of 3-hydroxybenzyl alcohol with ethyl bromide as describe in method C above followed by conversion of the alcohol to the amine as described in method D above provided desired amine.
    • EXAMPLE A43
  • Figure US20050250707A1-20051110-C00048
  • Amine was generated as described above for Example A43 using propylbromide as the alkylating agent
    • EXAMPLE A33
  • Figure US20050250707A1-20051110-C00049
  • Amine was generated from displacement of bromide in 3-nitrobenzylbromide with di BOC amine as described in method F above. Reduction of the nitro moiety to the aniline (method G above) followed by acetylation (method H above) and BOC removal (method F above) provided desired amine.
    • EXAMPLE A36, EXAMPLE A37 And EXAMPLE A40
  • Figure US20050250707A1-20051110-C00050
  • Amines were generated from conversion of the corresponding primary alcohols as described in method E above. Displacement of the bromide with di BOC amine and deprotection with TFA (method F above) provided the desired amines.
    • EXAMPLE A39
  • Figure US20050250707A1-20051110-C00051
  • Amine was generated from 3-dimethylaminobenzyl alcohol as described in method D above.
    • EXAMPLE A34
  • Figure US20050250707A1-20051110-C00052
  • Amine was generated by reduction of the corresponding methyl ester to the primary alcohol (Wipf, J. Org Chem. 1994, 59, 4875-86.). Conversion to the bromide (method E above) followed by displacement with diBOC amine and deprotection (method F above) provided desired amine.
    • EXAMPLE A35
  • Figure US20050250707A1-20051110-C00053
  • Amine was generated from the corresponding carboxylic acid. Reduction of the acid as described in method B above followed by bromide displacement as described in method E above gave the primary bromide. Conversion of the bromide to the primary amine followed the procedure described in method F above.
    • EXAMPLE A42
  • Figure US20050250707A1-20051110-C00054
  • Amine was generated from 3-benzyloxybenzyl alcohol. Conversion to the azide and reduction of both the azide and benzyl protecting group were accomplished using method D as described above with longer hydrogenation time.
    • EXAMPLE A44
  • Figure US20050250707A1-20051110-C00055
  • Amine was generated by LiAlH4 reduction of 2-cyanophenol (Ludeman, S. M., et. al. J. Med. Chem. 1975, 18, 1252-3.).
    • EXAMPLE A50
  • Figure US20050250707A1-20051110-C00056
  • Amine was generated from the condensation of o-tolualdehyde with 2-aminoethanol followed by reduction with sodium borohydride (Tetrahedron Assym. 1997, 8, 2367-74.).
    • EXAMPLE A48
  • Figure US20050250707A1-20051110-C00057
  • Amine was generated from the corresponding aldehyde by the reductive amination procedure described in method I above.
    • EXAMPLE A7
  • Figure US20050250707A1-20051110-C00058
  • Amine was generated by a reductive amination with the corresponding aldehyde (Arch. Pharm. 1987, 320, 647-54.).
    • EXAMPLE A49
  • Figure US20050250707A1-20051110-C00059
  • Amine was generated on the thiazolidine core as follows:
  • Diphenylchlorophosphate (1.0 ml, 4.2 mmol) followed by triethylamine (0.59 ml, 4.2 mmol) were added to a cooled 0° C. solution of BOC-DMTA 1 (1.0 g, 3.8 mmol) in EtOAc (10 ml). The mixture was stirred for 1 h and at which time triethylamine (0.59 ml, 4.2 mmol) and ethanolamine (0.25 ml, 4.2 mmol) were added. The reaction was left to stir overnight at ambient temperature and then partitioned between 1N HCl and EtOAc. The organic layer was washed with NaHCO3(saturated aqueous) and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo to a pale yellow oil 2. The oil was stirred with thionyl chloride (2 ml) for 45 min at room temperature. The mixture was concentrated in vacuo and the residual oil was partitioned between 1N NaOH and EtOAc. The organic layer was extracted with 1N HCl (2×20 ml). The combined aqueous layers were made basic with 1N NaOH and then extracted with EtOAc (3×60 ml). The organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo to give (R)-5,5-Dimethyl-thiazolidine-4-carboxylic acid (2-chloro-ethyl)-amide 3 as a clear oil (0.39 g, 55%).
  • The following amines were prepared as described:
    Figure US20050250707A1-20051110-C00060
    • EXAMPLE A31 EXAMPLE A32 EXAMPLE A38
  • The above amines were prepared according to Carlsen, H. J., J. Heterocycle Chem. 1997, 34, 797-806.
    Figure US20050250707A1-20051110-C00061
    • EXAMPLE A41
  • The above amine was prepared according to O'Brien, P. M., J. Med. Chem. 1994, 37, 1810-1822.
    Figure US20050250707A1-20051110-C00062
    • EXAMPLE A7
  • The above amine was prepared according to Weinheim, G. Arch. Pharm. 1987, 320, 647-654.
    Figure US20050250707A1-20051110-C00063
    The synthesis of compounds with the general structure 5 is as follows. The boc-protected thiazolidine carboxylic acid 1 is coupled to the requisite amines 2 to yield amino amides 3 using a two step process. The process includes treatment of 1 with 2 in the presence of either diphenylchlorophosphate or HATU, followed by exposure to methane sulfonic acid. Final compounds 5 are obtained by a DCC-mediated coupling of 3 and 4 followed by deprotection of the P2 phenol. Final compounds were purified either by flash chromatography or preparative HPLC.
    Figure US20050250707A1-20051110-C00064
    An alternative approach to the general structure 5 is as follows. The thiazolidine ester 6 is coupled to acid 7 under carbodiimide reaction conditions, resulting in product 8 which is converted to acid 9 by mild base hydrolysis. Acid 9 is combined with various amines, using diphenylphosphoryl azide, followed by cleavage of the P2 acetate to yield final compounds 5. The products were purified by either flash chromatography or preparative HPLC.
    Figure US20050250707A1-20051110-C00065
    • EXAMPLE A1 3-[2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid, (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide
  • The title compound was prepared as follows. (R)-5,5-Dimethyl-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 1 (0.3 g, 1.15 mmol) was dissolved in EtOAc (3 mL) and cooled to 0° C. Diphenyl chlorophosphate (0.26 mL, 1.26 mmol) was added followed by TEA (0.18 mL, 1.26 mmol). The reaction was stirred at 0° C. for 1 h, and treated with (S)-1,2,3,4-Tetrahydro-1-naphthylamine (0.19 g, 1.26 mmol). The reaction mixture was stirred at room temperature overnight, then partitioned between 1N HCl (5 mL) and EtOAc (10 mL). The organic layer was washed with saturated NaHCO3, brine, dried over Na2SO4 and concentrated to a light yellow oil. The resulting crude oil was dissolved in EtOAc (5 mL) and the cooled to 0° C. Methanesulfonic acid (0.36 mL, 5.32 mmol) was added and the solution was stirred at 0° C. for 15 minutes, then at room temperature for 1 h. The mixture was re-cooled to 0° C. and quenched with 5% Na2CO3 (5 mL) then extracted with EtOAc (10 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo to give 3a as a yellow oil. The yellow oil 3a (0.34 g, 1.15 mmol) was dissolved in EtOAc (12 mL). AMB-AHPBA 4 (0.40 g, 1.09 mmol) was added followed by HOBt (0.15 g, 1.09 mmol). The mixture was stirred at room temperature 1 h, then cooled to 0° C. DCC (0.24 g, 1.15 mmol) was slowly added as solution in EtOAc (6 mL). The mixture was warmed to room temperature and stirred overnight. The mixture was filtered and the filtrate was washed with 1N HCl (10 mL), saturated NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4 and concentrated to give a crude white solid (contaminated with DCU). The DCU was removed by flash chromatography (30% to 50% EtOAc in hexanes) to provide a white solid, which was dissolved in MeOH (2 mL) and treated with 4N HCl in 1,4-dioxane (0.26 mL, 1.1 mmol). The reaction was stirred at room temperature overnight then partitioned between 1N HCl (10 mL) and EtOAc (10 mL). The organic layer was washed with saturated NaHCO3, dried over Na2SO4 and concentrated to a residue which was purified by flash chromatography (60% EtOAc in hexanes) to provide the title compound as a white solid: mp=125-126° C.; IR (cm−1) 3320, 2932, 1704, 1644, 1530, 1454, 1361, 1284; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.28 (d, J=8.6, 1H), 8.21 (d, J=8.8, 1H), 7.35-6.91 (m, 10H), 6.76 (d, J=8.0, 1H), 6.54 (d, J=7.5, 1H), 5.34 (d, J=6.0, 1H), 5.13 (d, J=9.0, 1H), 5.02 (d, J=9.0, 1H), 4.60-4.30 (m, 4H), 2.81-2.68 (m, 4H), 1.81 (s, 3H), 1.78-1.60 (m, 4H), 1.48 (s, 3H), 1.45 (s, 3H); Anal. Calcd for C34H39N3O5S.1.5H2O: C, 64.95; H, 6.73; N, 6.68. Found: C, 64.88; H, 6.31; N, 6.18.
    • EXAMPLE A2 (R)-3-((2S,3R)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-methoxy-benzylamide
  • Figure US20050250707A1-20051110-C00066
  • White solid: mp=108-110° C.; IR (neat, cm−1) 3310, 2965, 1644, 1586, 1531, 1455, 1359, 1284; 1HNMR (DMSO-d6) δ 9.37 (s, 1H), 8.40 (t, J=6.0, 1H), 8.09 (d, J=8.1, 1H), 7.31-6.52 (m, 12H), 5.49 (d, J=6.0, 1H), 5.12 (d, J=9.3, 1H), 5.00 (d, J=9.3, 1H), 4.44-4.35 (m, 3H), 4.42 (s, 1H), 4.09 (dd, J=15.0, 6.0, 1H), 3.69 (s, 3H), 2.87-2.67 (m, 2H), 1.82 (s, 3H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. Calcd for C32H37N3O6S.0.75H2O: C, 63.50; H, 6.41; N, 6.94. Found: C, 63.60; H, 6.23; N, 6.80.
  • The following examples were prepared by the specific method outlined above using the requisite amine 2.
    • EXAMPLE A3 (R)-3-(2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methoxy-benzylamide
  • Figure US20050250707A1-20051110-C00067
  • White solid: mp=123-125° C.; IR (cm−1) 3318, 2965, 1644, 1525, 1495, 1464, 1286, 1246, 1120, 1030; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.26 (t, J=5.9, 1H), 8.14 (d. J=8.0, 1H), 7.39-7.13 (m, 6H), 6.95-6.76 (m, 5H), 6.53 (d, J=7.5, 1H), 5.49 (d, J=6.0, 1H), 5.13 (d, J=9.0, 1H), 5.01 (d, J=9.0, 1H), 4.47 (s, 1H), 4.41-4.16 (m, 4H), 3.78 (s, 3H) 2.90-2.62 (m, 2H), 1.81 (s, 3H), 1.49 (s, 3H). 1.32 (s, 3H); Anal. Calcd for C32H37N3O6S.0.75H2O: C, 63.50; H, 6.41; N, 6.94. Found: C, 63.68; H, 6.20; N, 6.54.
    • EXAMPLE A4 3-(2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-trifluoromethyl-benzylamide
  • Figure US20050250707A1-20051110-C00068
  • White solid: mp=108-110° C.; IR (cm−1) 3308, 3065, 1646, 1540, 1456, 1362, 1329, 1284, 1165, 1125, 1074; 1H NMR (DMSO-d6) δ 9.38 (s, 1H), 8.56 (t, J=6.0, 1H), 8.12 (d, J=8.2, 1H), 7.65 (s, 1H), 7.60-7.47 (m, 3H), 7.28-7.13 (m, 5H), 6.96-6.92 (m, 1H), 6.77 (d, J=8.0, 1H), 6.53 (d, J=7.5, 1H), 5.45 (d, J=6.0, 1H), 5.14 (d, J=9.2, 1H), 5.00 (d, J=9.2, 1H), 4.53-4.41 (m, 4H), 4.22 (dd, J=16.0, 6.0, 1H), 2.86-2.66 (m, 2H), 1.81 (s, 3H), 1.49 (s, 3H), 1.31 (s, 3H); Anal. Calcd for C32H34F3N3O5S: C, 61.04; H, 5.44; N, 6.67. Found: C, 61.03; H, 5.56; N, 6.51.
    • EXAMPLE A5 3-(2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methyanoyl]amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxlic acid fluoro trifluoromethyl-benzylamide
  • Figure US20050250707A1-20051110-C00069
  • 1H NMR (DMSO-d6) δ 9.33 (s, 1H), 8.69 (t, J=5.6, 1H), 8.12-6.56 (m, 1H), 5.50 (d, J=6.0, 1H), 5.22 (d, J=9.3, 1H), 5.06 (d, J=9.3, 1H), 4.60-4.36 (m, 5H), 4.50 (s, 1H), 2.89-2.67 (m, 2H), 1.83 (s, 3H), 1.55 (s, 3H), 1.39 (s, 3H); Anal. Calcd for C32H33N3O5SF4: C, 59.34; H, 5.14; N, 6.49; S, 4.95. Found: C, 59.06; H, 5.31; N, 6.22; S, 4.66.
    • EXAMPLE A6 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 4-methoxy-benzylamide
  • Figure US20050250707A1-20051110-C00070
  • IR (neat cm−1) 3335, 2920, 1641, 1516, 1463, 1374, 1285, 1249, 1172, 1118; 1H NMR (DMSO-d6) δ 9.38 (s, 1H), 8.37 (t, J=5.5, 1H), 8.12 (d, J=8.2, 1H), 7.33-7.13 (m, 7H), 6.94 (t, J=7.7, 1H), 6.84-6.79 (m, 3H), 6.54 (d, J=7.0, 1H), 5.48 (d, J=6.6, 1H), 5.12 (d, J=9.2, 1H), 5.00 (d, J=9.2, 1H), 4.49-4.42 (m, 3H), 4.32 (dd, J=6.2, 14.8, 6, 1H), 4.09 (dd, J=14.8, 5.3, 1H), 3.67 (s, 3H), 2.87-2.68 (m, 2H), 1.82 (s, 3H), 1.48 (s, 3H), 1.32 (s, 3H); HRMS (ESI) m/z calcd for C32H37N3O6SNa (M+Na)+ 614.2301, found 614.2305; Anal. Calcd for C32H37N3O6S.0.75H2O: C, 63.50; H, 6.41; N, 6.94. Found: C, 63.65; H, 6.43; N, 6.74.
    • EXAMPLE A7 3-[2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiiazolidine-4-carboxylic acid methyl-(2-methyl-benzyl)-amide
  • Figure US20050250707A1-20051110-C00071
  • 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.44 (t, J=7.98, 1H), 8.13-8.07 (m, 2H), 7.34-7.13 (m, 9H), 6.93 (t, J=7.9, 1H), 6.78 (d, J=7.7, 1H), 6.53 (d, J=7.1, 1H), 5.58 (d, J=6.8, 1H), 5.45 (d, J=7.0, 1H), 5.12 (dd J=7.8 8.2 1H), 4.51-4.31 (m, 6H), 2.86-2.67 (m, 2H), 2.19 (s, 3H), 1.81 (s, 3H), 1.51 (s, 3H), 1.34 (s, 3H); Anal. Calcd for C33H39N3O5S.0.37H2O: C, 66.45; H, 6.72; N, 7.15. Found: C, 66.34; H, 7.28; N, 7.45.
    • EXAMPLE A8 3-[2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiiazolidine-4-carboxylic acid methyl-(3-methyl-thiophen-2-ylmethyl)-amide
  • Figure US20050250707A1-20051110-C00072
  • IR (neat or KBr cm−1) 3150, 3000, 2942, 2187, 1712, 1600, 1567, 1505; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.44 (t, J=7.98, 1H), 8.13-8.07 (m, 2H), 7.34-7.13 (m, 5H), 6.93 (t, J=7.9, 1H), 6.78 (d, J=7.7, 1H), 6.53 (d, J=7.1, 1H), 5.45 (d, J=7.0, 1H), 5.12 (dd, J=7.8, 8.2 1H), 4.51-4.31 (m, 4H), 2.86-2.67 (m, 2H), 2.19 (s, 3H), 1.81 (s, 3H), 1.51 (s, 3H), 1.34 (s, 3H); Anal. Calcd for C30H35N3O5S2: calculated C, 61.94 H, 6.06 N, 7.22. Found C, 62.38 H, 6.23, N, 7.17.
    • EXAMPLE A9 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 4-trifluoromethyl-benzylamide
  • Figure US20050250707A1-20051110-C00073
  • IR (neat cm−1) 3343, 2931, 1543, 1530, 1454, 1326, 1122; 1HNMR (DMSO-d6) δ 9.38 (s, 1H), 8.57 (t, J=5.0, 1H), 8.15 (d, J=8.4, 1H), 7.59 (d, J=8.2,2H), 7.50 (d, J=8.2,2H), 7.28-7.13 (m, 5H), 6.93 (t, J=7.5, 1H), 6.77 (d, J=7.7, 1H), 6.54 (d, J=7.3, 1H), 5.50 (s br, 1H), 5.15 (d, J=9.2, 1H), 5.02 (d, J=9.2, 1H), 4.47-4.21 (m, 5H), 2.85-2.67 (m, 2H), 1.81 (s, 3H), 1.51 (s, 3H), 1.34 (s, 3H); ); HRMS (ESI) m/z calcd for C32H34F3N3O5SNa (M+Na)+ 652.2063, found 652.2044; Anal. Calcd for C32H34F 3N3O5S.0.25H2O: C, 60.60; H, 5.48; N, 6.63. Found: C, 60.50; H, 5.29; N, 6.48.
    • EXAMPLE A10 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (2-oxo-2-phenyl-ethyl)-amide
  • Figure US20050250707A1-20051110-C00074
  • 1HNMR (DMSO-d6) δ 9.39 (s, 1H), 8.36 (t, J=4.8, 1H), 8.15 (d, J=8.1, 1H), 7.98 (d, J=7.4, 1H), 7.65 (m, 1H), 7.52 (m, 2H), 7.32-7.11 (m, 6H), 6.93 (t, J=7.9, 1H), 6.76 (d, J=7.9, 1H), 6.54 (d, J=7.5, 1H), 5.42 (d, J=6.4, 1H), 5.08 (d, J=9.3, 1H), 5.02 (d, J=9.0, 1H), 4.78-4.30 (m, 5H), 2.84-2.66 (m, 2H), 1.81 (s, 3H), 1.57 (s, 3H), 1.45 (s, 3H); HRMS (ESI) m/z calcd for C32H35N3O6SNa (M+Na)+ 612.2139, found 612.2141.
    • EXAMPLE A11 3-(2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl-amino}-4-phenyl-butanoyl-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-fluoro-4-trifluoromethyl-benzylamide
  • Figure US20050250707A1-20051110-C00075
  • 1H NMR (DMSO-d6) δ 9.34 (s, 1H), 8.62 (t, J=5.9, 1H), 8.09-6.54 (m, 11H), 5.45 (s br, 1H), 5.18 (d, J=9.2, 1H), 5.03 (d, J=9.2, 1H), 4.55-4.00 (m, 5H), 4.45 (s, 1H), 2.86-2.49 (m, 2H), 1.82 (s, 3H), 1.53 (s, 3H), 1.36 (s, 3H); Anal. Calcd for C32H33N3O5SF4: C, 59.34; H, 5.14; N, 6.49; S, 4.95. Found: C, 59.14; H, 5.29; N, 6.21; S, 4.67.
    • EXAMPLE A12 3-(2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methyanoyl-amino}-4-phenyl-butanoyl)-5,5-dimehtyl-thiazolidine-4-carboxylic acid-2-trifluoromethyl-4-fluoro-benzylamide
  • Figure US20050250707A1-20051110-C00076
  • 1H NMR (DMSO-d6) δ 9.33 (s, 1H), 8.65 (t, J=5.9, 1H), 8.12-6.54 (m, 11H), 5.45 (d, J=6.9, 1H), 5.18 (d, J=9.2, 1H), 5.05 (d, J=9.2, 1H), 4.59-4.34 (m, 5H), 4.50 (s, 1H), 2.85-2.67 (m, 2H), 1.82 (s, 3H), 1.53 (s, 3H), 1.37 (s, 3H); Anal. Calcd for C32H33N3O5SF4: C, 59.34; H, 5.14; N, 6.49; S, 4.95. Found: C, 59.26; H, 5.35; N, 6.23; S, 4.69.
    • EXAMPLE A13 3-[2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl-5,5-dimethyl-thiazolidine-4-carboxylic acid 4-methanesulfonyl-benzamide
  • Figure US20050250707A1-20051110-C00077
  • 1H NMR (DMSO-d6) δ 9.38 (s, 1H), 8.37 (t, J=5.5, 1H,), 8.12 (d, 1H, J=8.2, 1H,), 7.33-7.13 (m, 7H), 6.94 (t, 1H, J=7.7, 1H,), 6.84-6.79 (m, 3H), 6.54 (d, 1H, J=7.3, 1H), 5.48 (d, J=6.6, 1H), 5.12 (d, J=9.2, 1H,), 5.00 (d, 1H, J=9.2, 1H), 4.49-4.42 (m, 3H), 4.32 (dd, J=14.8, 6.2, 1H,), 4.09 (dd, 1H, J=14.8, 5.3, 1H), 3.47 (s, 3H), 2.87-2.68 (m, 2H), 1.82 (s, 3H), 1.48 (s, 3H), 1.32 (s, 3H); Anal. Calcd for C32H37N3O7S2: C, 60.07; H, 5.83; N, 6.57. Found C, 60.25; H, 6.13; N, 6.74.
    • EXAMPLE A14 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid allylamide
  • Figure US20050250707A1-20051110-C00078
  • IR (neat cm−1) 3342, 2966, 1637, 1531, 1460, 1366, 1284, 1108; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.13-8.07 (m, 2H), 7.34-7.13 (m, 5H), 6.93 (t, J=7.9, 1H), 6.78 (d, J=7.7, 1H), 6.53 (d, J=7.0, 1H), 5.82-5.70 (m. I H), 5.46 (d, J=6.6, 1H), 5.23-4.97 (m, 4H), 4.40 (m, 3H), 3.81-3.59 (m, 2H), 2.86-2.67 (m, 2H), 1.81 (s, 3H), 1.50 (s, 3H), 1.35 (s, 3H); HRMS (ESI) m/z calcd for C27H33N3O5S Na (M+Na)+ 534.2039, found 534.2062; Anal. Calcd for C27H33N3O5S: C, 63.38; H, 6.50; N, 8.21. Found: C, 63.68; H, 6.57; N, 8.29.
    • EXAMPLE A15 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 4-dimethylamino-benzylamide
  • Figure US20050250707A1-20051110-C00079
  • IR (neat cm−1) 3331, 2931, 1643, 1519, 1455, 1349, 1284; 1HNMR (DMSO-d6) δ69.37 (s, 1H), 8.26 (m, 1H), 8.12 (d, J=7.1, 1H), 7.38-6.92 (m, 8H), 6.78 (t, J=7.9, 1H), 6.60 (d, J=8.6, 1H), 6.55 (d, J=7.3, 1H), 6.42 (d, J=8.2, 1H), 5.46 (d, J=6.0, 1H), 5.11 (d, J=9.3, 1H), 5.00 (d, J=9.3, 1H), 4.45 (m, 3H), 4.25 (m, 1H), 4.03 (m, 1H), 2.80 (s, 3H), 2.87-2.73 (m, 2H), 1.82 (s, 3H), 1.48 (s, 3H), 1.32 (s, 3H); HRMS (ESI) m/z calcd for C33H40N4O5SNa (M+Na)+ 627.2612, found 627.2607.
    • EXAMPLE A16 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 4-amino-benzylamide
  • Figure US20050250707A1-20051110-C00080
  • Pale yellow solid: mp=107-109° C.; IR (cm−1) 3378, 2919, 1631, 1518, 1453, 1382, 1281, 1121; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.21 (t, J=6.0, 1H), 7.40-7.10 (m, 6H), 8.12 (d, J=8.1, 1H), 6.92 (d, J=8.4, 2H), 6.77 (d, J=7.2, 1H), 6.54 (d, J=7.2, 1H), 6.44 (d, J=8.4, 2H), 5.44 (d, J=6.0, 1H), 5.10 (d, J=9.2, 1H), 4.99 (d, J=9.2, 1H), 4.90 (s, 2H), 4.50-4.32 (m, 3H), 4.22-3.93 (m, 2H), 2.90-2.60 (m, 2H), 1.81 (s, 3H), 1.47 (s, 3H), 1.31 (s, 3H); Anal. Calcd for C31H36N4O5S.0.25H2O: C, 64.06; H, 6.33; N, 9.64. Found: C, 64.17; H, 6.38; N, 9.60.
    • EXAMPLE A17 3-(2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid prop-2-ynylamide
  • Figure US20050250707A1-20051110-C00081
  • 1H NMR (DMSO-d6) δ 9.33 (s, 1H), 8.38 (t, J=5.5, 1H), 8.08 (d, J=8.3, 1H), 7.35-6.53 (m, 8H), 5.46 (d, J=6.6, 1H), 5.10 (d, J=9.2, 1H), 5.02 (d, J=9.2, 1H), 4.44-4.40 (m, 1H), 4.40 (s, 1H), 3.85 (m, 3H), 3.08 (t, J=2.5, 1H), 2.88-2.68 (m, 2H), 1.82 (s, 3H), 1.51 (s, 3H), 1.37 (s, 3H); Anal. Calcd for C27H31N3O5S: C, 63.63; H, 6.13; N, 8.24; S, 6.29. Found: C, 63.50; H, 6.33; N, 7.81; S, 5.68.
    • EXAMPLE A18 3-(2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoylamino}-4-phenyl-butanoyl)]-5,5-dimethyl-thiazolidine-4-carboxylic acid (2-methylsulfanyl-phenyl)-amide
  • Figure US20050250707A1-20051110-C00082
  • 1H NMR (DMSO-d6) δ 9.33 (s, 1H), 8.41 (t, J=5.7, 1H), 8.10 (d, J=8.3, 1H) 8.09-6.54 (m, 12H), 5.46 (d, J=6.6, 1H), 5.14 (d, J=9.2, 1H), 5.04 (d, J=9.2, 1H), 4.50-4.02 (m, 4H), 4.50 (s, 1H), 2.89-2.69 (m, 2H), 2.51 (s, 3H), 1.84 (s, 3H), 1.53 (s, 3H), 1.39 (s, 3H); Anal. Calcd for C32H37N3O5S2: C, 63.24; H, 6.14; N, 6.91. Found: C, 63.01; H, 6.30; N, 6.53.
    • EXAMPLE A19 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid phenethyl-amide
  • Figure US20050250707A1-20051110-C00083
  • 1H NMR (DMSO-d6) δ 9.41 (s, 1H), 8.38(t, J=4.8, 1H), 8.16 (d, J=8.1, 1H), 8.01 (d, J=7.4, 1H), 7.64 (m, 1H), 7.52 (m, 2H), 7.32-7.11 (m, 6H), 6.93 (t, J=7.9, 1H), 6.76 (d, J=7.9, 1H), 6.54 (d, J=7.5, 1H), 5.42 (d, J=6.4, 1H), 5.10 (d, J=9.3, 1H), 5.05 (d, J=9.0, 1H), 4.80-4.32 (m, 5H), 2.84-2.66 (m, 4H), 1.80 (s, 3H), 1.56 (s, 3H), 1.45 (s, 3H); Anal. Calcd for C32H37N3O5S: C, 66.76; H, 6.48; N, 7.30. Found C, 66.50; H, 6.56; N, 7.23.
    • EXAMPLE A20 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid ((S)-1-phenyl-ethyl)-amide
  • Figure US20050250707A1-20051110-C00084
  • White solid: mp=114-115° C.; IR (neat, cm−1) 3306, 2971, 1643, 1531, 1451, 1372, 1284, 1211, 1107; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.45 (d, J=8.2, 1H), 8.19 (d, J=8.2, 1H), 7.32-7.18 (m, 10H), 6.96-6.91 (m, 1H), 6.76 (d, J=8.1, 1H), 6.54 (d, J=7.5, 1H), 5.36 (d, J=7.2, 1H), 5.08 (d, J=9.7, 1H), 5.01 (d, J=9.7, 1H), 4.95-4.85 (m, 2H), 4.48 (s, 1H), 4.45-4.30 (m, 1H), 2.80-2.60 (m, 2H), 1.79 (s, 3H), 1.47 (s, 3H), 1.36 (d, J=7.2, 3H), 1.30 (d, J=7.0, 3H); Anal. Calcd for C32H37N3O5S.0.25H2O: C, 66.24; H, 6.51; N, 7.24. Found C, 66.30; H, 6.56; N, 6.89.
    • EXAMPLE A21 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid ((R)-1-phenyl-ethyl)-amide
  • Figure US20050250707A1-20051110-C00085
  • White solid: mp=114-115° C.; IR (neat, cm−1) 3299, 1643, 1583, 1520, 1454, 1377, 1284, 1104; 1H NMR (DMSO-d6) δ 9.35 (s, 1H), 8.36 (d, J=8.2, 1H), 8.15 (d, J=8.2, 1H), 7.44-7.13 (m, 10H), 6.96-6.91 (m, 1H), 6.75 (d, J=8.1, 1H), 6.52 (d, J=6.7, 1H), 5.38 (d, J=6.9, 1H), 5.15 (d, J=9.7, 1H), 4.99 (d, J=9.7, 1H), 5.28-4.74 (m, 1H), 4.52 (s, 1H), 4.49-4.35 (m, 2H), 2.80-2.60 (m, 2H), 1.79 (s, 3H), 1.50 (s, 3H), 1.38 (s, 3H), 1.34 (d, J=7.0, 3H); Anal. Calcd for C32H37N3O5S.0.25H2O: C, 66.24; H, 6.51; N, 7.24. Found: C, 66.38; H, 6.52; N, 7.30.
    • EXAMPLE A22 3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide
  • Figure US20050250707A1-20051110-C00086
  • IR (neat or KBr cm−1) 3302, 2922, 2351, 2333, 1768, 1750, 1646, 1537; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.44 (s, 1H), 8.13 (d, J=7.9 1H), 7.34-7.13 (m, 5H), 6.99-6.77 (m, 4H), 6.78 (d, J=7.7, 1H), 5.93 (d, J=7.1, 2H), 5.15 (d, J=7.0, 1H), 5.08 (d, J=7.8, 1H), 4.43 (d, J=9.32, 2H), 4.34 (m, 2H), 4.12 (d, J=6.18, 1H), 4.08 (d, J=6.08, 1H, 2.86-2.67 (m, 2H), 2.55 (s, 1H), 1.81 (s, 3H), 1.51 (s, 3H), 1.39 (s, 3H); Anal. Calcd C32H31N3O7S.0.65 TFA.1.0H2O: C, 57.31 H, 5.44 N, 6.02. Found: C, 57.58 H, 5.47 N, 5.85.
    • EXAMPLE A23 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid allyl-methyl-amide
  • Figure US20050250707A1-20051110-C00087
  • IR (neat, cm−1) 3380, 2943, 1637, 1460, 1284, 1HNMR (DMSO-d6) δ 9.37 (s, 1H), 8.24 (d, J=8.4, 1H), 7.34-7.15 (m, 5H), 6.94 (t, J=7.5, 1H), 6.77 (d, J=7.7, 1H), 6.53 (d, J=7.5, 1H), 5.99 (m, 1H), 5.70-5.65 (m, 1H), 5.49-5.00 (m, 5H), 4.30-3.85 (m, 4H), 3.08 (s, 3H), 2.78-2.65 (m, 2H), 1.80 (s, 3H), 1.58 (s, 3H), 1.38 (s, 3H); HRMS (ESI) m/z calcd for C28H35N3O5SNa (M+Na)+ 548.2190, found 548.2178.
    • EXAMPLE A24 (R)-3-(2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid fluoro-trifluoromethyl-benzylamide
  • Figure US20050250707A1-20051110-C00088
  • 1H NMR (DMSO-d6) δ 9.34 (s, 1H), 8.32 (t, J=6.0, 1H, 8.20 (d, J=8.4, 1H), 7.70-7.56 (m, 3H), 7.37 (d, J=6.9, 2H), 7.27 (t, J=7.5, 2H), 7.18 (t, J=7.4, 1H), 6.97 (t, J=7.0, 1H), 6.79 (d, J=7.0, 1H), 6.58 (d, J=6.6, 1H), 5.15 (d, J=9.0, 1H), 5.02 (d, J=9.0, 1H), 4.60-4.48 (m, 3H), 4.48-4.32 (m, 2H), 2.88-2.65 (m, 2H), 1.83 (s, 3H), 1.48 (s, 3H), 1.34 (s, 3H); HRMS (ESI) m/z calcd for C32H33N3O5SF4Na (M+Na)+ 670.1969, found 670.1999; Anal. Calcd for C32H33N3O5S F4.1H2O, 0.3 TFA: C, 55.94; H, 5.08; N, 6.00. Found: C, 55.74; H, 4.98; N, 5.94.
    • EXAMPLE A25 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-trifluoromethoxy-benzylamide
  • Figure US20050250707A1-20051110-C00089
  • White solid: mp=102-105° C.; IR (cm−1) 3306, 2966, 1644, 1586, 1520, 1216, 1166; 1H NMR (DMSO-d6) δ 9.38 (s, 1H), 8.53 (t, J=6.0, 1H), 8.12 (d, J=8.1, 1H), 7.40-7.13 (m, 9H), 6.96-6.91 (m, 1H), 6.77 (d, J=8.2, 1H), 6.54 (d, J=7.7, 1H), 5.48 (d, J=6.4, 1H), 5.13 (d, J=9.2, 1H), 5.00 (d, J=9.2, 1H), 4.46-3.97 (m, 5H), 2.87-2.67 (m, 2H), 1.81 (s, 3H), 1.50 (s, 3H), 1.30 (s, 3H); Anal. Calcd for C32H34F3N3O6S.0.25H2O: C, 59.11; H, 5.35; N, 6.46. Found: C, 58.91; H, 5.40; N, 6.30.
    • EXAMPLE A26 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-ethoxy-benzylamide
  • Figure US20050250707A1-20051110-C00090
  • White solid: mp=105-107° C.; IR (cm−1) 3322, 3063, 2978, 1643, 1585, 1538, 1454, 1354, 1265, 1159, 1050; 1H NMR (DMSO-d6) δ 9.38 (s, 1H), 8.40 (t, J=5.6, 1H), 8.11 (d, J=8.2, 1H), 7.30-6.70 (m, 1H), 6.53 (d, J=7.5, 1H), 5.48 (d, J=5.9, 1H), 5.11 (d, J=8.9, 1H), 5.00 (d, J=8.9, 1H), 4.50-4.20 (m, 4H), 4.07 (dd, J=15.0, 5.3, 1H), 3.94 (dd, J=14.0, 6.9, 2H), 2.90-2.62 (m, 2H), 1.81 (s, 3H), 1.49 (s, 3H), 1.34 (s, 3H), 1.25 (t, J=6.9, 3H); Anal. Calcd for C33H39N3O6S.0.75H2O: C, 64.01; H, 6.59; N, 6.79. Found: C, 63.89; H, 6.27; N, 6.44.
    • EXAMPLE A27 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid methyl-prop-2-ynyl-amide
  • Figure US20050250707A1-20051110-C00091
  • IR (neat, cm−1) 3378, 1643, 1461, 1279,1108, 1H NMR (DMSO-d6) δ 9.37 (s, 1H), 8.21 (d, J=9.2, 1H), 7.33-7.13 (m, 5H), 6.94 (t, J=7.7, 1H), 6.78 (d, J=8.1, 1H), 6.52 (d, J=7.0, 1H), 5.45 (d, J=6.8, 1H), 5.16 (d, J=9.2, 1H), 5.02 (d, J=9.2, 1H), 4.98 (s, 1H), 4.47-4.13 (s, 3H), 4.03-3.92 (m, 1H), 3.17 (s, 3H), 2.88 (s, 1H), 2.79-2.50 (m, 2H), 1.80 (s, 3H), 1.57 (s, 3H), 1.36 (s, 3H); Anal. Calcd for C28H33N3O5S.0.6H2O: C, 62.95; H, 6.45; N, 7.86. Found: C, 62.95; H, 6.39; N, 7.69.
    • EXAMPLE A28 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl]methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (2-methyl-allyl)-amide
  • Figure US20050250707A1-20051110-C00092
  • 1H NMR (DMSO-d6) δ 9.33, (s, 1H), 8.18-7.79 (m, 2H), 7.39-7.12 (m, 5H), 6.92 (t, J=8.1, 1H), 6.75 (d, J=8.1, 1H), 6.53 (d, J=7.0, 1H), 5.09 (d, J=9.2, 1H), 4.96 (d, J=9.2, 1H), 4.70 (s, 1H), 4.43 (s, 1H), 4.40 (br s, 2H) 3.81-3.49 (m, 4H), 2.85-2.65 (m, 2H), 1.82 (s, 3H), 1.63 (s, 3H), 1.49 (s, 3H), 1.35 (s, 3H); Anal. Calcd for C28H35N3O5S: C, 63.97; H, 6.71; N, 7.99. Found: C, 63.85; H, 6.92; N, 7.65.
    • EXAMPLE A29 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-amino-benzylamide
  • Figure US20050250707A1-20051110-C00093
  • IR (neat, cm−1) 3401, 2943, 1643, 1525, 1461, 1373; 1HNMR (DMSO-d6) δ9.36 (s, 1H), 8.28 (t, J=8.0, 1H), 8.12 (d, J=8.9, 1H), 7.33-6.37 (m, 12H), 5.45 (d, J=7.0, 1H), 5.10 (d, J=8.9, 1H), 4.99 (d, J=8.9, 1H), 4.50-4.35 (m, 3H), 4.30-3.90 (m 2H), 2.90-2.70 (m, 2H), 2.06 (s, 2H), 1.81 (s, 3H), 1.48 (s, 3H), 1.33 (s, 3H); Anal. Calcd for C31H36N4O5S.0.5H2O: C, 63.57; H, 6.37; N, 9.57. Found: C, 63.59; H, 6.38; N, 9.58.
    • EXAMPLE A30 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid cyanomethylamide
  • Figure US20050250707A1-20051110-C00094
  • 1HNMR (DMSO-d6) δ 9.34 (s, 1H), 8.65 (s, 1H), 8.15 (m, 1H), 7.42-7.19 (m, 5H), 6.94 (t, J=7.9, 1H), 6.81 (d, J=7.9, 1H), 6.62 (d, J=7.9,1H), 5.22 (d, J=9.7, 1H), 5.05 (d, J=9.7, 1H), 4.61-4.36 (m, 4H), 3.01-2.71 (m, 4H), 1.84 (s, 3H), 1.47 (s, 3H), 1.34 (s, 3H); Anal. Calcd for C26H30N4O5S: C, 61.16; H, 5.92; N, 10.97. Found: C, 61.24; H, 6.14; N, 10.62.
    • EXAMPLE A31 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (Z)-but-2-enylamide
  • Figure US20050250707A1-20051110-C00095
  • 1HNMR (DMSO-d6) δ 9.37 (s, 1H), 8.35 (m, 1H), 8.12 (m, 1H), 7.15-6.98 (m, 6H), 6.77 (d, J=7.7, 1H), 6.68 (d, J=7.5, 1H), 5.60-5.33 (m, 3H), 5.18 (d, J=9.2, 1H), 5.02 (d, J=9.2, 1H), 4.52-4.39 (m, 3H), 3.79-3.68 (m, 2H), 2.92-2.62 (m, 2H), 1.80 (s, 3H), 1.61 (d, J=6.9, 3H), 1.51 (s, 3H), 1.38 (s, 3H); Anal. Calcd for C28H35N3O5S: C, 63.97; H, 6.71; N, 7.99. Found: C, 63.73; H, 6.75; N, 7.83.
    • EXAMPLE A32 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (3-methyl-but-2-enyl)-amide
  • Figure US20050250707A1-20051110-C00096
  • 1H NMR (DMSO-d6) δ 9.33 (s, 1H), 8.19 (d, J=8.6, 1H), 7.96 (s br, 1H), 7.39-7.18 (m, 5H), 6.91 (t, J=7.6, 1H), 6.79 (d, J=7.9, 1H), 6.55 (d, J=7.1, 1H), 5.41 (m br, 1H), 5.21 (m, 2H), 5.02 (d, J=9.1, 1H), 4.57-4.37 (m, 3H), 3.79-3.61 (m, 2H), 2.90-2.71 (m, 2H), 1.81 (s, 3H), 1.63 (s, 6H), 1.52 (s, 3H), 1.40 (s, 3H); Anal. Calcd for C29H37N3O5S: C, 64.54; H, 6.91; N, 7.79. Found: C, 64.75; H, 6.82; N, 7.43.
    • EXAMPLE A33 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-acetylamino-benzylamide
  • Figure US20050250707A1-20051110-C00097
  • White solid: mp=145-147° C.; IR (neat, cm−1) 3378, 2919, 1637, 1514, 1461, 1361; 1H NMR (DMSO-d6) δ 9.87 (s, 1H), 9.36 (s, 1H), 8.45-8.40 (m, 1H), 8.12 (d, J=7.9, 1H), 7.49-6.91 (m, 10H), 6.77 (d, J=7.9, 1H), 6.55 (d, J=7.9, 1H), 5.49 (d, J=7.0, 1H), 5.10 (d, J=9.3, 1H), 5.00 (d, J=9.3, 1H), 4.44-3.95 (m, 5H), 2.90-2.62 (m, 2H), 2.00 (s, 3H), 1.80 (s, 3H), 1.48 (s, 3H), 1.32 (s, 3H); Anal. Calcd for C32H38N4O6S.1.5H2O: C, 61.38; H, 6.40; N, 8.68. Found: C, 61.49; H, 6.14; N, 8.35.
    • EXAMPLE A34 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid ((Z)-2-methyl-but-2-enyl)-amide
  • Figure US20050250707A1-20051110-C00098
  • 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.16 (d, J=8.4, 1H), 8.00 (t, J=5.3, 1H), 7.36-7.13 (m, 5H), 6.94 (t, J=7.7, 1H), 6.77 (d, J=8.1, 1H), 6.53 (d, J=7.3, 1H), 5.37 (d, J=5.7, 1H), 5.24 (m, 1H), 5.12 (d, J=9.0, 1H), 5.00 (d, J=9.0, 1H), 4.48-4.39 (m, 3H), 3.71 (d, J=3.7, 2H), 2.82-2.65 (m, 2H), 1.80 (s, 3H), 1.61 (m, 6H), 1.49 (s, 3H), 1.35 (s, 3H); HRMS (ESI) m/z calcd for C29H37N3O5SNa (M+Na)+ 562.2346, found 562.2360; Anal. Calcd for C29H37N3O5S: C, 64.54; H, 6.91; N, 7.79. Found: C, 64.33; H, 6.92; N, 7.60.
    • EXAMPLE A35 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid ((E)-2-methyl-but-2-enyl)-amide
  • Figure US20050250707A1-20051110-C00099
  • 1HNMR (DMSO-d6) δ 9.37 (s, 1H), 8.11 (d, J=8.2, 1H), 7.96(t, J=5.5, 1H), 7.34-7.13 (m, 5H), 6.94 (t, J=7.7, 1H), 6.77 (d, J=8.1, 1H), 6.53 (d, J=7.3, 1H), 5.44 (d, J=6.6, 1H), 5.34 (d, J=6.6, 1H), 5.10 (d, J=9.0, 1H), 4.98 (d, J=9.1, 1H), 4.47-4.36 (m, 3H), 3.71 (dd, J=14.7, 6.6, 1H), 3.46 (dd, J=14.5, 4.8, 1H), 2.85-2.67 (m, 2H), 1.81 (s, 3H), 1.50 (m, 9H), 1.35 (s, 3H); HRMS (ESI) m/z calcd for C29H37N3O5SNa (M+Na)+ 562.2346, found 562.2220.
    • EXAMPLE A36 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (E)-pent-2-enylamide
  • Figure US20050250707A1-20051110-C00100
  • White solid: mp=113-115° C.; IR (neat, cm−1) 3315, 2964, 1643, 1584, 1530, 1454, 1371, 1283, 1104, 969; 1HNMR (DMSO-d6) δ9.35 (s, 1H), 8.11 (d, J=8.2,1H), 8.02 (t, J=5.6, 1H), 7.33-7.13 (m, 5H), 6.96-6.90 (m, 1H), 6.76 (d, J=8.2, 1H), 6.52 (d, J=7.5, 1H), 5.66-5.56 (m, 1H), 5.43 (d, J=6.8, 1H), 5.38-5.31 (m, 1H), 5.10 (d, J=8.9, 1H), 4.99 (d, J=8.9, 1H), 4.47-4.39 (m, 2H), 4.38 (s, 1H), 3.72-3.53 (m, 2H), 2.84-2.66 (m, 2H), 1.98-1.83 (m, 2H), 1.80 (s, 3H), 1.48 (s, 3H), 1.34 (s, 3H), 0.87 (t, J=7.3, 3H); Anal. Calcd for C29H37N3O5S.0 5H2O: C, 63.48; H, 6.98; N, 7.66. Found: C, 63.30; H, 7.00; N, 7.28.
    • EXAMPLE A37 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (Z)-pent-2-enylamide
  • Figure US20050250707A1-20051110-C00101
  • White solid: mp=112-113° C.; IR (neat, cm−1) 3320, 2965, 1659, 1643, 1538, 1455, 1372, 1285, 1210, 1105, 1048; 1H NMR (DMSO-d6) δ 9.35 (s, 1H), 8.11 (d, J=7.9, 1H), 8.03 (t, J=5.3, 1H), 7.35-7.13 (m, 5H), 6.96-6.90 (m, 1H), 6.76 (d, J=8.1, 1H), 6.53 (d, J=7.3, 1H), 5.42 (d, J=6.7, 1H), 5.37-5.35 (m, 1H), 5.29-5.23 (m, 1H), 5.09 (d, J=9.2, 1H), 4.99 (d, J=9.2, 1H), 4.45-4.38 (m, 2H), 4.36 (s, 1H), 3.80-3.62 (m, 2H), 2.84-2.70 (m, 2H), 2.07-1.97 (m, 2H), 1.80 (s, 3H), 1.48 (s, 3H), 1.34 (s, 3H), 0.90 (t, J=7.5, 3H); Anal. Calcd for C29H37N3O5S.0 5H2O: C, 63.48; H, 6.98; N, 7.66. Found: C, 63.60; H, 6.92; N, 7.48.
    • EXAMPLE A38 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (E)-but-2-enylamide
  • Figure US20050250707A1-20051110-C00102
  • 1H NMR (DMSO-d6) δ 9.39 (s, 1H), 8.19 (m br, 1H), 8.03 (m br, 1H), 7.40-7.16 (m, 5H), 6.94 (t, J=7.1, 1H), 6.79 (d, J=7.7, 1H), 6.55 (d, J=7.5, 1H), 5.64-5.31 (m, 3H), 5.19 (d, J=9.2, 1H), 5.02 (d, J=9.2, 1H), 4.55-4.38 (m, 3H), 3.80-3.69 (m, 2H), 2.84-2.70 (m, 2H), 1.80 (s, 3H), 1.61 (s br, 3H), 1.51 (s, 3H), 1.39 (s, 3H); Anal. Calcd for C28H35N3O5S: C, 63.73; H, 7.07; N, 7.96. Found: C, 63.41; H, 7.23; N, 7.71.
    • EXAMPLE A39 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-dimethylamino-benzylamide
  • Figure US20050250707A1-20051110-C00103
  • White solid: mp=105-106° C.; IR (neat, cm−1) 2219, 2966, 1732, 1644, 1585, 1531, 1494, 1454, 1373, 1264, 1047; 1H NMR (DMSO-d6) δ 9.37 (s, 1H), 8.33 (t, J=6.1, 1H), 8.08 (d, J=8.1, 1H), 7.32-6.52 (m, 12H), 5.54 (d, J=6.0, 1H), 5.10 (d, J=9.2, 1H), 4.99 (d, J=9.2, 1H), 4.43-4.31 (m, 4H), 4.03 (dd, J=15.3, 5.3, 1H), 2.84 (s, 6H), 2.84-2.67 (m, 2H), 1.81 (s, 3H), 1.49 (s, 3H), 1.35 (s, 3H). Anal. Calcd for C33H40N4O5S.0.1H2O: C, 65.35; H, 6.68; N, 9.24. Found: C, 65.49; H, 6.67; N, 9.30.
    • EXAMPLE A40 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid ((E)-4,4,4-trifluoro-but-2-enyl)-amide
  • Figure US20050250707A1-20051110-C00104
  • White foam; IR (neat, cm−1) 3332, 1661, 1641, 1584, 1531, 1443, 1280, 1119; 1HNMR (DMSO-d6) δ 9.36 (s, 1H), 8.32 (t, J=5.6, 1H), 8.15 (d, J=8.4, 1H), 7.35-7.12 (m, 5H), 7.00-6.90 (m, 1H), 6.77 (d, J=7.3, 1H), 6.52 (d, J=7.3, 1H), 6.49-6.40 (m, 1H), 6.08-6.00 (m, 1H), 5.49 (d, J=6.4, 1H), 5.15 (d, J=9.2, 1H), 5.01 (d, J=9.2, 1H), 4.50-4.40 (m, 2H), 4.38 (s, 1H), 4.10-3.90 (m, 1H), 3.80-3.70 (m, 1H), 2.90-2.60 (m, 2H), 1.80 (s, 3H), 1.51 (s, 3H), 1.34 (s, 3H); Anal. Calcd for C28H32F3N3O5S: C, 58.02; H, 5.56; N, 7.25. Found: C, 58.37; H, 5.70; N, 6.91.
    • EXAMPLE A41 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (1-cyano-1,1-dimethyl-methyl)-amide
  • Figure US20050250707A1-20051110-C00105
  • 1H NMR (DMSO-d6) δ 9.39 (s, 1H), 8.31-8.12 (m, 2H), 7.38-7.17 (m, 5H), 6.97 (t, J=7.3, 1H), 6.79 (d, J=7.7, 1H), 6.59 (d, J=7.4, 1H), 5.41 (m br, 1H), 5.21 (d, J=9.2, 1H), 5.00 (d, J=9.2, 1H), 4.58-4.35 (m, 3H), 2.85-2.62 (m, 2H), 1.81 (s, 3H), 1.62 (s, 6H), 1.47 (s, 3H), 1.39 (s, 3H); Anal. Calcd for C28H34N4O5S: C, 62.43; H, 6.36; N, 10.40. Found: C, 62.12; H, 6.55; N, 10.13.
    • EXAMPLE A42 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-hydroxy-benzylamide
  • Figure US20050250707A1-20051110-C00106
  • 1H NMR (DMSO-d6) δ 9.37 (s, 1H), 9.30 (s, 1H), 8.35 (t, J=5.9, 1H), 8.11 (d, J=8.1, 1H), 7.33-7.15 (m, 5H), 7.04 (t, J=7.7, 1H), 6.94 (t, J=7.9, 1H), 6.77 (d, J=8.1, 1H), 6.70-6.54 (m, 4H), 5.49 (s br, 1H), 5.11 (d, J=9.2, 1H), 5.00 (d, J=9.3, 1H), 4.43 (m, 3H), 4.27 (dd, J=15.2, 6.0, 1H), 4.07 (dd, J=15.0, 5.5, 1H), 2.88-2.67 (m, 2H), 1.82 (s, 3H), 1.49 (s, 3H), 1.33 (s, 3H); Anal. Calcd for C31H35N3O6S.H2O: C, 62.50; H, 6.26; N, 7.05. Found: C, 62.66; H, 6.19; N, 6.83.
    • EXAMPLE A43 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-propoxy-benzylamide
  • Figure US20050250707A1-20051110-C00107
  • White foam; IR (cm−1) 3319, 2966, 1644, 1585, 1531, 1454, 1373, 1264, 1047; 1H NMR (DMSO-d6) δ 9.37 (s, 1H), 8.40 (t, J=5.8, 1H), 8.10 (d, J=8.4, 1H), 7.31-6.71 (m, 1H), 6.53 (d, J=7.3, 1H), 5.46 (d, J=6.4, 1H), 5.12 (d, J=9.2, 1H), 5.00 (d, J=9.2, 1H), 4.50-4.20 (m, 4H), 4.11-3.83 (m, 3H), 2.90-2.62 (m, 2H), 1.81 (s, 3H), 1.72-1.60 (m, 2H), 1.49 (s, 3H), 1.34 (s, 3H), 0.92 (t, J=7.3, 3H). Anal. Calcd for C34H41N3O6S.0.25H2O: C, 65.42; H, 6.70; N, 6.73. Found: C, 65.49; H, 6.67; N, 6.70.
    • EXAMPLE A44 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-hydroxy-benzylamide
  • Figure US20050250707A1-20051110-C00108
  • 1H NMR (DMSO-d6) δ 9.50 (s, 1H), 9.36 (s, 1H), 8.33 (t, J=5.5, 1H), 8.14 (d, J=8.2, 1H), 7.32-7.12 (m, 6H), 7.04-6.91 (m, 2H), 6.76 (m, 2H), 6.68 (t, J=7.5, 1H), 6.54 (d, J=7.5, 1H), 5.46 (d, J=6.6, 1H), 5.13 (d, J=9.2, 1H), 5.01 (d, J=9.3, 1H), 4.47 (m, 3H), 4.28-4.19 (m, 2H), 2.86-2.67 (m, 2H), 1.82 (s, 3H), 1.49 (s, 3H), 1.32 (s, 3H); HRMS (ESI) m/z calcd for C31H36N3O6S (M+H)+ 578.2325, found 578.2325.
    • EXAMPLE A45 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (3,3,3-trifluoro-propyl)-amide
  • Figure US20050250707A1-20051110-C00109
  • 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.20 (t, J=5.5, 1H), 8.13 (d, J=8.2, 1H), 7.34-7.13 (m, 5H), 6.93 (t, J=7.7, 1H), 6.76 (d, J=8.1, 1H), 6.08 (d, J=7.5, 1H), 5.44 (d, J=6.8, 1H), 5.10 (d, J=9.2, 1H), 5.05 (d, J=9.2, 1H), 4.48-4.38 (m, 2H), 4.35 (s, 1H), 3.32-3.25 (m, 2H), 2.75-2.70 (m, 2H), 2.44-2.35 (m, 2H), 1.80 (s, 3H), 1.49 (s, 3H), 1.34 (s, 3H); HRMS (ESI) m/z calcd for C27H33N3O5SF3 (M+H)+ 568.2093, found 568.2118.
    • EXAMPLE A46 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid methyl-propyl-amide
  • Figure US20050250707A1-20051110-C00110
  • White solid: mp=108-110° C.; IR (cm−1) 3325, 2964, 1637, 1522, 1456, 1372, 1284; 1H NMR (DMSO-d6) δ 9.35 (s, 1H), 8.22 (d, J=8.6, 1H), 7.34-7.12 (m, 5H), 6.96-6.90 (m, 1H), 6.77-6.75 (m, 1H), 6.53-6.50 (m, 1H), 5.46 (d, J=6.4, 1H), 5.18-4.70 (m, 3H), 4.48-4.20 (m, 2H), 3.31 (s, 3H), 2.90-2.50 (m, 2H), 1.80 (s, 3H), 1.80-1.77 (m, 2H), 1.56 (s, 3H), 1.56-1.36 (m, 2H), 1.37 (s, 3H), 0.79 (t, J=7.5, 3H). Anal. Calcd for C28H37N3O5S.1.0H2O: C, 61.63; H, 7.20; N, 7.60. Found: C, 62.03; H, 6.93; N, 7.33.
    • EXAMPLE A47 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 4-trifluoromethoxy-benzylamide
  • Figure US20050250707A1-20051110-C00111
  • White solid: 1H NMR (DMSO) δ 9.37 (s, 1H), 8.51 (t, J=5.9, 1H), 8.13 (d, J=7.3, 1H), 7.39 (d, J=8.6, 1H), 7.32-7.10 (m, 8H), 7.00-6.90 (m, 1H), 6.76 (d, J=8.2, 1H), 6.53 (d, J=7.3, 1H), 5.49 (d, J=6.6, 1H), 5.14 (d, J=9.3, 1H), 5.00 (d, J=9.3, 1H), 4.49-4.37 (m, 4H), 4.17 (dd, J=15.0, 5.7, 1H), 2.90-2.64 (m, 2H), 1.81 (s, 3H), 1.49 (s, 3H), 1.32 (s, 3H); HRMS (ESI) m/z calcd for C32H35N3O6F3S (M+H)+ 646.2199, found 646.2184.
    • EXAMPLE A48 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-amide
  • Figure US20050250707A1-20051110-C00112
  • 1HNMR (DMSO-d6) δ9.36 (s, 1H), 8.55 (t, J=5.8, 1H), 8.14 (d, J=8.4, 1H), 7.29-7.11 (m, 8H), 6.94 (t, J=7.8, 1H), 6.77 (d, J=7.9, 1H), 6.54 (d, J=7.4, 1H), 5.58 (d, J=8.2, 1H), 5.17 (d, J=9.2, 1H), 5.02 (d, J=9.2, 1H), 4.49-4.39 (m, 3H), 4.43 (s, 1H), 4.21 (dd, J=5.4, 15.3, 1H), 2.83 (m, 1H), 2.71 (dd, J=13.5, 10.7, 1H), 2.20 (s, 3H), 1.51 (s, 3H), 1.34 (s, 3H); HRMS (ESI) m/z calcd for C32H34F2N3O7S (M+H)+ 642.2086, found 642.2099; Anal. Calcd for C32H33F2N3O7S: C, 59.90; H, 5.18; N, 6.55. Found: C, 60.01; H, 5.27; N, 6.29.
    • EXAMPLE A49 (R)-3-[(2S,3S)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid (2-chloro-ethyl)-amide
  • Figure US20050250707A1-20051110-C00113
  • 1HNMR (DMSO-d6) δ 9.40 (s, 1H), 8.31 (t, 1H, J=5.5), 8.17 (d, 1H, J=8.4), 7.37-7.16 (m, 5H), 6.96 (t, 1H, J=7.9), 6.79 (d, 1H, J=8.1), 6.55 (d, 1H, J=7.5), 5.47 (d, 1H, J=6.8), 5.11 (d, 1H, J=9.3), 5.03 (d, 1H, J=9.3), 4.50-4.45 (m, 2H), 4.41 (s, 1H), 3.64-3.58 (m, 2H), 3.46-3.34 (m, 2H), 2.86-2.69 (m, 2H), 1.82 (s, 3H), 1.53 (s, 3H), 1.40 (s, 3H). Exact mass calculated for C26H33N3O5SCI (M+H)+ 534.1829, found 534.1841.
    • EXAMPLE A50 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (2-hydroxy-ethyl)-(2-methyl-benzyl)-amide
  • Figure US20050250707A1-20051110-C00114
  • 1HNMR (DMSO-d6) δ 9.38 (s, 1H), 8.29 (d, J=8.4, 1H), 7.42-6.87 (m, 10H), 6.78 (d, J=7.1, 1H), 6.55 (d, J=6.8, 1H), 5.44 (d, J=6.8, 1H), 5.26 (d, J=10.0, 1H), 5.08 (s, 1H), 5.04 (d, J=9.2, 1H), 4.82-4.67 (m, 2H), 4.55-4.24 (m, 3H), 3.67 (m, 2H), 3.47 (m, 2H), 2.78 (m, 2H), 2.24 (s, 3H), 1.82 (s, 3H), 1.61 (s, 3H), 1.45 (s, 3H); HRMS (ESI) m/z calcd for C34H42N3O6S (M+H)+ 620.2794, found 620.2798; Anal. Calcd for C34H41N3O6S I H2O: C, 64.03; H, 6.80; N, 6.59. Found: C, 63.66; H, 6.40; N, 6.59.
    • EXAMPLE A51 3-[2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiiazolidine-4-carboxylic acid methyl-(2-ethyl-benzyl)-amide
  • Figure US20050250707A1-20051110-C00115
  • White solid: 1H NMR (DMSO-d6) δ 9.40 (s, 1H), 8.45 (t, J=7.99, 1H), 8.10 (d, J=8.1, 1H), 7.41-6.91 (m, 12H), 6.62 (d, J=7.8, 1H), 5.41 (d, J=6.8, 1H), 5.12 (dd, J=8.1, 7.8, 1H), 4.44-4.35 (m, 3H), 4.42 (s, 1H), 2.91-2.67 (m, 2H), 2.54-2.21 (q, J=6.89, 2H), 2.1 (s, 3H), 1.88 (s, 3H), 1.56 (t, J=6.90, 3H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. (C34H41N3O5S.0.75H2O) calculated C (62.34), H (6.43), N (6.23), found C (62.72), H (6.52), N (5.97). HRMS (ESI) m/z calcd for 604.2845, found 604.2845.
    • EXAMPLE A52 3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid (2-methylamino-ethyl)-amide
  • Figure US20050250707A1-20051110-C00116
  • White solid: 1H NMR (DMSO-d6) δ 9.40 (s, 1H), 8.45-8.01 (m, 1H), 7.41-7.13 (m, 12H), 6.98 (t, J=7.8, 1H), 6.78 (d, J=6.85, 1H), 6.55 (d, J=6.99, 1H), 5.41 (m, 1H), 5.12-4.98 (m, 2H), 4.44-4.35 (m, 2H), 3.15 (m, 2H), 2.91-2.67 (m, 2H), 1.84 (s, 3H), 1.66 (q, J=8.2, 4H), 1.34 (s, 3H); Anal. (C27H36N4O5S.0.50H2O) calculated C (60.31), H (6.94), N (10.42), found C (60.59), H (6.50), N (8.08). HRMS (ESI) m/z calcd for 556.2771, found 556.2770.
    Figure US20050250707A1-20051110-C00117
  • Amides of the general structure 3 (synthesized in the same manor as in the Methods A section) are coupled to boc-protected acid 15, and exposed to methane sulfonic acid to yield amines 16. Subjecting amines 16 to the reaction conditions depicted yielded a series of amides 17 and ureas 19.
  • Synthesis of amines of the general type 16.
    Figure US20050250707A1-20051110-C00118
  • The title compound was prepared as follows. (R)-5,5-Dimethyl-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 1 (1.95 g, 7.47 mmol) was dissolved in EtOAc (25 mL) and cooled to 0° C. Diphenyl chlorophosphate (1.71 mL, 8.23 mmol) was added followed by TEA (1.14 mL, 8.23 mmol). The reaction was stirred at 0° C. for 1 h, and treated with (S)-Cyclohex-2-enylamine (0.8 g, 8.23 mmol). The reaction mixture was stirred at room temperature overnight, then partitioned between 1N HCl (25 mL) and EtOAc (30 mL). The organic layer was washed with saturated NaHCO3, brine, dried over Na2SO4 and concentrated to a yellow oil. The resulting oil (2.54 g, 7.47 mmol) was dissolved in EtOAc (30 mL) and then cooled to 0° C. Methanesulfonic acid (2.27 mL, 33.62 mmol) was added and the solution was stirred at 0° C. for 15 minutes, then at room temperature for 4 h. The mixture was re-cooled to 0° C. and quenched with 10% Na2CO3 (30 mL) then extracted with EtOAc (30 mL). Organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo to give a yellow oil 3. The resulting yellow oil (1.86 g, 7.74 mmol) was dissolved in EtOAc (77 mL). BOC-AHPBA 4 (2.29 g, 7.74 mmol) was added followed by HOBt (1.05 g, 7.74 mmol). The mixture was stirred at room temperature 1 h, then cooled to 0° C. DCC (1.60 g, 7.74 mmol) was slowly added as solution in EtOAc (30 mL). The mixture was allowed to gradually warm to room temperature and stirred overnight. The mixture was filtered and the filtrate was washed with 1N HCl (40 mL), saturated NaHCO3 (40 mL), brine (40 mL), dried over Na2SO4 and concentrated to give a crude white solid (contaminated with DCU). The DCU was removed by flash chromatography (30% to 50% EtOAc in hexanes) to provide a white solid (4 g, 7.73 mmol), which was dissolved in EtOAc (30 mL) and then cooled to 0° C. Methanesulfonic acid (2.35 mL, 34.76 mmol) was added and the solution was stirred at 0° C. for 15 minutes, then at room temperature for 3 h. The mixture was re-cooled to 0° C. and quenched with 10% Na2CO3 (35 mL) then extracted with EtOAc (30 mL). Organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo to give a material which was recrystalized from 60% EtOAc in hexanes to provide the titled compound (2.41 g, 80%) as a white solid. 1H NMR (DMSO-d6) δ 8.21 (d, J=8.1, 1H), 7.31-7.17 (m, 5H), 5.80 (d, J=5.6, 1H), 5.52-5.48 (m, 2H), 5.30-5.25 (m, 2H), 4.89 (s, 2H), 4.26 (s, 1H), 4.21-4.00 (m, 3H), 3.15-2.70 (m, 2H), 2.50-2.00 (m, 2H), 2.00-1.00 (m, 4H), 1.49 (s, 3H), 1.31 (s, 3H); Anal. Calcd for C22H31N3O3S: C, 63.28; H, 7.48; N, 10.06. Found: C, 63.40; H, 7.20; N, 9.98.
    The Following Amines a-h were Prepared by the Specific Method Outlined above Using the Requisite Amine.
    Figure US20050250707A1-20051110-C00119
  • 1H NMR (DMSO-d6) δ 8.36 (t, J=6.0,1H), 7.36-7.14 (m, 5H), 5.70 (m, 1H), 5.34 (s br, 1H), 5.12 (d, J=17.0, 1H), 496-4.88 (m, 3H), 4.34 (s, 1H), 4.10 (d, J=7.0, 1H), 3.80-3.55 (m, 2H), 3.06 (d, J=13.0, 1H), 2.87 (t, J=9.0, 1H), 2.38 (dd, J=13.0,10.0, 1H), 1.52 (s, 3H), 1.33 (s, 3H).
    Figure US20050250707A1-20051110-C00120
  • 1H NMR (DMSO-d6) δ 8.69 (t, J=5.3,1H), 7.34-7.14 (m, 5H), 5.34 (s br, 1H), 4.90 (s, 2H), 4.29 (s, 1H), 4.08 (d, J=7.0, 1H), 3.90-3.70 (m, 2H), 3.07 (dd, J=13.4,2.5,1H), 2.96 (t, J=2.6,1H), 2.88, (ddd, J=9.8, 8.0, 2.8, 1H), 2.37 (dd, J=13.2, 9.9, 1H), 1.50 (s, 3H), 1.32 (s, 3H).
    Figure US20050250707A1-20051110-C00121
  • 1H NMR (DMSO-d) δ 8.13 (t, J=5.4, 1H), 7.35-7.15 (m, 5H), 5.28 (d, J=8.1, 1H), 4.79 (m, 2H), 4.27 (s, 1H), 4.07 (t, J=7.1, 1H), 3.10-2.71 (m, 4H), 2.37 (dd, J=13.2, 9.9, 1H), 1.49 (s, 3H), 1.34 (m, 2H), 1.33 (s, 3H), 0.77 (t, J=7.4, 3H).
    Figure US20050250707A1-20051110-C00122
  • Isolated yield: 84%; MS (APCI, m/z): 461, 463 (M+H)
    Figure US20050250707A1-20051110-C00123
  • Isolated yield: 93%; MS (APCI, m/z): 464 (M+H).
    Figure US20050250707A1-20051110-C00124
  • Isolated yield: 86%; MS (APCI, m/z): 496 (M+H).
    Figure US20050250707A1-20051110-C00125
  • Isolated yield: 87%. MS-APCI (m/z+): 458.
  • Synthesis of Final Products of the General Type 17 from 16a-h, General Methods:
  • Amide formation—To a solution of acid, amine 16 and HOBT in CH2Cl2 was added EDC and the solution stirred overnight at room temperature. The solution was concentrated in vacuo and the residue dissolved in ethyl acetate and a small portion of water. The solution was washed with saturated NH4Cl or 0.5N HCl (2×), saturated NaHCO3 (2×), brine (1×), dried with MgSO4 and concentrated in vacuo. The resulting residue subjected to flash silica gel chromatography or preparative HPLC to afford the desired product.
  • Urea formation #1—The corresponding amine and isocyanate (1.1-1.2 eq.) were taken in dichloromethane and stirred at room temperature under nitrogen. (1.5 hr to overnight). The solvent was then removed in vacuo and the resulting residue subjected to flash silica gel chromatography or preparative HPLC to afford the desired product.
  • Urea formation #2—The corresponding amine was dissolved in CH2Cl2 and treated with diisopropylethylamine (1.5 eq.) and phosgene (1 eq., 20% soln. in toluene) at −78° C. The resulting solution was warmed to room temperature and treated with the amine of general structure 16. The resulting residue subjected to flash silica gel chromatography or preparative HPLC to afford the desired product.
    • Specific Urea Synthesis EXAMPLE B1 3-(2-hydroxy-3-{[1-(3-hydroxy-pyrrolidin-yl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid-2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00126
  • (R)-Pyrrolidin-3-ol (0.21 g, 2.40 mmol) was dissolved in dry CH2Cl2 (15 mL) and cooled to −78° C. under argon with magnetic stirring. To this solution was added Diisopropylethylamine (0.63 mL, 3.63 mmol) followed by Phosgene as a 20% solution in toluene (1.2 mL, 2.40 mmol). The resulting yellow solution was stirred for 20 min at −78° C. then allowed to warm to room temperature. The solution was concentrated and re-dissolved in dry CH2Cl2 (5 mL) and THF (5 mL). To this was added Diisopropylethylamine (0.31 mL, 1.81 mmol) followed by 16c. The result was stirred for 16 h at 23° C. then diluted with EtOAc (50 mL). The mixture was washed sequentially with 10% citric acid (1×50 mL), saturated NaHCO3 (1×50 mL), H2O (1×50 mL). The organics were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash column chromatography (5% MeOH in EtOAc) to yield the title compound (0.12 g, 18%) as a white foam.
  • 1H NMR (DMSO-d6) δ 8.38 (t, J=5.7, 1H), 7.34-7.09 (m, 10H), 5.99 (d, J=8.3, 1H), 5.04 (d, J=9.5, 1H), 4.96 (d, J=9.5, 1H), 4.49 (s, 1H), 4.48-4.38 (m, 3H), 4.22-3.83 (m, 4H), 3.29-3.04 (m, 3H), 2.77-2.70 (m, 2H), 2.28 (s, 3H), 1.52 (s, 3H), 1.32 (s, 3H), 1.82-1.69 (m, 2H); HRMS (ESI) m/z calcd for C29H38N4O5SNa (M+Na)+ 577.2455, found 577.2440; Anal. Calcd for C29H38N4O5S.2H2O: C, 58.96; H, 7.17; N, 9.48; S, 5.43. Found: C, 58.90; H, 6.40; N, 9.23; S, 5.24.
  • The following examples were prepared by the corresponding specific method outlined above using the requisite P2 fragment.
    • EXAMPLE B2 Isoxazole-5-carboxylic acid {(1S,2S)-1-benzyl-3-[(R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00127
  • White solid: mp=82-84° C.; IR (neat, cm−1) 3313, 2967, 1656, 1538, 1454, 1372, 1283, 1211, 1108, 916; 1H NMR (DMSO-d6) δ 8.91 (d, J=8.6, 1H), 8.67 (d, J=2.0, 1H), 8.35 (t, J=5.0, 1H), 7.31-7.08 (m, 9H), 7.03 (d, J=2.0, 1H), 5.63 (d, J=6.9, 1H), 5.02 (d, J=8.6, 1H), 4.97 (d, J=8.6, 1H), 4.60-4.30 (m, 4H), 4.14-4.00 (m, 1H), 2.90-2.75 (m, 2H), 2.23 (s, 3H), 1.49 (s, 3H), 1.28 (s, 3H); HRMS (ESI) m/z calcd for C28H32N4O5SNa (M+Na)+ 559.1986, found 559.1994; Anal. Calcd for C28H32N4O5S.0.5H2O: C, 61.63; H, 6.10; N, 10.27. Found: C, 61.40; H, 5.91; N, 9.97.
    • EXAMPLE B3 Isoxazole-3-carboxylic acid {(1S,2S)-1-benzyl-3-[(R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00128
  • White solid; IR (neat, cm−1) 3436, 1643, 1537, 1425, 1378; 1H NMR (DMSO-d6) δ 9.03 (s, 1H), 8.66 (d, J=8.7, 1H), 8.32 (t, J=5.3, 1H), 7.30-7.11 (m, 9H), 6.79 (s, 1H), 5.67 (d, J=6.8, 1H), 4.97 (s, 2H), 4.47-4.32 (m, 4H), 4.09 (dd, J=15.0, 5.0, 1H), 2.84 (m, 2H), 2.24 (s, 3H), 1.49 (s, 3H), 1.34 (m, 3H); HRMS (ESI) m/z calcd for C28H32N4O5SNa (M+Na)+ 559.1986, found 559.1980.
    • EXAMPLE B4 5-Chloro-isoxazole-3-carboxylic acid {(1S,2S)-1-benzyl-3-[(R)-5,5-dimethyl-4-(2-methyl-benylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00129
  • White solid; IR (neat, cm−1) 3320, 2969, 1657, 1547, 1434, 1372, 1266; 1H NMR (DMSO-d6) δ 8.74 (d, J=8.2, 1H), 8.29 (t, J=5.5, 1H), 7.28-7.08 (m, 9H), 6.90 (s, 1H), 5.72 (d, J=7.1, 1H), 4.96 (s, 2H), 4.44 (m, 3H), 4.32 (dd, J=15.2, 6.0, 1H), 4.09 (dd, J=15.2, 4.6, 1H), 2.85 (m, 2H), 2.83 (s, 3H), 1.49 (s, 3H), 1.33 (s, 3H); HRMS (ESI) m/z calcd for C28H31N4O5SClNa (M+Na)+ 593.1596, found 593.1569.
    • EXAMPLE B5 (R)-3-{(2S,3S)-2-Hydroxy-4-phenyl-3-[(1-thiophen-2-yl-methanoyl)-amino]-butanoyl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00130
  • White solid: mp=98-101° C.; IR (neat, cm−1) 3416, 1644, 1538, 1455, 1372, 1291, 1107; 1H NMR (DMSO-d6) δ 8.56 (d, J=8.0, 1H), 8.38 (t, J=4.8, 1H), 7.85 (d, J=3.5, 1H), 7.69 (d, J=4.8, 1H), 7.36-7.08 (m, 10H), 5.38 (d, J=7.2, 1H), 5.10 (d, J=8.8, 1H), 4.98 (d, J=88, 1H), 4.54-4.20 (m, 5H), 2.90-2.70 (m, 2H), 2.25 (s, 3H), 1.49 (s, 3H), 1.34 (s, 3H); HRMS (ESI) m/z calcd for C29H33N3O4S2Na (M+Na)+ 574.1805, found 574.1818; Anal. Calcd for C29H33N3O4S2.0.75H2O: C, 61.62; H, 6.15; N, 7.43. Found: C, 61.31; H, 5.97; N, 7.28.
    • EXAMPLE B6 (R)-3-{(2S,3S)-2-Hydroxy-4-phenyl-3-[(1-thiophen-3-yl-methanoyl)-amino]-butanoyl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00131
  • White solid: mp=98-100° C.; IR (neat, cm−1) 3312, 3086, 2966, 1644, 1538, 1455, 1372, 1286, 1109; 1H NMR (DMSO-d6) δ 8.42-8.34 (m, 2H), 8.14 (m, 1H), 7.54-7.06 (m, 1H), 5.74 (d, J=9.3, 1H), 5.35 (d, J=6.8, 1H), 4.99 (d, J=9.3, 1H), 4.53 (d, J=3.0, 1H), 4.50 (s, 1H), 4.42 (dd, J=15.0,7.0, 1H), 4.40-4.30((m, 1H), 4.15 (dd, J=15.0, 5.0, 1H), 2.90-2.70 (m, 2H), 2.26 (s, 3H), 1.50 (s, 3H), 1.35 (s, 3H); HRMS (ESI) m/z calcd for C29H33N3O4S2Na (M+Na)+ 574.1805, found 574.1789; Anal. Calcd for C29H33N3O4S2.1H2O: C, 61.14; H, 6.19; N, 7.38. Found: C, 60.74; H, 5.90; N, 7.15.
    • EXAMPLE B7 (R)-3-{(2S,3S)-2-Hydroxy-4-phenyl-3-[((S)-1-tetrahydro-furan-2-yl-methanoyl)amino]-butanoyl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00132
  • White solid: mp=82-84° C.; IR (neat, cm−1) 3314, 2969, 1651, 1531, 1456, 1372, 1109, 1071; 1H NMR (DMSO-d6) δ 8.35 (t, J=6.0, 1H), 7.60 (d, J=9.2, 1H), 7.31-7.09 (m, 9H), 5.45 (d, J=6.8, 1H), 4.97 (d, J=9.5, 1H), 4.93 (d, J=9.5, 1H), 4.46 (s, 1H), 4.41-4.07 (m, 4H), 3.77-3.65 (m, 3H), 2.78-2.64 (m, 2H), 2.26 (s, 3H), 2.00-1.80 (m, 1H), 1.60 (m, 1H), 1.49 (s, 3H), 1.44-1.38 (m, 2H), 1.34 (s, 3H); HRMS (ESI) m/z calcd for C29H37N3O5SNa (M+Na)+ 562.2346, found 562.2345; Anal. Calcd for C29H37N3O5S.0.5H2O: C, 63.48; H, 6.98; N, 7.66. Found: C, 63.61; H, 6.85; N, 7.58.
    • EXAMPLE B8 3-(2-hydroxy-3-{[1-(3-hydroxy-pyrrolidin-yl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid-2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00133
  • 1H NMR (DMSO-d6) δ 8.38 (t, J=5.5, 1H), 7.34-7.09 (m, 10H), 5.99 (d, J=8.2, 1H), 5.04 (d, J=9.5, 1H), 4.96 (d, J=9.5, 1H), 4.49 (s, 1H), 4.48-4.38 (m, 3H), 4.35-4.16 (m, 3H), 4.00 (m, 1H), 3.29-3.04 (m, 3H), 2.78-2.70 (m, 2H), 2.28 (s, 3H), 1.83-1.65 (m, 2H), 1.52 (s, 3H), 1.36 (s, 3H); HRMS (ESI) m/z calcd for C29H38N4O5SNa (M+Na)+577.2455, found 577.2473; Anal. Calcd for C29H39N4O5S.2H2O: C, 58.96; N, 9.48. Found: C, 58.68; N, 9.11.
    • EXAMPLE B9 (R)-3-{(2S,3S)-2-Hydroxy-4-phenyl-3-[((R)-1-tetrahydro-furan-2-yl-methanoyl)-amino]-butanoyl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00134
  • White solid; IR (neat, cm−1) 3324, 2959, 2873, 1724, 1651, 1526, 1455, 1372, 1289, 1073; 1H NMR (DMSO-d6) δ 8.35 (t, J=4.9, 1H), 7.77 (d, J=8.9, 1H), 7.52-7.09 (m, 9H), 5.51 (d, J=6.6, 1H), 4.97-4.89 (m, 2H), 4.52-3.66 (m, 8H), 2.90-2.60 (m, 2H), 2.25 (s, 3H), 1.99-1.63 (m, 4H), 1.48 (s, 3H), 1.33 (s, 3H); HRMS (ESI) m/z calcd for C29H37N3O5SNa (M+Na)+ 562.2346, found 562.2366. Anal. Calcd for C29H37N3O5S.0.25H2O: C, 64.01; H, 6.95; N, 7.72. Found: C, 64.20; H, 6.90; N, 7.82.
    • EXAMPLE B10 3,5-Dimethyl-isoxazole-4-carboxylic acid {(1S,2S)-1-benzyl-3-[(R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00135
  • Isolated yield: 92%; 1H-NMR (400 MHz, dmso-d6): δ 8.38 (t, 1H), 8.13 (d, 1H), 7.04-7.35 (m, 10H), 5.52 (d, 1H), 5.09 (d, 1H), 5.0 (d, 1H), 4.53 (m, 1H), 4.5 (s, 1H), 4.48 (m, 2H), 4.17 (dd, 1H), 2.87 (dd, 1H), 2.7 (q, 1H), 2.26 (s, 6H), 2.09 (s, 3H), 1.52 (s, 3H), 1.35 (s, 3H); IR (KBr in cm−1): 3313, 1643, 1521, 743; MS (APCI, m/z): 565 (M+H), 519, 265; C30H36N4O5S1.0.69H2O Calculated: C, 62.43; H, 6.53; N, 9.71, Observed: C, 63.81; H, 6.43; N, 9.92; HPLC: Rf (min.) 20.167; Purity: 98%.
    • EXAMPLE B11 2,4-Dimethyl-thiazole-5-carboxylic acid {1-benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00136
  • Isolated yield: 80%; 1H-NMR (400 MHz, dmso d6): δ 8.35 (t, 1H), 8.14 (d, 1H), 7.0-7.35 (m, 10H), 5.48 (d, 1H), 5.04 (d, 1H), 5.0 (d, 1H), 4.52 (m, 1H), 4.4 (s, 1H), 4.35 (m, 2H), 4.14 (dd, 1H), 2.78 (d, 2H), 2.57 (s, 3H), 2.30 (s, 3H), 2.26 (s, 3H), 1.48 (s, 3H), 1.35 (s, 3H); IR (KBr in cm−1): 3310, 1641, 1534, 743; MS (APCI, m/z): 581 (M+H), 317, 265, 259; C30H36N4O4S2.0.39H2O Calculated: C, 61.30; H, 6.31; N, 9.53, Observed: C, 62.04; H, 6.25; N, 9.65; HPLC: Rf (min.) 19.613; Purity: 98%.
    • EXAMPLE B12 (R)-3-{(2S,3S)-2-Hydroxy-3-[(1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-butyryl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00137
  • Isolated yield: 82%; 1H-NMR (400 MHz, dmso-d6): δ 8.35 (t, 1H), 7.91 (d, 1H), 7.35-7.04 (m, 10H), 6.78 (s, 2H), 5.96 (s, 1H), 5.35 (d, 1H), 5.13 (s, 1H), 5.0 (d, 1H), 4.48 (s, 2H), 4.38 (dd, 1H), 4.30 (m, 1H), 4.13 (dd, 1H), 3.7 (s, 3H), 2.8 (m, 2H), 2.26 (s, 3H), 1.52 (s, 3H), 1.35 (s, 3H); IR (KBr in cm−1): 3324, 1639, 1538, 735; MS (APCI, m/z): 549 (M+H), 503, 382, 285; C30H36N4O4S1.2.44H2O Calculated: C, 60.80; H, 6.95; N, 9.45, Observed: C, 65.67; H, 6.61; N, 10.21; HPLC: Rf (min.) 20.745; Purity: 100%.
    • EXAMPLE B13 (R)-3-{((2S,3S)-3-[(1,5-Dimethyl-1H-pyrazole-4-carbonyl)-amino]-2-hydroxy-4-phenyl-butyryl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00138
  • Isolated yield: 68%; 1H-NMR (400 MHz, dmso-d6): δ 8.30 (t, 1H), 7.83 (d, 1H), 7.31-7.04 (m, 10H), 6.30 (s, 1H), 5.48 (d, 1H), 4.92 (s, 2H), 4.30-4.48 (m, 4H), 4.17 (dd, 1H), 3.7 (s, 3H), 2.74 (m, 2H), 2.26 (s, 3H), 2.18 (s, 3H), 1.48 (s, 3H), 1.30 (s, 3H); IR (KBr in cm−1): 3313, 1645, 1532, 744; MS (APCI, m/z): 564 (M+H), 300, 272; C30H37N5O4S1.0.5H2O Calculated: C, 62.86; H, 6.69; N, 12.22, Observed: C, 63.92; H, 6.62; N, 12.42; HPLC: Rf (min.) 19.724; Purity: 100%.
    • EXAMPLE B14 3-{(S)-3-[(5-Chloro-1,3-dimethyl-1H-pyrazole-4-carbonyl)-amino]-2-hydroxy-4-phenyl-butyryl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00139
  • Isolated yield: 92%; 1H-NMR (400 MHz, dmso-d6): δ 8.35 (t, 1H), 7.74 (d, 1H), 7.30-7.0 (m, 10H), 5.44 (d, 1H), 4.96 (q, 2H), 4.48 (m, 1H), 4.35 (m, 2H), 4.13 (dd, 1H), 2.74 (m, 2H), 2.22 (s, 3H), 2.09 (s, 3H), 148 (s, 3H), 1.26 (s, 3H); IR (KBr in cm−1): 3438, 3313, 1693, 1649, 1513, 1372, 754; MS (APCI, m/z): 598 (M+H), 334, 276, 174; C30H36N5O4S1C11.0.17H2O Calculated: C, 59.93; H, 6.09; N, 11.65, Observed: C, 60.24; H, 6.07; N, 11.71; HPLC: Rf (min.) 19.829; Purity: 100%.
    • EXAMPLE B15 2-Amino-4-methyl-thiazole-5-carboxylic acid {(S)-1-benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00140
  • Isolated yield: 42%; 1H-NMR (400 MHz, dmso-d6): δ 8.48 (brs, 1H), 8.35 (brs, 1H), 7.44 (d, 1H), 7.35-7.04 (m, 9H), 6.91 (s, 1H), 5.37 (d, 1H), 4.96 (q, 2H), 4.48-4.0 (m, 5H), 2,96 (m, 2H), 2.22 (2, 3H), 2.13 (s, 3H), 1.48 (s, 3H), 1.30 (s, 3H); IR (KBr in cm−1): 3307, 1625, 1495; MS (APCI, m/z): 582 (M+H), 442, 318; C29H35N5O4S2Cl1 Calculated: C, 60.13; H, 6.5; N, 10.82, Observed: C, 59.87; H, 6.06; N, 12.04; HPLC: Rf (min.) 17.981; Purity: 98%.
    • EXAMPLE B16 3-[2-Hydroxy-3-(2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00141
  • Isolated yield: 76%; 1H-NMR (400 MHz, dmso-d6): δ 8.31 (t, 1H), 8.22 (d, 1H), 7.32-7.04 (m, 13H), 5.48 (d, 1H), 5.13 (d, 1H), 5.0 (d, 1H), 4.48 (s, 2H), 4.38 (dd, 2H), 4.09 (dd, 1H), 2.83 (d, 1H), 2.70 (t, 1H), 2.26 (s, 3H), 2.01 (s, 3H), 1.48 (s, 3H), 1.33 (s, 3H); IR (KBr in cm−1): 3309, 1641, 1520, 742; MS (APCI, m/z): 560 (M+H), 514, 296, 265; C32H37N3O4S1.0.64H2O Calculated: C, 67.40; H, 6.59; N, 7.37, Observed: C, 68.79; H, 6.49; N, 7.52; HPLC: Rf (min.) 21.024; Purity: 98%.
    • EXAMPLE B17 3-[3-(2,3-Dimethyl-benzoylamino)-2-hydroxy-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00142
  • Isolated yield: 72%; 1H-NMR (400 MHz, dmso-d6): δ 8.33 (t, 1H), 8.22 (d, 1H), 7.35-6.83 (m, 12H), 5.48 (d, 1H), 5.13 (d, 1H), 5.04 (d, 1H), 4.48-4.30 (m, 4H), 4.09 (dd, 1H), 2.84 (d, 1H), 2.70 (t, 1H), 2.26 (s, 3H), 2.17 (s, 3H), 1.87 (s, 3H), 1.48 (s, 3H), 1.30 (s, 3H); IR (KBr in cm−1): 3307, 1640, 1515, 743; MS (APCI, m/z): 574 (M+H), 528, 310, 265; C33H39N3O4S1.0.54H2O Calculated: C, 68.05; H, 6.76; N, 7.21, Observed: C, 69.20; H, 6.76; N, 7.34; HPLC: Rf (min.) 21.449; Purity: 99%.
    • EXAMPLE B18 6-Oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid {1-benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl)-amide
  • Figure US20050250707A1-20051110-C00143
  • Isolated yield: 67%; 1H-NMR (400 MHz, dmso-d6): δ 8.35 (t, 1H), 8.09 (d, 1H), 7.30-7.0 (m, 10H), 5.6 (d, 1H), 4.91 (d, 1H), 4.83 (d, 1H), 4.44 (s, 1H), 4.30 (m, 3H), 4.17 (dd, 1H), 2.78 (d, 2H), 2.61 (t, 2H), 2.30 (t, 2H), 2.22 (s, 3H), 1.48 (s, 3H), 1.30 (s, 3H); IR (KBr in cm−1): 3306, 1650, 1521, 742; MS (APCI, m/z): 566 (M+H), 520, 265; C29H35N5O5S1.0.7H2O Calculated: C, 60.23; H, 6.34; N, 12.11, Observed: C, 61.57; H, 6.24; N, 12.38; HPLC: Rf (min.) 18.455; Purity: 97%.
    • EXAMPLE B19 2,4-Dimethyl-5-oxo-2,5-dihydro-isoxazole-3-carboxylic acid (1-benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00144
  • Isolated yield: 73%; 1H-NMR (400 MHz, dmso-d6): δ 8.91 (d, 1H), 8.35 (t, 1H), 7.30-7.04 (m, 9H), 5.70 (d, 1H), 5.0 (d, 2H), 4.44 (s+m, 3H), 4.31 (dd, 1H), 4.13 (dd, 1H), 2.91 (s+m, 4H), 2.65 (t, 1H), 2.22 (s, 3H), 1.52 (s, 3H), 1.48 (s, 3H), 1.30 (s, 3H); IR (KBr in cm−1): 3325, 2932, 1729, 1649, 1527, 742; MS (APCI, m/z): 581 (M+H), 539, 493, 225; C30H36N4O6S1 Calculated: C, 62.29; H, 5.61; N, 9.19, Observed: C, 62.05; H, 6.25; N, 9.65; HPLC: Rf (min.) 19.638; Purity: 100%.
    • EXAMPLE B20 (R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2,4-dimethyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid allylamide
  • Figure US20050250707A1-20051110-C00145
  • 1H NMR (DMSO-d6) δ 8.23 (s, 1H), 8.10-8.03 (m, 2H), 7.33-7.12 (m, 5H), 6.85 (d, J=7.7, 1H), 6.51 (d, J=7.7, 1H), 5.82-5.70 (m, 1H), 5.44 (d, J=6.8, 1H), 5.22-4.97 (m, 4H), 4.50-4.30 (m, 3H), 3.84-3.60 (m, 2H), 2.84-2.66 (m, 2H), 2.13 (s, 3H), 1.85 (s, 3H), 1.49 (s, 3H), 1.35 (s, 3H); HRMS (ESI) m/z calcd for C28H36N3O5S (M+H)+ 526.2376, found 526.2380; Anal. Calcd for C28H35N3O5S.0.2TFA: C, 62.19; H, 6.47; N, 7.66. Found: C, 62.27; H, 6.78; N, 7.26.
    • EXAMPLE B21 3-(2-Hydroxy-3-{[1-(3-hydroxy-2,4-dimethyl-phenyl)-methyanoyl]-amino}-4-phenyl-butznoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid prop-2-ynylamide
  • Figure US20050250707A1-20051110-C00146
  • 1H NMR (DMSO-d6) δ 8.40 (t, J=5.4, 1H), 8.22 (s, 1H), 8.02 (d, J=8.2, 1H), 7.35-6.52 (m, 7H), 5.44 (d, J=6.8, 1H), 5.10 (d, J=9.1, 1H), 5.02 (d, J=9.1, 1H), 4.46-4.40 (m, 2H), 4.40 (s, 1H), 3.86 (s br, 2H), 3.08 (t, J=1.8, 1H), 2.82-2.72 (m, 2H), 2.15 (s, 3H), 1.88 (s, 3H), 1.51 (s, 3H), 1.37 (s, 3H); HRMS (ESI) m/z calcd for C28H34N3O5S (M+H)+ 524.2219, found 524.2219; Anal. Calcd for C28H33N3O5S.0.5H2O: C, 63.13; H, 6.43; N, 7.89; S, 6.02. Found: C, 62.80; H, 6.64; N, 7.71; S, 5.69.
    • EXAMPLE B22 3-{2-Hydroxy-3-[(1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-butyryl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-chloro-benzylamide Chiral
  • Figure US20050250707A1-20051110-C00147
  • Isolated yield: 50%; 1H-NMR (400 MHz, dmso-d6): 6.40-7.40 (m, 1H), 6.00 (m, 1H), 4.20-5.20 (m, 7H), 3.71, 3.54 (s 3H), 2.70-2.90 (m, 2H), 1.52 (d, J=2.0 Hz, 3H), 1.32 (d, J=2.1 Hz, 3H); MS (APCI, m/z): 570 (M+H).
    • EXAMPLE B23 3,5-Dimethyl-isoxazole-4-carboxylic acid {1-benzyl-3-[4-(2-chloro-benzylcarbamoyl)-5,5-dimethyl-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl]-amide
  • Figure US20050250707A1-20051110-C00148
  • Isolated yield: 55%; 1H-NMR (400 MHz, dmso-d6): 7.00-7.40 (m, 9H), 4.36-5.08 (m, 7H), 2.70-2.90 (m, 2H), 2.34,2.25 (s, 3H), 2.18,2.12 (s, 3H), 1.56 (d, J=8.5 Hz, 3H), 1.35 (d, J=6.2 Hz, 3H); MS (APCI, m/z): 586 (M+H); C29H33ClN4O5S.0.42H2O Calculated: C, 58.77; H, 5.75; N, 9.45, Observed: C, 58.37; H, 5.73; N, 9.19.
    • EXAMPLE B24 3-{2-Hydroxy-3-[(1-methyl-1H-pyrrole-2-carbonyl)-amino]4-phenyl-butyryl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2,6-difluoro-benzylamide
  • Figure US20050250707A1-20051110-C00149
  • Isolated yield: 75%; 1H-NMR (400 MHz, dmso-d6): 6.40-7.40 (m, 10H), 6.00 (m, 1H), 4.20-5.20 (m, 7H), 3.64, 3.61 (s 3H), 2.70-2.90 (m, 2H), 1.52, 1.49 (s, 3H), 1.33, 1.29 (s, 3H); MS (APCI, m/z): 571 (M+H); C29H32F2N4O4S Calculated: C, 61.04; H, 5.65; N, 9.82, Observed: C, 60.86; H, 5.94; N, 9.71.
    • EXAMPLE B25 3,5-Dimethyl-isoxazole-4-carboxylic acid {1-benzyl-3-[4-(2,6-difluoro-benzylcarbamoyl)-5,5-dimethyl-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00150
  • Isolated yield: 75%; 1H-NMR (400 MHz, dmso-d6): 6.60-7.40 (m, 8H), 4.26-5.08 (m, 7H), 2.70-2.90 (m, 2H), 2.32, 2.28 (s, 3H), 2.16,2.13 (s, 3H), 1.56,1.53 (s, 3H), 1.37, 1.34 (s, 3H); MS (APCI, m/z): 587 (M+H); C29H32F2N4O5S Calculated: C, 59.37; H, 5.50; N, 9.55, Observed: C, 59.12; H, 5.88; N, 9:50.
    • EXAMPLE B26 3-{2-Hydroxy-3-[(1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-butyryl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-trifluoromethyl-benzylamide
  • Figure US20050250707A1-20051110-C00151
  • Isolated yield: 83%; 1H-NMR (400 MHz, dmso-d6): 6.40-7.60 (m, 1H), 6.00 (m, 1H), 4.20-5.20 (m, 7H), 3.70, 3.54 (s 3H), 2.70-2.90 (m, 2H), 1.52 (s, 3H), 1.36, 1.29 (s, 3H); MS (APCI, m/z): 619 (M+H); C30H33F3N4O4S Calculated: C, 59.79; H, 5.52; N, 9.30, Observed: C, 59.42; H, 5.55; N, 9.06.
    • EXAMPLE B27 3,5-Dimethyl-isoxazole-4-carboxylic acid {1-benzyl-3-[5,5-dimethyl-4-(2-trifuoromethyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00152
  • Isolated yield: 93%; 1H-NMR (400 MHz, dmso-d6): 7.05-7.60 (m, 9H), 4.36-5.08 (m, 7H), 2.70-2.90 (m, 2H), 2.30, 2.21 (s, 3H), 2.15, 2.05 (s, 3H), 1.54, 1.52 (s, 3H), 1.39, 1.32 (s, 3H); MS (APCI, m/z): 619 (M+H); C30H33F3N4O5S Calculated: C, 58.24; H, 5.38; N, 9.06, Observed: C, 57.87; H, 5.68; N, 9.02.
    • EXAMPLE B28 N-[(1S,2S)-3-(4-Allylcarbamoyl-5,5-dimethyl-thiazolidin-3-yl)-1-benzyl-2-hydroxy-3-oxo-propyl]-nicotinamide
  • Figure US20050250707A1-20051110-C00153
  • White solid: 1H NMR (DMSO-d6) δ 8.81 (d, J=8.6, 1), 8.77 (d, J=6.2, 1H), 8.12 (m, 1H), 7.99 (m, 1H), 7.63 (m, 1H), 7.32-7.12 (m, 7H), 5.78 (m, 1H), 5.18 (m, 2H), 4.56 (m, 3H), 4.40 (m, 4H), 2.87-2.67 (m, 2H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. (C26H32N4O4S.0.5H2O.0.5 TFA) calculated C (57.65), H (6.36), N (10.19), found C (57.73), H (5.91), N (10.15). HRMS (ESI) m/z calcd for 483.2075, found 497.2066.
    • EXAMPLE B29 3-[2-Hydroxy-3-(4-methoxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00154
  • Isolated yield: 5.6%. 1H NMR (400 MHz, DMSO-d6): δ 8.32 (t, 1H), 8.09 (d, 1H), 7.33-7.27 (m, 3H), 7.23-7.19 (m, 2H), 7.15-7.08 (m, 5H), 6.69 (d, 2H), 5.46 (d, 1H), 5.13 (d, 1H), 4.99 (d, 1H), 4.49 (s, 2H), 4.41-4.36 (m, 2H), 4.10 (dd, 1H), 3.71 (s, 3H), 2.84-2.81 (m, 1H), 2.72 (t, 1H), 2.24 (s, 3H), 2.07 (s, 3H), 1.48 (s, 3H), 1.33 (s, 3H); MS-APCI (m/z+): 326, 590 (M+H). HPLC: Rf (min.) 21.26; Purity: 100%; C33H39N3O5S1.0.4H2O: calcd: C, 66.40; H, 6.72; N, 7.04, found: C, 66.38; H, 6.71; N, 6.94.
    • EXAMPLE B30 (R)-3-((2S,3S)-2-Hydroxy-4-phenyl-3-[(1-o-tolyl-methanoyl)-amino]-butanoyl}-5,5-dimethyl-thiazolidine-4-carboxylic acid propylamide
  • Figure US20050250707A1-20051110-C00155
  • IR (neat, cm−1) 3318, 2964, 1642, 1530, 1445, 1372, 1H NMR (DMSO) 88.21 (d, J=8.4, 1H), 7.90 (t, J=5.6, 1H), 7.35-7.07 (m, 9H), 5.45 (d, J=6.8, 1H), 5.09 (d, J=9.2, 1H), 5.00 (d, J=9.2, 1H), 4.50-4.38 (m, 2H), 4.37 (s, 1H), 3.01 (q, J=6.9, 2H), 2.90-2.60 (m, 2H), 2.02 (s, 3H), 1.49 (s, 3H), 1.44-1.35 (m, 2H), 1.34 (s, 3H), 0.82 (t, J=7.5, 3H); HRMS (ESI) m/z calcd for C27H36N3O4S (M+H)+ 498.2424, found 498.2427.
    • EXAMPLE B31 (R)-3-((2S,3S)-3-{[1-(3-Fluoro-2-methyl-phenyl)-methanoyl]-amino}-2-hydroxy-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid propylamide
  • Figure US20050250707A1-20051110-C00156
  • White solid: 1H NMR (DMSO) δ 8.34 (d, J=8.1, 1H), 7.91 (t, J=5.9, 1H), 7.40-7.10 (m, 7H), 6.93 (d, J=6.9, 1H), 5.51 (d, J=6.2, 1H), 5.08 (d, J=8.8, 1H), 5.00 (d, J=8.8, 1H), 4.50-4.39 (m, 2H), 4.38 (s, 1H), 3.00 (dd, J=12.3, 5.9, 2H), 2.90-2.60 (m, 2H), 1.89 (s, 3H), 1.49 (s, 3H), 1.40-1.34 (m, 2H), 1.34 (s, 3H), 0.82 (t, J=7.7, 3H); HRMS (ESI) m/z calcd for C27H35N3O4FS (M+H)+ 516.2332, found 516.2339.
    • EXAMPLE B32 (R)-3-((2S,3S)-3-{[1-(3-Fluoro-2-methyl-phenyl)-methanoyl]-amino}-2-hydroxy-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-methoxy-benzylamide
  • Figure US20050250707A1-20051110-C00157
  • White solid: 1HNMR (DMSO) δ8.43 (t, J=5.9, 1H), 8.34 (d, J=8.1, 1H), 7.31-6.72 (m, 12H), 5.57 (d, J=6.8, 1H), 5.12 (d, J=9.3, 1H), 5.01 (d, J=9.3, 1H), 4.50-4.30 (m, 4H), 4.12 (dd, J=15.7,5.9, 1H), 3.69 (s, 3H), 2.95-2.62 (m, 2H), 1.90 (s, 3H), 1.49 (s, 3H), 1.34 (s, 3H); HRMS (ESI) m/z calcd for C32H37N3O5SF (M+H)+ 594.2434, found 594.2438.
    • EXAMPLE B33 (R)-3-((2S,3S)-3-{[1-(3-Fluoro-2-methyl-phenyl)-methanoyl]-amino}-2-hydroxy-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid allylamide
  • Figure US20050250707A1-20051110-C00158
  • White solid: 1H NMR (DMSO) δ 8.34 (d, J=8.3, 1H), 8.10 (t, J=5.7, 1H), 7.40-6.90 (m, 8H), 5.81-5.69 (m, 1H), 5.54 (d, J=6.6, 1H), 5.30-4.90 (m, 4H), 4.50-4.35 (m, 3H), 3.80-3.65 (m, 2H), 2.90-2.60 (m, 2H), 1.89 (s, 3H), 1.49 (s, 3H), 1.35 (s, 3H); HRMS (ESI) m/z calcd for C27H33N3O4SF (M+H)+ 514.2182, found 514.2176.
    • EXAMPLE B34 3-[(2S,3S)-2-Hydroxy-3-(3-hydroxy-2,5-dimethyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid allylamide
  • Figure US20050250707A1-20051110-C00159
  • 1H NMR (DMSO-d6) δ 9.23 (s, 1H), 8.09 (m, 2H), 7.35-7.17 (m, 5H), 6.60 (s, 1H), 6.37 (s, 1H), 5.74 (m, 1H), 5.41 (brs, 1H), 5.20 (dd, J=17.2, 1.6, 1H), 5.11 (d, J=9.2, 1H), 5.02 (dd, J=10.2, 1.5, 1H), 5.00 (d, J=9.1, 1H), 4.46-4.37 (m, 3H), 3.79 (ddd, J=15.9, 5.5, 5.3, 1H), 3.63 (ddd, J=15.9, 5.4, 5.3, 1H), 2.82 (dd, J=13.9, 0.3, 1H), 2.71 (dd, J=13.6, 10.7, 1H), 2.16 (s, 3H), 1.76 (s, 3H), 1.51 (s, 3H), 1.36 (s, 3H); Anal. Calcd for C28H35N4O5S.0.3H2O: C, 63.32; H, 6.76; N, 7.91, Found: C, 63.35; H, 6.70; N, 7.71.
    • EXAMPLE B35 3-[(2S,3S)-3-(5-Fluoro-3-hydroxy-2-methyl-benzoylamino)-2-hydroxy-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid allylamide
  • Figure US20050250707A1-20051110-C00160
  • 1H NMR (DMSO-d6) δ 9.94 (s, 1H), 8.23 (d, J=8.2, 1H), 8.10 (t, J=5.6, 1H), 7.33-7.17 (m, 5H), 6.58 (dd, J=10.6, 2.5, 1H), 6.32 (dd, J=8.8, 2.5, 1H), 5.78 (m, 1H), 5.54 (brs, 1H), 5.21 (dd, J=17.2, 1.7, 1H), 5.10 (d, J=9.1, 1H), 5.03 (dd, J=10.2, 1.5, 1H), 5.01 (d, J=9.1, 1H), 4.50-4.42 (m, 3H), 3.78 (ddd, J=15.9, 5.4, 5.4, 1H), 3.63 (ddd, J=15.9, 5.4, 5.3, 1H), 2.84 (dd, J=14.5,3.3, 1H), 2.70 (dd, J=13.5, 10.3, 1H), 1.75 (s, 3H), 1.50 (s, 3H), 1.36 (s, 3H); Anal. Calcd for C27H32FN3O5S.0.3H2O: C, 60.61; H, 6.14; N, 7.85, Found: C, 60.63; H, 6.08; N, 8.07.
    • EXAMPLE B36 (R)-3-((2S,3S)-3-{[1-(3-Fluoro-2-methyl-phenyl)-methanoyl]-amino}-2-hydroxy-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00161
  • 1H NMR (DMSO) δ 8.85-8.35 (m, 2H), 7.38-6.90 (m, 12H), 5.55 (d, J=5.9, 1H), 5.12 (d, J=9.2, 1H), 5.01 (d, J=9.2, 1H), 4.58-4.32 (m, 4H), 4.10 (dd, J=15.0,4.6, 1H), 2.92-2.62 (m, 2H), 2.24 (s, 3H), 1.90 (s, 3H), 1.49 (s, 3H), 1.34 (s, 3H); HRMS (ESI) m/z calcd for C32H37N3O4FS (M+H)+ 578.2489, found 578.2486; Anal. Calcd for C32H36N3O4FS.0.2 EtOAc: C, 66.17; H, 6.37; N, 7.06. Found: C, 66.30; H, 6.54; N, 6.74.
    • EXAMPLE B37 (R)-3-((2S,3S)-3-{[1-(4-Fluoro-2-methyl-phenyl)-methanoyl]-amino}-2-hydroxy-4-phenyl-butanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00162
  • White solid: 1H NMR (DMSO) δ 8.40-8.30 (m, 2H), 7.35-6.90 (m, 12H), 5.53 (d, J 6.8, 1H), 5.13 (d, J=9.0, 1H), 5.00 (d, J=9.0, 1H), 4.48 (s, 1H), 4.47-4.45 (m, 2H), 4.38 (dd, J=15.0, 5.9, 1H), 4.10 (dd, J=15.0, 4.8, 1H), 2.90-2.62 (m, 2H), 2.24 (s, 3H), 2.04 (s, 3H), 1.48 (s, 3H), 1.33 (s, 3H); HRMS (ESI) m/z calcd for C32H37N3O4SF (M+H)+ 578.2463, found 578.2489.
    • EXAMPLE B38 Nicotinic acid 3-[(1S,2S)-3-((R)-4-allylcarbamoyl-5,5-dimethyl-thiazolidin-3-yl)-1-benzyl-2-hydroxy-3-oxo-propylcarbamoyl]-2-methyl-phenyl ester
  • Figure US20050250707A1-20051110-C00163
  • White solid: 1H NMR (DMSO) δ 9.26 (dd, J=2.0, 0.9, 1H), 8.90 (dd, J=5.6, 2.0, 1H), 8.47 (dt, J=7.9,2.0, 1H), 8.40 (d, J=8.2, 1H), 8.1 (t, J=5.7, 1H), 7.65 (ddd, J=7.9, 5.6, 0.9, 1H), 7.40-7.10 (m, 8H), 5.82-5.68 (m, 1H), 5.6 (d, J=6.2, 1H), 5.30-4.90 (m, 4H), 4.50-4.40 (m, 2H), 4.40 (s, 1H), 3.80-3.70 (m, 2H), 3.00-2.60 (m, 2H), 1.85 (s, 3H), 1.49 (s, 3H), 1.34 (s, 3H).
    • EXAMPLE B39 (R)-3-[(2S,3S)-2-Hydroxy-3-(4-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00164
  • White solid: 1H NMR (DMSO) δ 9.55 (s, 1H), 8.32 (t, J=4.9, 1H), 8.00 (d, J=8.4, 1H), 7.36-7.00 (m, 10H), 6.54-6.48 (m, 2H), 5.44 (d, J=6.6, 1H), 5.13 (d, J=9.2, 1H), 4.99 (d, J=9.2, 1H), 4.50-4.32 (m, 4H), 4.11 (dd, J=15.0, 4.8, 1H), 3.50-2.80 (m, 2H), 2.25 (s, 3H), 2.04 (s, 3H), 1.49 (s, 3H), 1.33 (s, 3H); Anal. Calcd for C32H37N3O5S.0.25H2O: C, 66.24; H, 6.51; N, 7.24. Found: C, 66.25; H, 6.55; N, 7.35.
    • EXAMPLE B40 6-Amino-pyridine-2-carboxylic acid {(1S,2S)-1-benzyl-3-[(R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl)-amide
  • Figure US20050250707A1-20051110-C00165
  • 1H NMR (DMSO-d6) δ 8.44 (d, 1H, J=5.6), 8.36 (d, 1H, J=9.3), 7.69-7.49 (t, 1H, J 0.7), 7.34-7.06 (m, 10H), 6.61 (d, 1H, J=8.4), 6.27 (br s, 2H) 5.47 (d, 1H, J=7.1), 0.00 (m, 2H), 4.54-4.43 (m, 2H), 4.50 (s, 1H), 4.38 (dd, 1H, J=6.4, 15.2), 4.19 (dd, 1H, J=4.6, 14.7), 2.87-2.65 (m, 2H), 2.28 (s, 3H), 1.53 (s, 3H), 1.38 (s, 3H). Exact mass calculated for C30H36N5O4S (M+H)+ 562.2488, found 562.2493.
    • EXAMPLE B41 ((1S,2S)-1-Benzyl-3-[(R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-2,3-dichloro-isonicotinamide
  • Figure US20050250707A1-20051110-C00166
  • 1H NMR (DMSO-d6) δ 8.89 (d, 1H, J=8.42), 8.40 (t, 1H, J=5.5), 8.38 (d, 1H, J=4.8), 7.30-7.08 (m, 10H), 5.58 (d, 1H, J=7.3), 5.07 (d, 1H, J=8.8), 5.00 (d, 1H, J=8.8), 4.54-4.50 (m, 1H), 4.51 (s, 1H), 4.43-4.36 (m, 2H), 4.16 (dd, 1H, J=5.1, 15.0), 2.89-2.85 (m, 1H), 2.71-2.63 (m, 1H), 2.26 (s, 3H), 1.50 (s, 3H), 1.35s (s, 3H). Exact mass calculated for C30H33N4O4SCl2 (M+H)+ 615.1600, found 615.1581. Anal. Calcd for C30H32N4O4SCl2: C, 58.54; H, 5.24; N, 9.10. Found: C, 58.48; H, 5.10; N, 8.80.
    • EXAMPLE B42 {(1S,2S)-Benzyl-3-[(R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-3-chloro-isonicotinamide
  • Figure US20050250707A1-20051110-C00167
  • 1H NMR (DMSO-d6) δ 8.82 (d, 1H, J=8.6), 8.62 (s, 1H), 8.52 (d, 1H, J=4.9), 8.39 (d, 1H, J=5.1), 7.29-7.09 (m, 10H), 5.54 (d, 1H, J=7.1), 5.09 (d, 1H, J=9.0), 4.99 (d, 1H, J=9.0), 4.56-4.49 (m, 1H), 4.51 (s, 1H), 4.44-4.37 (m, 2H), 4.15 (dd, 1H, J=5.1, 15.0), 2.88-2.83 (m, 1H), 2.74-2.65 (m, 1H), 2.26 (s, 3H), 1.50 (s, 3H), 1.35s (s, 3H). Exact mass calculated for C30H33N4O4SCl (M)+ 581.1989, found 581.1983.
    • EXAMPLE B43 (R)-3-[(2S,3S)-2-Hydroxy-3-(3-hydroxy-2,5-dimethyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00168
  • 1H NMR (DMSO-d6) δ 9.24 (s, 1H), 8.31 (t, J=5.6, 1H), 8.10 (d, J=8.2, 1H), 7.34-7.09 (m, 9H), 6.60 (s, 1H), 6.38 (s, 1H), 5.42 (br s, 1H), 5.14 (d, J=9.1, 1H), 5.01 (d, J=9.1, 1H), 4.50 (s, 1H), 4.50-4.37 (m, 3H), 4.11 (dd, J=15.1, 4.7, 1H), 2.76 (m, 2H), 2.26 (s, 3H), 2.16 (s, 3H), 1.77 (s, 3H), 1.50 (s, 3H), 10.35 (s, 3H); HRMS (ESI) m/z calcd for C33H40N3O5S (M+H)+ 590.2689, found 590.2676; Anal. Calcd for C33H39N3O5S.0.3H2O: C, 66.60; H, 6.71; N, 7.06. Found: C, 66.65; H, 6.69; N, 7.05.
    • EXAMPLE B44 N-{(1S,2S)-1-Benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-2-methyl-nicotinamide
  • Figure US20050250707A1-20051110-C00169
  • White solid: 1H NMR (DMSO-d6) δ 8.53-8.33 (m, 2H), 7.47 (d, J=7.82, 1H), 7.38-7.10 (m, 12H), 5.62 (d, J=7.94, 1H), 5.18 (dd, J=9.6, 7.6, 2H), 4.43-4.37 (m, 3H), 4.17 (dd, J=7.81, 6.99, 1H), 2.87-2.67 (m, 2H), 2.28 (s, 3H), 2.21 (s, 3H), 1.49 (s 3H), 1.34 (s, 3H); Anal. (C31H36N4O4S.1.0H2O.1.0MeCN) calculated C (63.95), H (6.67), N (11.30), found C (63.94), H (6.75), N (11.26). HRMS (ESI) m/z calcd for 561.2544, found 561.2556.
    • EXAMPLE B45 Pyridine-2-carboxylic acid {(1S,2S)-1-benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-amide
  • Figure US20050250707A1-20051110-C00170
  • White solid: 1H NMR (DMSO-d6) δ 8.89 (d, J=7.86,), 8.66 (d, J=4.2, 1H), 8.39 (t, J=6.54, 1H), 7.89 (m 2H), 7.32-7.12 (m, 9H), 5.68 (d, J=7.28, 1H), 5.03 (dd J=9.7, 8.3, 2H), 4.56(m 3H), 4.40 (d, J=7.5, 1H), 4.35 (d, J=7.5, 1H), 4.21 (d, J=6.7, 1H), 2.87-2.67 (m, 2H), 2.25 (s 3H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. (C30H34N4O4S.0.1H2O.0.1 EtOAc) calculated C (65.52), H (6.33), N (10.05), found C (65.78), H (6.69), N (9.66). HRMS (ESI) m/z calcd for 547.2380, found 547.2373.
    • EXAMPLE B46 Pyridine-2-5-hydroxy-carboxylic acid {(1S,2S)-1-benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}--amide
  • Figure US20050250707A1-20051110-C00171
  • White solid: 1H NMR (DMSO-d6) δ 8.89 (d, J=7.9, 1), 8.66 (d, J=4.2, 1H), 8.39 (t, J=6.54, 1H), 7.89 (m 2H), 7.32-7.12 (m, 9H), 5.68 (d, J=7.2, 1H), 5.03 (dd J=9.7, 8.3, 2H), 4.56 (m 3H), 4.40 (d, J=7.5, 1H), 4.35 (d, J=7.5, 1H), 4.21 (d, J=6.7, 1H), 2.87-2.67 (m, 2H), 2.25 (s 3H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. (C30H34N4O5S.0.5H2O.0.5 EtOAc) calculated C (62.29), H (6.42), N (9.91), found C (62.53), H (6.84), N (10.10). HRMS (ESI) m/z calcd for 563.2325, found 563.2328.
    • EXAMPLE B47 N-{(1S,2S)-1-Benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-nicotinamide
  • Figure US20050250707A1-20051110-C00172
  • White solid 1H NMR (DMSO-d6) δ 8.89 (d, J=7.9, 1H), 8.66 (d, J=4.2, 1H), 8.39 (t, J=6.54, 1H), 7.89 (m 2H), 7.32-7.12 (m, 9H), 5.68 (d, J=7.3, 1H), 5.03 (dd J=9.7, 8.3, 2H), 4.56(m 3H), 4.40 (d, J=7.5, 1H), 4.35 (d, J=7.5, 1H), 4.21 (d, J=6.7, 1H), 2.87-2.67 (m, 2H), 2.25 (s 3H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. (C30H34N4O4S.0.5H2O.0.5 MeCN) calculated C (64.61), H (6.39), N (10.94), found C (65.02), H (6.58), N (10.90). HRMS (ESI) m/z calcd for 547.2372, found 547.2379.
    • EXAMPLE B48 N-{(1S,2S)-1-Benzyl-3-[5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl-2-hydroxy-3-oxo-propyl}-nicotinamide
  • Figure US20050250707A1-20051110-C00173
  • White solid: 1H NMR (DMSO-d6) δ 8.89 (d, J=7.9, 1H), 8.66 (d, J=4.2, 1H), 8.39 (t, J=6.54, 1H), 7.89 (m 2H), 7.32-7.12 (m, 9H), 5.68 (d, J=7.28, 1H), 5.03 (dd J=9.7, 8.3, 2H), 4.56 (m, 3H), 4.40 (d, J=7.5, 1H), 4.35 (d, J=7.5, 1H), 4.21 (d, J=6.7, 1H), 2.87-2.67 (m, 2H), 2.25 (s 3H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. (C30H34N4O5S.1.3H2O) calculated C (61.42), H (6.32), N (9.49), found C (61.64), H (6.17), N (9.12). HRMS (ESI) m/z calcd for 563.2326, found 563.2328.
    • EXAMPLE B49 N-[(1S,2S)-3-(4-Allylcarbamoyl-5,5-dimethyl-thiazolidin-3-yl)-1-benzyl-2-hydroxy-3-oxo-propyl]-2-methyl-nicotinamide
  • Figure US20050250707A1-20051110-C00174
  • White solid: 1H NMR (DMSO-d6) δ 8.58 (m, 1H), 8.29 (d, J=7.54, 1H), 7.78 (d, J=7.88, 2H), 7.32-7.12 (m, 7H), 5.78 (m, 1H), 5.18 (dd J=9.7,8.3, 2H), 4.56 (m, 3H), 4.40 (m, 4H), 2.87-2.67 (m, 2H), 2.25 (s 3H), 1.49 (s, 3H), 1.34 (s, 3H); Anal. (C26H32N4O4S.0.5H2O.0.5 TFA) calculated C (57.68), H (6.66), N (8.31), found C (57.66), H (6.18), N (8.77). HRMS (ESI) m/z calcd for 497.2232, found 497.2223.
    Figure US20050250707A1-20051110-C00175
  • The synthesis of compounds with the general structure 24 is as follows. The boc-protected carboxylic acids 20a-f are coupled to the requisite amines 2 to yield amino amides 23 using a two step process. The process includes treatment of 20 with 2 in the presence of either diphenyl chlorophosphate or EDCI, followed by exposure to HCl or methane sulfonic acid. Final compounds 24 are obtained by a DCC-mediated coupling of 23 and 4 followed by deprotection of the P2 phenol. Final compounds were purified either by flash chromatography or preparative HPLC.
    Figure US20050250707A1-20051110-C00176
  • The synthesis of compounds of the general structure 31 (where P2 is not 2-methyl-3-hydroxy benzamide) is as follows. Amino amides of the general structure 23 were coupled to the Boc-acid intermediate 15 using DCC coupling conditions. The resulting intermediate 29 was deprotected under acidic conditions to yield amine of the general structure 30. Final compounds were obtained by modification of amine 30 by methods described in General Methods B section to give P2 amides and ureas.
  • Methods Used for Synthesis of Compounds with P1 Variations.
  • EDCI coupling—To a solution of acid, amine and HOBT in CH2Cl2 was added EDCI and the solution stirred overnight at room temperature. The solution was concentrated in vacuo and the residue dissolved in ethyl acetate and a small portion of water. The solution was washed with saturated NH4Cl (2×), saturated NaHCO3 (2×), brine (1×), dried with MgSO4 and concentrated in vacuo. The crude used without further purification unless otherwise noted.
  • DCC coupling—A solution of acid, amine and HOBT was prepared in ethyl acetate. To the solution was then added DCC in an EtOAc solution at 0° C. and the mixture was stirred overnight at room temperature. The mixture was filtered and the filtrate was concentrated in vacuo. The residue dissolved in ethyl acetate washed with saturated NH4Cl (1×), saturated NaHCO3 (1×), brine (1×), dried over Na2SO4 and concentrated in vacuo. The crude was used without further purification unless otherwise noted.
  • 4N HCl Boc deprotection—To a solution of Boc-amine in dioxane was added 4N HCl solution in dioxane and the solution stirred overnight at room temperature. The solution was poured into saturated NaHCO3 and the product was extracted into ethyl acetate. The organic solution was washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude was used without further purification unless otherwise noted.
  • MeSO3H Boc deprotection—To a solution of Boc-amine in ethyl acetate at 0° C. was added methane sulfonic acid and the solution stirred 3-6 h at room temperature. The solution was cooled to 0° C. and sufficient saturated NaHCO3 was added to quench the acid. The solution was diluted with ethyl acetate, washed with saturated NaHCO3 and brine, dried over Na2SO4 and concentrated in vacuo. The crude used without further purification unless otherwise noted.
  • KCN Phenolic acetate deprotection—A solution of phenolic acetate and KCN in ethanol was heated at 50° C. overnight. The solution was concentrated in vacuo. The residue was purified by flash chromatography eluted with 0 to 5% methanol in CH2Cl2 unless otherwise noted.
  • NaOMe/MeOH Phenolic acetate deprotection—0.5 N NaOCH3/MeOH Phenolic acetate deprotection—A solution of phenolic acetate in EtOAc and methanol was cooled to 0° C. in an ice bath. 0.5 N NaOCH3/MeOH was then added dropwise and then stirred at 0° C. for 1.5-2 hrs following addition. Additional EtOAc was then added, the 0.15 N HCl (4.5 eq.) added dropwise. The phases were separated and organic phase washed with 2.5% Na2CO3 aqueous solution, then with 0.1 N HCl/brine (2:1), followed with brine, dried with MgSO4 and concentrated in vacuo. The resulting residue subjected to flash silica gel chromatography to afford the desired product unless otherwise noted.
  • HCl/MeOH Phenolic acetate deprotection—To a solution of phenolic acetate in methanol was added 4N HCl in dioxane and the solution stirred at room temperature ca. 4 h. The solution was concentrated in vacuo. The residue was purified by flash chromatography eluted with 0 to 5% methanol in CH2Cl2 unless otherwise noted.
    Fragments of the General Structure 20.
    Figure US20050250707A1-20051110-C00177
  • Source of Boc-carboxylic Acids 20a-f
  • Boc-acids 20a and 20b were prepared following the procedure of Demange, L.; Menez, A.; Dugave, C. Tet. Lett. 1998, 39, 1169.
  • Boc-acids 20c, 20d, 20e and 20f were prepared following the procedure of Karanewsky, D.; et al. J. Med. Chem. 1990, 33, 1459.
  • Specific Method C
    • EXAMPLE C1 (S)-4,4-Difluoro-1-[(2S,3S)-2-hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-pyrrolidine-2-carboxylic acid 2-methyl-benzylamide.
  • Figure US20050250707A1-20051110-C00178
    The title compound was prepared according to general methods using the corresponding Boc-protected pyrrolidinic acid (0.96 g, 3.8 mmol), o-methylbenzyl amine (0.57 mL, 4.6 mmol), HOBT (0.62 g, 4.6 mmol), EDCI (0.88 g, 4.6 mmol), CH2Cl2 (50 mL). To give the crude Boc-amide (MS-APCI (m/z+): 355, 255) (1.35 g, 3.8 mmol). The Boc was removed using the general 4N HCl Boc deprotection. 4N HCl in 1,4-dioxane (5 mL), 1,4-dioxane (5 mL). The result was amino amide of general structure 23. Isolated yield: 0.79 g (71%, 2 steps). 1H NMR (400 MHz, DMSO-d6): δ 9.02 (t, 1H), 7.24-7.14 (m, 4H), 4.55 (t, 1H), 4.35 (dd, 1H), 4.30 (dd, 1H), 3.73 (m, 2H), 2.94 (m, 2H), 2.52 (m, 1H), 2.27 (s, 3H); 19F NMR (376 MHz, DMSO-d6): 6-95.3 (dq, J=235, 15 Hz, 1F), 96.5 (dq, J=235, 12 Hz, 1F); MS-APCI (m/z+): 255.
  • Amino amide 23 (100 mg, 0.34 mmol) was coupled to carboxylic acid 4 (140 mg, 0.38 mmol) using the general DCC coupling method outlined above. HOBT (51 mg, 0.38 mmol), DCC (78 mg, 0.38 mmol), TEA (50 μL, 0.36 mmol), CH2Cl2 (10 mL). The crude was purified by chromatography eluted with 10% acetone in CH2Cl2. Isolated yield: 0.13 g (63%). MS-APCI (m/z+): 608. This material was subjected to the general KCN phenolic acetate deprotection conditions (130 mg, 0.21 mmol), KCN (1 mg, 15 μmol), ethanol (10 mL). The crude was precipitated from diethyl ether and ethyl acetate with hexanes at −78° C. Isolated yield: 0.110 g (84%). 1H NMR (400 MHz, DMSO-d6): δ 9.37 (s, 1H), 8.36 (t, 1H), 8.16 (d, 1H), 7.32-7.09 (m, 9H), 6.93 (t, 1H), 6.76 (d, 1H), 6.54 (d, 1H), 5.49 (d, 1H), 4.66 (dd, 1H), 4.34-4.15 (m, 6H), 2.85-2.67 (m, 3H), 2.40 (m, 1H), 2.22 (s, 3H), 1.79 (s, 3H); 19F NMR (376 MHz, DMSO-d6): δ −98.7 (m, 2F); MS-APCI (m/z+): 566; HPLC Purity: 100%; Rf (min.) 19.01; Anal. C31H33N3O5F2.0.3H2° C., H, N calcd: C, 65.21; H, 5.93; N, 7.36; found: C, 65.11; H, 5.90; N, 7.17.
    • EXAMPLE C2 (2S,4R)-4-Fluoro-1-[(2S,3S)-2-hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-pyrrolidine-2-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00179
  • Isolated material was subjected to flash silica gel chromatography, eluting with EtOAc/hexanes (50/50) then with EtOAc EtOAc/hexanes (4:1) to afford the title compound. 1H NMR (400 MHz, DMSO-d6): δ 9.37 (s, 1H), 8.46 (t, 1H), 8.21 (d, 1H), 7.34 (d, 2H), 7.26 (d, 2H), 7.21 (t, 2H), 7.15-7.07 (m, 3H), 6.94 (t, 1H), 6.76 (d, 1H), 6.56 (d, 1H), 5.51+5.38 (bs+bs, 1H), 5.06 (d, 1H), 4.58 (t, 1H), 4.45 (dd, 1H), 4.35-4.27 (m, 2H), 4.21-4.09 (m, 3H), 3.94-3.91+3.84-3.81 (m+m, 1H), 2.69 (d, 2H), 2.23 (s, 3H), 2.19-2.01 (m, 1N), 1.83 (s, 3H); MS-APCI (m/z+): 548; HPLC: Rf (min.) 18.72; Purity: 96%. Anal. C31H34N3O5F.0.3H2O calcd: 67.33, 6.31, 7.60, found: 67.37, 6.25, 7.35.
    • EXAMPLE C3 (2S,4S)-4-Fluoro-1-[(2S,3S)-2-hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl-butyryl]-pyrrolidine-2-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00180
  • Isolated material was subjected to flash silica gel chromatography, eluting with EtOAc/hexanes (50/50) then with EtOAc to afford the title compound. 1H NMR (400 MHz, DMSO-d6): δ 9.37 (s, 1H), 8.21 (d, 1H), 7.96 (t, 1H), 7.29 (d, 2H), 7.23 (t, 2H), 7.18-7.13 (m, 2H), 7.10-7.04 (m, 3H), 6.90 (t, 1H), 6.75 (d, 1H), 6.52 (d, 1H), 5.55 (d, 1H), 5.45+5.32 (bs+bs, 1H), 4.54 (d, 1H), 4.42-4.36 (m, 1H), 4.29-4.40 (m, 5H), 2.98 (t, 1H), 2.73 (t, 1H), 2.32-2.21 (m, 2H), 2.19 (s, 3H), 1.78 (s, 3H); MS-APCI (m/z+): 548; HPLC: Rf (min.) 18.21; Purity: 99%; Anal. C31H34N3O5F.0.5H2O calcd: 66.89, 6.34, 7.55, found: 66.85, 6.22, 7.41.
    • EXAMPLE C4 (S)-3-((2S,3S)-2-Hydroxy-3-{1′-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-oxazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00181
  • White solid; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.80 (dd, J=8.8,4.8, 1H), 8.30 (t, J=5.5, 1H), 8.12 (d, J=8.6, 1H), 7.30-7.13 (m, 9H), 6.96 (t, J=7.9, 1H), 6.76 (d, J=7.9, 1H), 6.55 (d, J=7.2, 1H), 5.74 (d, J=8.8, 1H), 5.31 (d, J=3.8, 1H), 5.23 (d, J=4.2, 1H), 4.49 (dd, J=6.6, 6.5, 1H), 4.33-4.11 (m, 5H), 2.94-2.68 (m, 2H), 2.24 (s, 3H), 1.78 (s, 3H); HRMS (ESI) m/z calcd for C30H34N3O6 (M+H)+ 532.2448, found 532.2450.
    • EXAMPLE C5 (4S,5R)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5-methyl-oxazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00182
  • White solid; 1HNMR (DMSO-d6) δ9.38 (s, 1H), 8.51 (t, J=6.0, 1H), 8.15 (d, J=8.4, 1H), 7.33-7.13 (m, 9H), 6.96 (t, J=7.7, 1H), 6.79 (d, J=8.2, 1H), 6.58 (d, J=7.3, 1H), 5.69 (d, J=5.7, 1H), 5.50 (d, J=4.6, 1H), 5.10 (d, J=4.8, 1H), 4.39-4.22 (m, 4H), 4.11-4.01 (m, 2H), 2.90 (m, 1H), 2.74 (m, 1H), 227 (s, 3H), 1.82 (s, 3H), 1.37 (d, J=5.9, 1H); HRMS (ESI) m/z calcd for C31H36N3O6 (M+H)+ 546.2604, found 546.2595.
    • EXAMPLE C6 (S)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-oxazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00183
  • White solid; 1H NMR (DMSO-d6) δ 9.34 (s, 1H), 8.32 (t, J=5.8, 1H), 8.11 (J=9.0, 1H), 7.31-7.10 (m, 9H), 6.93 (t, J=7.9, 1H), 6.76 (d, J=8.1, 1H), 6.55 (d, J=6.5, 1H), 5.73 (d, J=4.0, 1H), 5.46 (d, J=4.1, 1H), 5.23 (d, J=3.9, 1H), 4.39-4.32 (m, 2H), 4.18 (m, 3H), 2.92 (m, 1H), 2.69 (m, 1H), 2.27 (s, 3H), 1.81 (s, 3H), 1.28 (s, 3H), 1.18 (s, 3H); HRMS (ESI) m/z calcd for C32H38N3O6 (M+H)+ 560.2761, found 560.2759; Anal. Calcd for C32H37N3O6.0.5H2O: C, 67.59; H, 6.74; N, 7.39. Found: C, 67.74; H, 6.75; N, 7.16.
    • EXAMPLE C7 (S)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-oxazolidine-4-carboxylic acid propylamide
  • Figure US20050250707A1-20051110-C00184
  • 1H NMR (DMSO-d6) δ 9.37 (s, 1H), 8.12 (d, J=9.3, 1H), 7.93 (t, J=5.6, 1H), 7.34-7.18 (m, 5H), 6.96 (t, J=8.1, 1H), 6.79 (d, J=8.1, 1H), 6.56 (d, J=7.1, 1H), 5.73 (d, J 6.2, 1H), 5.44 (d, J=4.0, 1H), 5.24 (d, J=3.8, 1H), 4.36 (m, 1H), 4.18 (m, 1H), 4.11 (s, 1H), 3.10-2.92 (m, 3H), 2.75-2.66 (m, 1H), 1.80 (s, 3H), 1.46-1.39 (m, 2H), 1.31 (s, 3H), 1.22 (s, 3H), 0.86 (t, J=7.2, 3H); HRMS (ESI) m/z calcd for C27H36N3O6 (M+H)+498.2604, found 498.2590.
    • EXAMPLE C8 (4S,5S)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5-methyl-oxazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00185
  • White solid; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.26 (t, J=5.5, 1H), 8.09 (d, J=8.8, 1H), 7.30-7.08 (m, 9H), 6.93 (t, J=7.7, 1H), 6.76 (d, J=7.9, 1H), 6.56 (d, J=7.5, 1H), 5.72 (d, J=64, 1H), 5.55 (d, J=3.7, 1H), 5.08 (d, J=3.8, 1H), 4.40-4.33 (m, 3H), 4.26-4.11 (m, 3H), 3.10-2.89 (m, 1H), 2.78-2.67 (m, 1H), 2.26 (s, 3H), 1.78 (s, 3H), 1.15 (d, J=6.2, 3H); HRMS (ESI) m/z calcd for C31H36N3O6 (M+H)+ 546.2604, found 546.2592.
    • EXAMPLE C9 (S)-3-(2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-oxazolidine-4-carboxylic acid 5-fluoro-2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00186
  • White solid; 1H NMR (DMSO-d6) δ 9.35 (s, 1H), 8.41 (t, J=5.6, 1H), 8.12 (d, J=8.9, 1H), 7.28-7.08 (m, 8H), 6.95-6.90 (m, 1H), 6.76 (d, J=8.1, 1H), 6.55 (d, J=7.2, 1H), 5.78 (d, J=6.1, 1H), 5.47 (d, J=3.8, 1H), 5.24 (d, J=3.8, 1H), 4.40-4.25 (m, 2H), 4.20-4.10 (m, 3H), 3.00-2.60 (m, 2H), 2.22 (s, 3H), 1.77 (s, 3H), 1.30 (s, 3H), 1.19 (s, 3H); Anal. Calcd for C32H36N3O6F: C, 66.54; H, 6.28; N, 7.27. Found: C, 66.37; H, 6.20; N, 7.21.
    • EXAMPLE C10 (S)-3-((2S,3S)-2-Hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenyl-butanoyl)-5,5-dimethyl-oxazolidine-4-carboxylic acid cyanomethyl-amide
  • Figure US20050250707A1-20051110-C00187
  • White solid; 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.72 (t, J=5.3, 1H), 8.11 (d, J=9.0, 1H), 7.29-7.16 (m, 5H), 6.94 (t, J=7.7, 1H), 6.76 (d, J=8.1, 1H), 6.50 (d, J=7.5, 1H), 5.85 (d, J=6.0, 1H), 5.49 (d, J=4.0, 1H), 5.23 (d, J=3.9, 1H), 4.35 (m, 1H), 4.18-4.12 (m, 3H), 4.11 (s, 1H), 2.92 (m, 1H), 2.70 (m, 1H), 1.76 (s, 3H), 1.29 (s, 3H), 1.19 (s, 3H); HRMS (ESI) m/z calcd for C26H31N4O6 (M+H)+ 495.2244, found 495.2239.
    • EXAMPLE C1 (S)-3-((2S,3S)-3-{[1-(3-Fluoro-2-methyl-phenyl)-methanoyl]-amino}-2-hydroxy-4-phenyl-butanoyl)-5,5-dimethyl-oxazolidine-4-carboxylic acid 2-methyl-benzylamide
  • Figure US20050250707A1-20051110-C00188
  • 1H NMR (DMSO-d6) δ 8.34 (m, 2H), 7.30-7.13 (m, 1H), 6.95 (d, J=7.1, 1H), 5.82 (d, J=6.4, 1H), 5.45 (d, J=3.9, 1H), 5.23 (d, J=4.0, 1H); 4.38-4.31 (m, 2H), 4.18-4.15 (m, 3H), 2.96 (m, 1H), 2.67 (m, 1H), 2.26 (s, 3H), 1.87 (s, 3H), 1.28 (s, 3H), 1.18 (s, 3H); HRMS (ESI) m/z calcd for C32H37N3O5F (M+H)+ 562.2717, found 562.2713.
    Figure US20050250707A1-20051110-C00189
  • The synthesis of compounds with the general structure 27 is as follows. The boc-protected thiazolidine carboxylic acid 1 is converted to amino-ketones 26 with requisite grignard reagents 25 in the presence of oxalyl chloride. Final compounds 27 are obtained by a DCC-mediated coupling of 26 and 4 followed by deprotection of the P2 phenol. Final compounds were purified either by flash chromatography or preparative HPLC.
  • Specific Method D
    • EXAMPLE D1 N-[(1S,2S)-1-Benzyl-3-((R)-5,5-dimethyl-4-pent-4-enoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propyl]-3-hydroxy-2-methyl-benzamide
  • Figure US20050250707A1-20051110-C00190
  • The title compound was prepared as follows. (R)-5,5-Dimethyl-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 1 (1.0 g, 3.80 mmol) was dissolved in benzene (10 mL) and cooled to 0° C. with magnetic stirring. Two drops of DMF were added followed by a drop wise addition of oxalyl chloride (0.33 mL, 3.80 mmol). When gas evolution ceased, the solution was concentrated to a yellow/red residue. The material was dissolved in dry THF (10 mL) and cooled to −78° C. with magnetic stirring. The grignard reagent, 3-butenylmagnesium bromide (7.7 mL, 3.80 mmol) was added dropwise over 10 min. The result was stirred at −78° C. for 1 h then at −55° C. for 30 min. The reaction was quenched at −55° C. with sat NH4Cl soln. (3 mL) and then poured into H2O (50 mL). The mixture was extracted with EtOAc (2×50 mL). The combined organics were washed with brine (1×100 mL), dried over Na2SO4, filtered, and concentrated. The result was the amino ketone 26 that was sufficiently pure to use in the subsequent step. The clear oil 26 (0.24 g, 1.15 mmol) was dissolved in EtOAc (10 mL). AMB-AHPBA 4 (0.40 g, 1.09 mmol) was added followed by HOBt (0.15 g, 1.09 mmol). The mixture was stirred at room temperature 1 h, then cooled to 0° C. DCC (0.24 g, 1.15 mmol) was slowly added as solution in EtOAc (6 mL). The mixture was warmed to room temperature and stirred overnight. The mixture was filtered and the filtrate was washed with 1N HCl (10 mL), saturated NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4 and concentrated to give a crude white solid (contaminated with DCU). The DCU was removed by flash chromatography (30% to 50% EtOAc in hexanes) to provide a white solid, which was dissolved in MeOH (2 mL) and treated with 4N HCl in 1,4-dioxane (0.26 mL, 1.1 mmol). The reaction was stirred at room temperature overnight then partitioned between 1N HCl (10 mL) and EtOAc (10 mL). The organic layer was washed with saturated sat. NaHCO3 (1×25 mL) dried over Na2SO4, filtered, and concentrated to a residue which was purified by flash chromatography (60% EtOAc in hexanes) to provide the title compound as a white amorphous solid: 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.23 (d, J=8.1, 1H), 7.35-7.14 (m, 5H), 6.96 (t, J=7.5, 1H), 6.78 (d, J=8.2, 1H), 6.52 (d, J=7.5, 1H), 5.81-5.69 (m. 2H), 5.32 (d, J=9.7, 1H), 5.11-5.91 (m, 3H), 4.40 (m, 3H), 2.89-2.61 (m, 4H), 2.37-2.14 (m, 2H), 1.81 (s, 3H), 1.55 (s, 3H), 1.30 (s, 3H); Anal. Calcd for C28H34N2O5S: C, 65.86; H, 6.71; N, 5.49. Found: C, 65.52; H, 6.55; N, 5.81.
  • The following examples were synthesized using the specific method outlined above using the appropriate grignard reagent for the desired compound.
    • EXAMPLE D2 N-{1-Benzyl-3-[5,5-dimethyl-4-(4,4,4-trifluoro-butanoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-3-hydroxy-2-methyl-benzamide
  • Figure US20050250707A1-20051110-C00191
  • 1H NMR (DMSO-d6) δ 9.34 (s, 1H), 8.16 (d, 1H, J=8.6), 7.29-6.49 (m, 8H), 5.88 (d, 1H, J=6.1), 5.33 (d, 1H, J=9.5), 5.10 (d, 1H, J=9.5), 4.56 (s br, 3H), 2.98-2.57 (m, 6H), 1.74 (s, 3H), 1.55 (s, 3H), 1.30 (s, 3H); HRMS (ESI) m/z calcd for C27H32N2O5SF3 (M+H)+ 553.1984, found 553.1984; Anal. Calcd for C27H31N2O5SF3.0.5H2O: C, 58.59; H, 5.66; N, 5.06; S, 5.79. Found: C, 58.96; H, 6.02; N, 5.58; S, 5.33.
    • EXAMPLE D3 N-{1-Benzyl-2-hydroxy-3-[4-(4-methoxy-butanoyl)-5,5-dimethyl-thiazolidin-3-yl]-3-oxo-propyl}-3-hydroxy-2-methyl-benzamide
  • Figure US20050250707A1-20051110-C00192
  • 1H NMR (DMSO-d6) δ 9.34 (s, 1H), 8.18 (d, 1H, J=8.2), 7.32-6.51 (m, 8H), 5.56 (d, 1H, J=7.8), 5.26 (d, 1H, J=9.5), 5.08 (d, 1H, J=9.5), 4.45-4.38 (m, 2H), 4.36 (s, 1H), 3.15 (s, 3H), 2.93-2.61 (m, 2H), 1.87-1.00 (m, 6H), 1.80 (s, 3H), 1.55 (s, 3H), 1.36 (s, 3H); HRMS (ESI) m/z calcd for C28H37N2O6S (M+H)+ 529.2165, found 529.2372;
  • Anal. Calcd for C28H36N2O6S. 0.5 H2O: C, 62.55; H, 6.94; N, 5.21; S, 5.96. Found: C, 62.89; H, 7.32; N, 5.96; S, 5.59.
    • EXAMPLE D4 (R)-3-[(2S,3S)-2-Hydroxy-3-(3-hydroxy-2,5-dimethyl-benzoylamino)-4-phenyl-butyryl]-5,5-dimethyl-thiazolidine-4-carboxylic acid allylamide
  • Figure US20050250707A1-20051110-C00193
  • White solid: 1H NMR (DMSO-d6) δ 9.23 (s, 1H), 8.09 (m, 2H), 7.35-7.17 (m, 5H), 6.60 (s, 1H), 6.37 (s, 1H), 5.82-5.68 (m, 1H), 5.41 (br s, 1H), 5.20 (dd, 1H, J=1.6, 17.2), 5.11 (d, 1H, J=9.2), 5.02 (dd, 1H, J=1.5, 10.2), 5.00 (d, 1H, J=9.1), 4.46-4.37 (m, 3H), 3.79 (ddd, 1H, J=5.3,5.5, 15.9), 3.63 (ddd, 1H, J=5.4, 5.3, 15.9), 2.82 (dd, 1H, J=0.3, 13.9), 2.71 (dd, 1H, J=10.7, 13.6), 2.16 (s, 3H), 1.76 (s, 3H), 1.51 (s, 3H), 1.36 (s, 3H); HRMS (ESI) m/z calcd for C28H36N3O5S (M+H)+ 526.6670, found 526.2376; Anal. Calcd for C28H35N3O5S 0.3H2O: C, 63.32; H, 6.76; N, 7.91, Found: C, 63.35; H, 6.70; N, 7.71.
    Combinatorial Chemistry Approach to HIV Protease P2′ Inhibitors
    Figure US20050250707A1-20051110-C00194
  • The combinatorial building block, 8, is prepared using the following method. The boc-protected thiazolidine carboxylic acid, 1, is treated with allyl bromide in the presence of NaHCO3 to yield the boc-protected thiazolidine allyl ester, 2. Deprotection of boc-protected allyl ester, 2, with HCl (g) in EtOAc gives the HCl salt of the thiazolidine allyl ester amine, 3, which is treated with TEA and coupled to 4 in the presence of HOBT and DCC to give the building block precursor, 5. Deprotection of the building block, 5, with 4N HCl yields the phenol, 6. Loading the building block, 6, on to activated cross-linked trityl chloride polystyrene beads, 7, was accomplished in the following manner. The polystyrene cross-linked trityl alcohol was activated to the trityl chloride, 7, by treatment with 20% acetyl chloride in anhydrous CH2Cl2 at room temperature. The trityl chloride beads were combined with the phenol 6 in the presence of Hunig's base in anhydrous CH2Cl2 to yield the substrate loaded polystyrene beads 8. Intermediates were purified either by flash chromatography or preparative HPLC.
    Figure US20050250707A1-20051110-C00195
  • The synthesis of the HIV protease combinatorial library was carried out in the following fashion. The allyl ester was removed by treatment with Pd[PPh3]4 and NMM in anhydrous THF to give carboxylate 9, which was treated with pentafluorophenol, pentafluorophenol trifluoromethyl acetate and pyridine in DMF to yield the pentafluoro ester, 10. The pentafluoro ester 10 was treated with various primary amines in a 96-well plate format to give amides 12. The final products were cleaved from the polystyrene crowns with TFA to give products 13. Each product was analyzed by LCMS and HPLC. The following table typifies compounds synthesized by this combinatorial method.
    TABLE 1
    Expected
    Mass Observed %
    P2′ (LCMS) Mass Inhibition
    Figure US20050250707A1-20051110-C00196
         		529 552(Na+) 38
    Figure US20050250707A1-20051110-C00197
         		528 529(MH+) 4
    Figure US20050250707A1-20051110-C00198
         		591 614(Na+) 18
    Figure US20050250707A1-20051110-C00199
         		555 578(Na+) 19
    Figure US20050250707A1-20051110-C00200
         		635 658(Na+) 5
    Figure US20050250707A1-20051110-C00201
         		656 656(MH+) 8
    Figure US20050250707A1-20051110-C00202
         		575 598(Na+) 86
    Figure US20050250707A1-20051110-C00203
         		541 564(Na+) 63
    Figure US20050250707A1-20051110-C00204
         		529 552(Na+) 49
  • Figure US20050250707A1-20051110-C00205
  • The solid phase combinatorial synthesis of HIV protease inhibitors was performed using the IRORI Directed Sorting Technology. Commercial 4-formyl-3-methoxyphenoxymethyl polystyrene resin 1a (PS-MB-CHO, Argonaut Technologies) or 4-formyl-3,5-dimethoxyphenoxymethyl polystyrene resin 1b (PL-FDMP resin, Polymer Laboratories) was loaded into individual Minikans.
  • Step A. Reductive Amination with P2′ Amines
  • To separate flasks containing sorted MiniKans was added DCM (3 mL/MiniKan). The appropriate primary P2′ amine (3 eq), sodium triacetoxyborohydride (5 eq), and acetic acid (3 eq) were added, and the mixtures were placed under argon, agitated with periodic venting at room temperature for 1-2 hours, and allowed to react overnight. For resin 1a, the filtrates were poured off and the MiniKans were washed with DCM, MeOH (2×), DCM (2×), Et3N/DCM (1:3, 3×), DCM (2×), MeOH (3×), and DCM (4×). For resin 1b, a washing sequence of DCM, MeOH (2×), DCM (2×), Et3N/DCM (1:3, 3×), DCM (2×), DMF, 1M NaOH/DMF (1:5, 3×), DMF (3×), MeOH (3×), and DCM (3×) was used. The MiniKans were dried under vacuum and taken on in Step B.
  • Step B. Peptide Coupling with P1′ Amino Acids
  • To separate flasks containing the sorted MiniKans was added DMF (3 mL/MiniKan). The appropriate FMOC-protected amino acid (2.5 eq) and 1-hydroxy-7-azabenzotriazole (HOAT) (3 eq) were added and mixed until dissolved, and 1,3-diisopropylcarbodiimide (DIC) (3 eq) was added. The containers were placed under argon and agitated at room temperature overnight. The filtrates were poured off, and the MiniKans were washed with DMF (3×), MeOH (3×), DCM (2×), and DMF (2×). The MiniKans were taken directly on to Step C.
  • Step C. FMOC Deprotection
  • A container of MiniKans in DMF and piperidine (25%) with a total reaction volume of 3 mL/MiniKan was agitated under argon at room temperature for 45 minutes. The filtrate was removed, and the reaction procedure was repeated. The MiniKans were filtered and washed with DMF (3×), MeOH (2×), DCM (3×), and DMF, and taken directly on to Step D.
  • Step D. Peptide Coupling with FMOC-APNS
  • FMOC-Allophenylnorstatine (APNS) (3 eq) was added to the flask of MiniKans in DMF (3 mL/MiniKan). After dissolution, HOAT (3.5 eq) and DIC (3.5 eq) were added. The mixture was placed under argon and agitated at room temperature overnight. The reaction was filtered and the MiniKans were washed with DMF (3×), MeOH (3×), DCM (3×), and DMF. FMOC deprotection was carried out as in Step C, and the MiniKans were washed with DMF (3×), MeOH (2×), DCM (3×), dried under vacuum and taken on to Step E or F.
  • Step E. Peptide Coupling with P2 Acids
  • To separate flasks containing the sorted MiniKans in DMF (3 mL/MiniKan) was added the appropriate P2 acid (3 eq), HOBT hydrate (4 eq), and (3-(dimethylamino)propyl)ethylcarbodiimide hydrochloride (EDAC) (3.5 eq). The reaction was agitated under argon at room temperature for 3 hours. After filtration, the MiniKans were washed with DMF (3×), MeOH (3×), and DCM (3×), dried under vacuum, and taken on to Step G.
  • Step F. Cleavage and Processing of the HIV Analogs
  • The individual MinKans were sorted into cleavage racks and a solution of 25% TFA in DCM (3 mL/MinKan) was added. The racks were agitated for 1.5 hours. The individual filtrates and DCM rinses were collected, concentrated, and purified by HPLC to provide the final compounds.
    TABLE 2
    Figure US20050250707A1-20051110-C00206
    Figure US20050250707A1-20051110-C00207
    Figure US20050250707A1-20051110-C00208
    Figure US20050250707A1-20051110-C00209
    Figure US20050250707A1-20051110-C00210
    Figure US20050250707A1-20051110-C00211
    Figure US20050250707A1-20051110-C00212
    Figure US20050250707A1-20051110-C00213
    Figure US20050250707A1-20051110-C00214
    Figure US20050250707A1-20051110-C00215
    Figure US20050250707A1-20051110-C00216
    Figure US20050250707A1-20051110-C00217
    Figure US20050250707A1-20051110-C00218
    Figure US20050250707A1-20051110-C00219
    Figure US20050250707A1-20051110-C00220
    Figure US20050250707A1-20051110-C00221
    Figure US20050250707A1-20051110-C00222
    Figure US20050250707A1-20051110-C00223
    Figure US20050250707A1-20051110-C00224
    Figure US20050250707A1-20051110-C00225
    Figure US20050250707A1-20051110-C00226
    Figure US20050250707A1-20051110-C00227
    Figure US20050250707A1-20051110-C00228
    Figure US20050250707A1-20051110-C00229
    Figure US20050250707A1-20051110-C00230
    Figure US20050250707A1-20051110-C00231
    Figure US20050250707A1-20051110-C00232
    Figure US20050250707A1-20051110-C00233
    Figure US20050250707A1-20051110-C00234
    Figure US20050250707A1-20051110-C00235
    Figure US20050250707A1-20051110-C00236
    Figure US20050250707A1-20051110-C00237
    Figure US20050250707A1-20051110-C00238
    Figure US20050250707A1-20051110-C00239
    Figure US20050250707A1-20051110-C00240
    Figure US20050250707A1-20051110-C00241
    Figure US20050250707A1-20051110-C00242
    Figure US20050250707A1-20051110-C00243
    Figure US20050250707A1-20051110-C00244
    Figure US20050250707A1-20051110-C00245
    Figure US20050250707A1-20051110-C00246
    Figure US20050250707A1-20051110-C00247
    Figure US20050250707A1-20051110-C00248
    Figure US20050250707A1-20051110-C00249
    Figure US20050250707A1-20051110-C00250
  • Figure US20050250707A1-20051110-C00251
    Scheme 3 Experimental
  • The solid phase combinatorial synthesis of HIV protease inhibitors was performed using the IRORI Directed Sorting Technology. Commercial 4-formyl-3-methoxyphenoxymethyl polystyrene resin 1a (PS-MB-CHO, Argonaut Technologies) or 4-formyl-3,5-dimethoxyphenoxymethyl polystyrene resin lb (PL-FDMP resin, Polymer Laboratories) was loaded into individual Minikans.
  • Step A. Reductive Amination with P2′ Amines
  • To separate flasks containing sorted MiniKans was added DCM (3 mL/MiniKan). The appropriate primary P2′ amine (3 eq), sodium triacetoxyborohydride (5 eq), and acetic acid (3 eq) were added, and the mixtures were placed under argon, agitated with periodic venting at room temperature for 1-2 hours, and allowed to react overnight. For resin 1a, the filtrates were poured off and the MiniKans were washed with DCM, MeOH (2×), DCM (2×), Et3N/DCM (1:3, 3×), DCM (2×), MeOH (3×), and DCM (4×). For resin 1b, a washing sequence of DCM, MeOH (2×), DCM (2×), Et3N/DCM (1:3, 3×), DCM (2×), DMF, 1M NaOH/DMF (1:5, 3×), DMF (3×), MeOH (3×), and DCM (3×) was used. The MiniKans were dried under vacuum and taken on in Step B.
  • Step B. Peptide Coupling with P1′ Amino Acids
  • To separate flasks containing the sorted MiniKans was added DMF (3 mL/MiniKan). The appropriate FMOC-protected amino acid (2.5 eq) and 1-hydroxy-7-azabenzotriazole (HOAT) (3 eq) were added and mixed until dissolved, and 1,3-diisopropylcarbodiimide (DIC) (3 eq) was added. The containers were placed under argon and agitated at room temperature overnight. The filtrates were poured off, and the MiniKans were washed with DMF (3×), MeOH (3×), DCM (2×), and DMF (2×). The MiniKans were taken directly on to Step C.
  • Step C. FMOC Deprotection
  • A container of MiniKans in DMF and piperidine (25%) with a total reaction volume of 3 mL/MiniKan was agitated under argon at room temperature for 45 minutes. The filtrate was removed, and the reaction procedure was repeated. The MiniKans were filtered and washed with DMF (3×), MeOH (2×), DCM (3×), and DMF, and taken directly on to Step D.
  • Step D. Peptide Coupling with FMOC-APNS
  • FMOC-Allophenylnorstatine (APNS) (3 eq) was added to the flask of MiniKans in DMF (3 mL/MiniKan). After dissolution, HOAT (3.5 eq) and DIC (3.5 eq) were added. The mixture was placed under argon and agitated at room temperature overnight. The reaction was filtered and the MiniKans were washed with DMF (3×), MeOH (3×), DCM (3×), and DMF. FMOC deprotection was carried out as in Step C, and the MiniKans were washed with DMF (3×), MeOH (2×), DCM (3×), dried under vacuum and taken on to Step E or F.
  • Step E. Peptide Coupling with P2 Acids
  • To separate flasks containing the sorted MiniKans in DMF (3 mL/MiniKan) was added the appropriate P2 acid (3 eq), HOBT hydrate (4 eq), and (3-(dimethylamino)propyl)ethylcarbodiimide hydrochloride (EDAC) (3.5 eq). The reaction was agitated under argon at room temperature for 3 hours. After filtration, the MiniKans were washed with DMF (3×), MeOH (3×), and DCM (3×), dried under vacuum, and taken on to Step G.
  • Step F. Cleavage and Processing of the HIV Analogs
  • The individual MinKans were sorted into cleavage racks and a solution of 25% TFA in DCM (3 mL/MinKan) was added. The racks were agitated for 1.5 hours. The individual filtrates and DCM rinses were collected, concentrated, and purified by HPLC to provide the final compounds.
    TABLE 3
    Figure US20050250707A1-20051110-C00252
    Figure US20050250707A1-20051110-C00253
    Figure US20050250707A1-20051110-C00254
    Figure US20050250707A1-20051110-C00255
    Figure US20050250707A1-20051110-C00256
    Figure US20050250707A1-20051110-C00257
    Figure US20050250707A1-20051110-C00258
    Figure US20050250707A1-20051110-C00259
    Figure US20050250707A1-20051110-C00260
    Figure US20050250707A1-20051110-C00261
    Figure US20050250707A1-20051110-C00262
    Figure US20050250707A1-20051110-C00263
    Figure US20050250707A1-20051110-C00264
    Figure US20050250707A1-20051110-C00265
    Figure US20050250707A1-20051110-C00266
    Figure US20050250707A1-20051110-C00267
    Figure US20050250707A1-20051110-C00268
    Figure US20050250707A1-20051110-C00269
    Figure US20050250707A1-20051110-C00270
    Figure US20050250707A1-20051110-C00271
    Figure US20050250707A1-20051110-C00272
    Figure US20050250707A1-20051110-C00273
    Figure US20050250707A1-20051110-C00274
    Figure US20050250707A1-20051110-C00275
    Figure US20050250707A1-20051110-C00276
    Figure US20050250707A1-20051110-C00277
    Figure US20050250707A1-20051110-C00278
    Figure US20050250707A1-20051110-C00279
    Figure US20050250707A1-20051110-C00280
    Figure US20050250707A1-20051110-C00281
    Figure US20050250707A1-20051110-C00282
    Figure US20050250707A1-20051110-C00283
    Figure US20050250707A1-20051110-C00284
    Figure US20050250707A1-20051110-C00285
    Figure US20050250707A1-20051110-C00286
    Figure US20050250707A1-20051110-C00287
    Figure US20050250707A1-20051110-C00288
    Figure US20050250707A1-20051110-C00289
    Figure US20050250707A1-20051110-C00290
    Figure US20050250707A1-20051110-C00291
    Figure US20050250707A1-20051110-C00292
    Figure US20050250707A1-20051110-C00293
    Figure US20050250707A1-20051110-C00294
    Figure US20050250707A1-20051110-C00295
    Figure US20050250707A1-20051110-C00296
    Figure US20050250707A1-20051110-C00297
    Figure US20050250707A1-20051110-C00298
    Figure US20050250707A1-20051110-C00299
    • Biological Evaluation
  • Cells and Virus
  • T-cell lines, CEM-SS, and MT-2, and viruses HIV-1 RF and HIV-1 NL4-3 (pNL4-3) were obtained from the National Institutes of Health (AIDS Research and Reference Reagent Program, Bethesda, Md.). HIV-1 NL4-3(184V/L90M) was derived from a clinical isolate that exhibited the protease inhibitor-resistance associated substitutions 184V and L90M, by cloning of an reverse transcriptase-polymerase chain reaction amplified fragment into the unique Age I and Spe I restriction sites of pNL4-3.
  • Cytopathic Effect (CPE) Inhibition Assays
  • The ability of compounds to protect cells against HIV infection was measured by the MTT dye reduction method, essentially as described (See Pauwels, R. Balzarini, J. Baba, M. Snoeck, R. Schols, D. Herdewijn, P. Desmyter, J. and De Clercq, E. 1988, “Rapid and automated tetrazolium-based calorimetric assay for the detection of anti-HIV compounds,”. J. Virol. Methods., 20: 309-321 and Weislow, O. S. Kiser, R. Fine, D. L. Bader, J. Shoemaker, R. H. and Boyd, M. R. 1989. “New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity”. J. Natl. Cancer Inst. 81:577-586). Subject cells were infected with test virus at an moi of 0.025 to 0.819 or mock infected with medium only and added at 2×104 cells per well into 96 well plates containing half-log dilutions of test compounds. Six days later, 50 μl of XTT (]mg/ml XTT tetrazolium, 0.02 nM phenazine methosulfate) was added to the wells and the plate was reincubated for four hours. Viability, as determined by the amount of XTT formazan produced, was quantified spectrophotometrically by absorbance at 450 nm. Data from CPE assays were expressed as the percent of formazan produced in compound-treated cells compared to formazan produced in wells of uninfected, compound-free cells. The fifty percent effective concentration (EC50) was calculated as the concentration of compound that effected an increase in the percentage of formazan production in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC50) was calculated as the concentration of compound that decreased the percentage of formazan produced in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells. The therapeutic index was calculated by dividing the cytotoxicity (CC50) by the antiviral activity (EC50).
  • Susceptibility Assays
  • Compounds were tested in phenotypic susceptibility assays at Virologic, Inc., (See Petropoulos C. J., Parkin N. T., Limoli K. L., Lie Y. S., Wrin T., Huang W., Tian H., Smith D., Winslow G. A., Capon D J, Whitcomb JM. 2000, “A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1,” Antimicrob Agents Chemother 44(4):920-928) or using the assay described here. MT-2 cells were infected with either HIV-1 NL4-3 or HIV-1 NL4-3(184V/L90M) and incubated in the presence of serial 0.5 log dilutions of test compounds. Three days later, culture supernatants were collected and virus production, as determined by p24 ELISA, was assayed. Percent inhibition was calculated as p24 concentration in compound-treated samples as compared to infected, compound-free controls. Inhibition of viral replication is determined by measuring reduction in HIV p24 present in the culture supernatant, using a Beckman-Coulter p24 HIV-1 Ag EIA kit and following the supplied protocol. Absorbance is read on a MRX microplate reader (Dynex Technologies). The EC50 was calculated as the concentration of compound that effected a decrease in the p24 production by infected, compound-treated cells to 50% of that produced by infected, compound-free cells.
  • HIV-1 Protease RET Assay
  • Ki's for the inhibitors of HIV-1 protease were determined using a resonance energy transfer (RET) assay. A mutant form of this enzyme (Q7S) is used for this assay because it is more stable against auto-proteolysis than the wild-type protein. This enzyme is first partially purified as inclusion bodies from cell lysate. It is then solublized in 8M urea and passed through a Q-Sepharose column (Pharmacia) for further purification. To refold this protein, samples containing Q7S is dialyzed into 50 mM sodium phosphate pH 7.0, 50 mM NaCl, 10 mM DTT, and 10% glycerol.
  • The commercially available peptide substrate (Molecular Probes Cat. # H-2930) RE(EDANS)SQNYPIVQK(DABCYL)R is used to assess activity and Ki's. This peptide is cleaved quantitatively by HIV-1 Pr at the Tyr-Pro bond. The EDANS fluorophore absorbs at 340 nm and emits at 490 nm. The reaction is carried out in a 96 well plate in a total volume of 100 μL and is run for 12 minutes at 37 C under steady-state conditions with 5 μM substrate and 2 nM active dimer enzyme concentration. The literature value Km for this substrate and enzyme is 103+/−8 μM (See Matayoshi, et al., “Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer,” Science 247, 954 (1990)). The buffer for this reaction is 0.1M sodium acetate pH 4.8, 1M NaCl, 1 mM EDTA, 5 mM dithiothreitol, 10% dimethyl sulfoxide and 1 mg/ml bovine serum albumin. Inhibition curves are fit using the Morrison tight binding equation.
    Example Ave. Ave CPE EC50 or
    No. Ki (nM) EC50 (mM) IC50 (mM)
    A3 1.7 0.37
    A4 4.1 0.591
    A5 2 0.433
    A6 0.22 0.036
    A7 0.49 0.104 0.832
    A8 0.23 0.036
    A9 4 0.565
    A10 51 >1
    A11 19 0.93
    A12 1.7 1.09
    A13 44.1 >1
    A14 0.44 0.052 0.071*
    A15 10.9 0.13
    A16 0.63 0.134
    A17 <0.1 0.045 0.102*
    A18 0.38 0.193
    A19 10 0.442
    A20 0.13 0.037 0.147*
    A21 1.9 0.717
    A22 0.32 0.061 0.226*
    A23 0.65 0.072
    A24 0.18 0.104 0.831
    A25 5.8 0.248
    A26 0.38 0.119 0.321*
    A27 0.62 0.072
    A28 <0.1 0.041
    A29 <0.1 0.117
    A30 1.1 0.507 0.829*
    A31 <0.1 0.041
    A32 <0.1 0.045 0.486
    A33 <0.1 0.577
    A34 <0.1 0.036
    A35 <0.1 0.017 0.063
    A36 0.59 0.519
    A37 0.13 0.161
    A38 0.17 0.078 0.401
    A39 0.27 0.367
    A40 1.2 0.275
    A41 1.6 0.527
    A42 0.23 0.126 0.307
    A43 0.35 0.561
    A44 0.14 0.022 0.472
    A45 0.51 0.165
    A46 0.31 0.091 0.79
    A47 2.3 1.813
    A48 0.19 0.417
    A49 1.2 0.13
    A50 0.26 0.224
    A51 1.3 0.667
    A52 37
    B1 2.5 0.905
    B2 0.78 0.369
    B3 4 0.409
    B8 0.31 0.095 0.405*
    B4 1.7 0.551
    B5 1.6 0.508
    B6 1.6 0.589
    B7 1.9 0.68
    B8 1.5 0.552
    B10 <0.1 1.1
    B11 1.2 1.175 1.716*
    B12 0.45 1.398
    B13 19% @64 nM
    B14 3.7 3.054
    B15 2 1.086
    B16 <0.1 0.298 1.754
    B17 0.42 0.534 1.579
    B18 0.29 0.457
    B19 <0.1 0.124 1.369
    B20 2.1 0.427
    B21 4.6 0.598
    B22 1.8 1.613
    B23 0.42 1.42
    B24 5.5 2.136
    B25 2.7 1.794
    B26 2.9 1.712
    B27 3.5
    B28 153
    B29 0.12 1.256
    B30 1.1 1.227
    B31 1.5 1.316
    B32 4.9
    B33 1.2 1.286
    B34
    B35
    B36 <0.1 0.615
    B37 0.11 0.736
    B38
    B39 0.16
    B40 2.8 1.396
    B41 0.15
    B42 0.73
    B43 0.2
    B44 0.76 0.629
    B45 19.7
    B46 12.5
    B47 6.9
    B48 12 >3.2
    B49 17.2
    C1 0.38 0.627 0.427
    C3 1.3 0.5
    C4 4.2
    C4 69
    C5 3.2
    C6 <0.1 0.164 1.475
    C7 7.9
    C8 0.26 0.447
    C9 0.34 0.233
    C10 36
    C11 1.1 1.562
    D1 <0.01 0.052 0.601
    D3 0.5 0.162 1.954
    D4 0.7 0.016 1.954

    *IC50 (mM) Data was determined at Virologic Inc against the 46I, 84V, 90M virus
  • The following compounds have been prepared according to the procedures described herein and have demonstrated the noted activity:
    MOLSTRUCTURE Ki EC50
    Figure US20050250707A1-20051110-C00300
         		209 10
    Figure US20050250707A1-20051110-C00301
         		1700 10
    Figure US20050250707A1-20051110-C00302
         		0.1 0.053
    Figure US20050250707A1-20051110-C00303
         		62
    Figure US20050250707A1-20051110-C00304
         		0.75
    Figure US20050250707A1-20051110-C00305
         		0.1 0.072
    Figure US20050250707A1-20051110-C00306
         		1.5 0.076
    Figure US20050250707A1-20051110-C00307
         		0.2 0.113
    Figure US20050250707A1-20051110-C00308
         		0.73 0.141
    Figure US20050250707A1-20051110-C00309
         		0.36 0.144
    Figure US20050250707A1-20051110-C00310
         		0.24 0.158
    Figure US20050250707A1-20051110-C00311
         		0.26 0.207
    Figure US20050250707A1-20051110-C00312
         		0.17 0.289
    Figure US20050250707A1-20051110-C00313
         		0.11 0.334
    Figure US20050250707A1-20051110-C00314
         		0.2 0.585
    Figure US20050250707A1-20051110-C00315
         		9.6 0.723
    Figure US20050250707A1-20051110-C00316
         		4.7 1.064
    Figure US20050250707A1-20051110-C00317
         		1.1 1.114
    Figure US20050250707A1-20051110-C00318
         		2.5 1.221
    Figure US20050250707A1-20051110-C00319
         		7.4
    Figure US20050250707A1-20051110-C00320
         		2.6 1.3095
    Figure US20050250707A1-20051110-C00321
         		2.6 1.3095
    Figure US20050250707A1-20051110-C00322
         		3.4
    Figure US20050250707A1-20051110-C00323
         		3.7 1.332
    Figure US20050250707A1-20051110-C00324
         		72
    Figure US20050250707A1-20051110-C00325
         		2.3 1.378
    Figure US20050250707A1-20051110-C00326
         		11.1 1.401
    Figure US20050250707A1-20051110-C00327
         		2.6 1.416
    Figure US20050250707A1-20051110-C00328
         		2.1 1.488
    Figure US20050250707A1-20051110-C00329
         		14 1.512
    Figure US20050250707A1-20051110-C00330
         		18.5
    Figure US20050250707A1-20051110-C00331
         		19.5 3
    Figure US20050250707A1-20051110-C00332
         		12.1
    Figure US20050250707A1-20051110-C00333
         		10.5 3.2
    Figure US20050250707A1-20051110-C00334
         		17.3 3.303
    Figure US20050250707A1-20051110-C00335
         		16.8 3.745
    Figure US20050250707A1-20051110-C00336
         		13.1
    Figure US20050250707A1-20051110-C00337
         		0.1
    Figure US20050250707A1-20051110-C00338
         		28 4.132
    Figure US20050250707A1-20051110-C00339
         		0.1
    Figure US20050250707A1-20051110-C00340
         		24.6 4.951
    Figure US20050250707A1-20051110-C00341
         		55.8 10
    Figure US20050250707A1-20051110-C00342
         		214 10
  • The following compounds have been prepared according to the procedures described herein and have demonstrated the noted activity:
  • While the invention has been described in terms of preferred embodiments and specific examples, those skilled in the art will recognize that various changes and modifications can be made through routine experimentation without departing from the spirit and scope of the invention. Thus, the invention should be understood as not being limited by the foregoing detailed description, but as being defined by the appended claims and their equivalents.

Claims (18)

1-19. (canceled)
20. A compound having the Formula I:
Figure US20050250707A1-20051110-C00343
wherein:
R1 is a 5- or 6-membered mono-cyclic carbocyclic or heterocyclic group, wherein said carbocyclic or heterocyclic group is saturated, partially unsaturated or fully unsaturated and is unsubstituted or substituted by one or more suitable substituents;
R2 is a substituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted phenyl group, a substituted phenylalkyl group, a substituted or unsubstituted phenylalkenyl group or a substituted or unsubstituted phenylalkynyl group,
R2′ is H or a substituted or unsubstituted C1-C4 alkyl group;
X is
Figure US20050250707A1-20051110-C00344
 wherein Rx is H or one or more suitable substituents;
Z is CH2 or CFH;
R3 is H or a substituted or unsubstituted C1-C4 alkyl group;
R4, R5, R6 and R7 are independently selected from H or a C1-C6 alkyl group; and
R8 and R8′ are independently selected from H, halo, a C1-C4 aliphatic group or a C1-C4 halo-substituted aliphatic group;
where any of said substituted alkyl, alkenyl or alkynyl groups or said alkyl, alkenyl or are substituted by one or more suitable substituents;
provided that said 5- or 6-membered mono-cyclic heterocycloalkyl, heterocycloalkenyl or heteroaryl group contains at least two heteroatoms when R2 is a substituted phenyl group, a substituted phenylalkyl group, a substituted or unsubstituted phenylalkenyl group or a substituted or unsubstituted phenylalkynyl group; or
provided that said alkyl, alkenyl or alkynyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more substituents selected from halo or keto; or
provided that said substituted phenyl group or phenyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more suitable substituents other than halo or methyl;
or a prodrug, pharmaceutically acceptable salt, pharmaceutically active metabolite, or pharmaceutically acceptable solvate thereof.
21. A compound having the Formula I:
Figure US20050250707A1-20051110-C00345
wherein:
R1 is a 5- or 6-membered monocyclic cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group, where said cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, alkylenedioxy, di-haloalkylenedioxy, aryloxy, cycloalkoxy, cycloalkylalkoxy, cycloalkenoxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenyloxy, heterocycloalkenylalkoxy, heteroaryloxy, alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, alkylamino, dialkylamino, keto, alkylsulfonyl, arylsulfonyl, alkylcarbonylamino, alkylthio, haloalkylthio and arylthio, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, heteroaryl moieties present in the above substituents are further substituted by one or more groups independently selected from alkyl, haloalkyl, aryl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, mercapto, alkylthio, haloalkylthio and arylthio groups;
R2 is a substituted alkyl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group, wherein said alkyl, alkenyl or alkynyl group is a straight or branched chained group, and
where said substituted alkyl, alkenyl or alkynyl group is substituted by one or more substituents independently selected from amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, cycloalkoxy, cycloalkylalkoxy, cycloalkenyloxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenyloxy, heterocycloalkenylalkoxy, heteroaryloxy, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylsulfenyl, arylsulfenyl, alkylthio, haloalkylthio, arylthio and heteroarylthio groups, wherein any of the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, or heteroaryl moieties present in the above substituents are further substituted by one or more groups independently selected from alkyl, haloalkyl, halogen, hydroxyl, alkoxy, haloalkoxy, alkylthio and haloalkylthio groups;
R2′ is H, methyl, ethyl or propyl, where said methyl, ethyl or propyl is unsubstituted or substituted by halo or hydroxyl;
X is
Figure US20050250707A1-20051110-C00346
 wherein Rx is H or one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyl, alkylenedioxy, di-haloalkylenedioxy, alkylamino, dialkylamino, alkylthio and haloalkylthio;
Z is CH2 or CFH;
R3 is H;
R4, R1, R6 and R7 are independently selected from H or methyl; and
R8 and R8′ are independently selected from H, halogen, methyl, monohalo-methyl, dihalo-methyl and tri-halomethyl;
or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
22. The compound according to claim 21, wherein:
R1 is phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl, where said phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, halogen, and hydroxyl;
R2 is a substituted alkyl group, a substituted or unsubstituted C1-C6 alkenyl group, or a substituted or unsubstituted C1-C6 alkynyl group, wherein said alkyl, alkenyl or alkynyl group is a straight or branched chained group, and
where said substituted alkyl, alkenyl or alkynyl group is substituted by one or more substituents independently selected from cyano, halogen and alkylamino;
R2′ is H, methyl or ethyl;
X is
Figure US20050250707A1-20051110-C00347
 wherein Rx is H, halogen, or alkoxy;
Z is CH2 or CFH;
R3, R4, R5, R8 and R8′ are each H; and
R6 and R7 are independently selected from H or methyl;
or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
23. A compound having the Formula I:
Figure US20050250707A1-20051110-C00348
wherein:
R1 is a 5- or 6-membered mono-cyclic cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group, where said cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl group is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, amino, cyano, halogen, hydroxyl, alkoxy, haloalkoxy, alkylenedioxy, dihaloalkylenedioxy, aryloxy, cycloalkyloxy, cycloalkylalkoxy, cycloalkenyloxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenyloxy, heterocycloalkenylalkoxy, heteroaryloxy, alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, alkylamino, dialkylamino, kato, alkylsulfonyl, arylsulfonyl, alkylcarbonylamino, alkylthio, haloalkylthio and arylthio, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, heteroaryl moieties present in the above substituents are substituted by one or more groups independently selected from alkyl, haloalkyl, aryl, nitro, amino, alkylamino, dialkylamino, halogen, hydroxyl, alkoxy, haloalkoxy, aryloxy, mercapto, alkylthio, haloalkylthio and arylthio groups;
R2 is a substituted phenyl group, a substituted phenylalkyl group, a substituted or unsubstituted phenylalkenyl group or a substituted or unsubstituted phenylalkynyl group;
where said alkyl, alkenyl or alkynyl moiety of said phenylalkyl, phenylalkenyl or phenylalkynyl group is a straight or branched chain moiety;
R2′ is H, methyl, ethyl or propyl, where said methyl, ethyl or propyl is unsubstituted or substituted with halo or hydroxyl;
X is
Figure US20050250707A1-20051110-C00349
 wherein Rx is H or one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyl, alkylenedioxy, di-haloalkylenedioxy, alkylamino, dialkylamino, alkylthio and haloalkylthio;
Z is CH2 or CFH;
R3 is H;
R4, R5, R6 and R7 are independently selected from H or methyl; and
R8 and R8′ are independently selected from H, halogen, methyl, monohalo-methyl, dihalo-methyl and tri-halomethyl;
provided that said 5- or 6-membered mono-cyclic heterocycloalkyl, heterocycloalkenyl or heteroaryl group contains at least two heteroatoms; or
provided that said alkyl, alkenyl or alkynyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more substituents selected from halo or keto; or
provided that said substituted phenyl group or phenyl moiety of said substituted phenylalkyl, phenylalkenyl or phenylalkynyl group is substituted by one or more substituents other than halo or methyl, where said one or more substituents is independently selected from haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkoxyalkyl, alkylcarbonylalkyl, haloalkoxyalkyl, aryloxyalkyl, alkylthioalkyl, haloalkylthioalkyl, arylthioalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, nitro, amino, cyano, hydroxyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, alkylenedioxy, aryloxy, cycloalkoxy, cycloalkylalkoxy, cycloalkenyloxy, cycloalkenylalkoxy, heterocycloalkoxy, heterocycloalkylalkoxy, heterocycloalkenyloxy, heterocycloalkenylalkoxy, heteroaryloxy, alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, arylcarbonyl, arylcarbonyloxy, aryloxycarbonyl, cycloalkylcarbonyl, cycloalkylcarbonyloxy, cycloalkyoxycarbonyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heterocycloalkylcarbonyl, heterocycloalkylcarbonyloxy, heterocycloalkyoxycarbonyl, carboxyl, carbamoyl, formyl, keto, thioketo, sulfo, alkylamino, cycloalkylamino, arylamino, heterocycloalkylamino, heteroarylamino, dialkylamino, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocycloalkylaminocarbonyl, heteroarylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, cycloalkylaminothiocarbonyl, arylaminothiocarbonyl, heterocycloalkylaminothiocarbonyl, heteroarylaminothiocarbonyl, dialkylaminothiocarbonyl, alkylsulfonyl, arylsulfonyl, alkylsulfenyl, arylsulfenyl, alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heterocycloalkylcarbonylamino, heteroarylcarbonylamino, alkylthiocarbonylamino, cycloalkylthiocarbonylamino, arylthiocarbonylamino, heterocycloalkylthiocarbonylamino, heteroarylthiocarbonylamino, alkylsulfonyloxy, arylsulfonyloxy, alkylsulfonylamino, arylsulfonylamino, mercapto, alkylthio, haloalkylthio, arylthio and heteroarylthio groups, wherein any of the alkyl, alkylene, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl moieties present in the above substituents are unsubstituted or substituted by one or more groups independently selected from alkyl, haloalkyl, halogen, hydroxyl, alkoxy, haloalkoxy, alkylthio and haloalkylthio groups;
or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
24. The compound according to claim 23, wherein:
R1 is phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl, where said phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, halogen, and hydroxyl;
R2 is a substituted phenylalkyl group, where said alkyl moiety of said substituted phenylalkyl group is a straight or branched chain alkyl moiety;
R2′ is H, methyl, ethyl or propyl, where said methyl, ethyl or propyl is unsubstituted or substituted with hydroxyl;
X is
Figure US20050250707A1-20051110-C00350
 wherein Rx is H, halogen, or alkoxy;
Z is CH2 or CFH;
R3, R4, R5, R8 and R8′ are each H; and
R6 and R7 are independently selected from H or methyl;
provided that R1 is selected from isoxazolyl, pyrazolyl, thiazolyl or tetrahydropyridazinyl, where said is isoxazolyl, pyrazolyl, thiazolyl or tetrahydropyridazinyl is unsubstituted or substituted with one or more substituents independently selected from alkyl, haloalkyl, halogen, and hydroxyl when R2 is a substituted or unsubstituted phenylalkyl group or
provided that R1 is selected from phenyl, pyrrolyl, pyrrolidinyl, isoxazolyl, pyrazolyl, thiazolyl, tetrahydrofuranyl, furanyl, thienyl or tetrahydropyridazinyl when R2 is a substituted phenylalkyl group and said phenyl moiety of said substituted phenylalkyl group comprises one or more substituents other than halo or methyl, where said one or more substituents is independently selected from haloalkyl, amino, hydroxyl, alkoxy, haloalkoxy, alkylenedioxy, di-haloalkylenedioxy, cycloalkylalkyloxy, dialkylamino, alkylsulfonyl and alkylthio;
or a prodrug, pharmaceutically active metabolite or pharmaceutically active salt or solvate thereof.
25. The compound, according to any one of claims 20, 21 or 23, having the formula:
Figure US20050250707A1-20051110-C00351
or a prodrug, pharmaceutically acceptable salt, pharmaceutically active metabolite, or pharmaceutically acceptable solvate thereof.
26. The compound, according to any one of claims 20, 21 or 23, having the formula:
Figure US20050250707A1-20051110-C00352
or a prodrug, pharmaceutically acceptable salt, pharmaceutically active metabolite, or pharmaceutically acceptable solvate thereof.
27. The compound, according to any one of claims 20, 21 or 23, having the formula:
Figure US20050250707A1-20051110-C00353
or a prodrug, pharmaceutically acceptable salt, pharmaceutically active metabolite, or pharmaceutically acceptable solvate thereof.
28. A pharmaceutical composition comprising:
a therapeutically effective amount of at least one HIV agent selected from compounds defined in any one of claims 20, 21 or 23; and
a pharmaceutically acceptable carrier, diluent, vehicle, or excipient.
29. The pharmaceutical composition according to claim 28 wherein the composition further comprises a therapeutically effective amount of at least one HIV infection/AIDS treatment agent selected from the group consisting of HIV/AIDS antiviral agents, immunomodulators, and anti-infective agents.
30. The pharmaceutical composition according to claim 29, wherein the composition further comprises a therapeutically effective amount of at least one antiviral agent selected from the group consisting of non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.
31. The pharmaceutical composition according to claim 30, further comprising a therapeutically effective amount of at least one HIV protease inhibitor.
32. A method of treating a mammalian disease condition mediated by HIV protease activity, comprising administering to a mammal in need thereof a therapeutically effective amount of at least one compound defined in any one of claims 20, 21 or 23.
33. A method of inhibiting the activity of HIV protease in a subject in need thereof, comprising contacting the HIV protease with an effective amount of at least one compound defined in any one of claims 20, 21 or 23.
34. A method of preventing or treating infection by HIV in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 20, 21 or 23.
35. The method according to claim 34, wherein the compound is administered in combination with a therapeutically effective amount of at least one HIV infection/AIDS treatment agent selected from the group consisting of HIV/AIDS antiviral agents, immunomodulators, and anti-infective agents.
36. A compound selected from
Figure US20050250707A1-20051110-C00354
Figure US20050250707A1-20051110-C00355
Figure US20050250707A1-20051110-C00356
Figure US20050250707A1-20051110-C00357
and the prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts and solvates thereof.
US11/155,568 2001-06-11 2005-06-20 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis Abandoned US20050250707A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/155,568 US20050250707A1 (en) 2001-06-11 2005-06-20 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29746001P 2001-06-11 2001-06-11
US29772901P 2001-06-12 2001-06-12
US10/166,979 US7179918B2 (en) 2001-06-11 2002-06-11 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US11/155,568 US20050250707A1 (en) 2001-06-11 2005-06-20 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/166,957 Division US6953858B2 (en) 2001-06-11 2002-06-11 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Publications (1)

Publication Number Publication Date
US20050250707A1 true US20050250707A1 (en) 2005-11-10

Family

ID=26970163

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/166,957 Expired - Fee Related US6953858B2 (en) 2001-06-11 2002-06-11 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US10/166,979 Expired - Fee Related US7179918B2 (en) 2001-06-11 2002-06-11 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US11/155,568 Abandoned US20050250707A1 (en) 2001-06-11 2005-06-20 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US11/450,943 Abandoned US20070021354A1 (en) 2001-06-11 2006-06-09 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/166,957 Expired - Fee Related US6953858B2 (en) 2001-06-11 2002-06-11 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US10/166,979 Expired - Fee Related US7179918B2 (en) 2001-06-11 2002-06-11 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/450,943 Abandoned US20070021354A1 (en) 2001-06-11 2006-06-09 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Country Status (27)

Country Link
US (4) US6953858B2 (en)
EP (3) EP1739082A1 (en)
JP (2) JP2005508867A (en)
KR (2) KR20040035601A (en)
CN (2) CN1599729A (en)
AP (2) AP1770A (en)
AR (2) AR036093A1 (en)
AU (2) AU2002316235A2 (en)
BR (2) BR0210344A (en)
CA (2) CA2450269A1 (en)
EA (2) EA200400023A1 (en)
GE (1) GEP20063890B (en)
HN (1) HN2002000136A (en)
HR (2) HRP20031015A2 (en)
IL (2) IL159022A0 (en)
IS (2) IS7049A (en)
MA (2) MA27347A1 (en)
MX (2) MXPA03011397A (en)
NO (2) NO20035489D0 (en)
NZ (2) NZ530024A (en)
OA (2) OA12696A (en)
PA (2) PA8547601A1 (en)
PE (2) PE20040241A1 (en)
PL (1) PL366622A1 (en)
TN (1) TNSN03130A1 (en)
TW (1) TW200538447A (en)
WO (2) WO2002100844A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103748059A (en) * 2011-05-13 2014-04-23 弗特克斯药品有限公司 Process for the preparation of protease inhibitors

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169932B2 (en) 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HN2002000136A (en) 2001-06-11 2003-07-31 Basf Ag INHIBITORS OF THE PROTEASE OF HIV VIRUS, COMPOUNDS CONTAINING THEMSELVES, THEIR PHARMACEUTICAL USES AND THE MATERIALS FOR SYNTHESIS
JP2006076882A (en) * 2002-09-13 2006-03-23 Sumitomo Pharmaceut Co Ltd New dipeptide compound and medicinal use thereof
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
BRPI0417223A (en) * 2003-12-04 2007-03-06 Pfizer methods of preparing compounds useful as protease inhibitors
EP1737818A2 (en) * 2003-12-04 2007-01-03 Pfizer, Inc. Methods for the preparation of stereoisomerically enriched amines
BRPI0417248A (en) * 2003-12-04 2007-03-06 Pfizer methods of preparing compounds usable as protease inhibitors
BRPI0417492A (en) * 2003-12-09 2007-05-29 Pfizer compositions comprising a hiv protease inhibitor
MXPA06008632A (en) * 2004-01-30 2006-09-04 Pfizer Therapeutic combinations.
KR20060127939A (en) * 2004-01-30 2006-12-13 화이자 인코포레이티드 Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor
WO2005121094A1 (en) * 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
RU2666530C2 (en) 2012-01-12 2018-09-11 Йейл Юниверсити Compounds and methods for enhanced degradation of target proteins and other polypeptides by an e3 ubiquitin ligase
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016149668A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3370715A4 (en) 2015-11-02 2019-05-15 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
PL3660004T3 (en) 2016-10-11 2023-10-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20230127371A (en) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 Tau-protein targeting protacs and associated methods of use
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
IL294423B2 (en) 2016-12-23 2024-01-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP2020505327A (en) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． EGFR proteolytic targeting chimeric molecules and related methods of use
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
BR112019015312A2 (en) 2017-01-26 2020-03-10 Arvinas Operations, Inc. MODULATORS OF PROTEOLYSIS BY THE ESTROGEN RECEPTOR AND ASSOCIATED METHODS OF USE
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
CA3095494C (en) 2018-04-04 2023-11-07 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CN112912376A (en) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN112574201B (en) * 2019-09-29 2024-04-19 四川科伦博泰生物医药股份有限公司 Arylamine compound, pharmaceutical composition containing arylamine compound, and preparation method and application of arylamine compound
CN110803996B (en) * 2019-11-13 2022-01-11 台州市创源工业技术有限公司 Synthesis method of hydroxybenzylamine
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20230157998A1 (en) 2020-03-06 2023-05-25 Pfizer Inc. Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629406A (en) * 1992-08-07 1997-05-13 Sankyo Company, Limited Inhibitors of HIV protease
US5644028A (en) * 1992-05-13 1997-07-01 Japan Energy Corporation Process for producing peptide derivatives and salts therefor
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US6222043B1 (en) * 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6418260A (en) * 1987-07-14 1989-01-23 Sanyo Electric Co Transistor
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
IL100899A (en) 1991-02-08 1997-06-10 Sankyo Co Beta-amino-alpha- hydroxycarboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ZA929869B (en) * 1991-12-20 1994-06-20 Syntex Inc Hiv protease inhibitors
DE69322127T2 (en) 1992-05-13 1999-06-24 Japan Energy Corp Process for the preparation of peptide derivatives and their salts
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0706794B1 (en) 1994-10-14 2001-12-12 Japan Energy Corporation Anti-aids pharmaceutical preparations and processes for the production thereof
JPH08259532A (en) 1995-03-24 1996-10-08 Japan Energy Corp Peptide-like compound or its pharmacologically acceptable salt
JPH1087489A (en) 1996-09-13 1998-04-07 Sankyo Co Ltd Medicine containing ahpba structure-containing dipeptide compound as active ingredient
JPH10101654A (en) 1996-10-02 1998-04-21 Japan Energy Corp New dipeptide compound, its pharmacologically permissible salt and its pharmaceutical use
JPH10182601A (en) 1996-12-27 1998-07-07 Japan Energy Corp New dipeptide compound or pharmacologically acceptable salt thereof and its pharmaceutical use
AR012374A1 (en) 1997-04-15 2000-10-18 Smithkline Beecham Corp PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSIONS AND USES FOR THE PREPARATION OF MEDICINES.
US6673772B2 (en) 1999-01-14 2004-01-06 Sumitomo Pharmaceuticals Company Limited Dipeptide compounds and their use as antiviral agents
EP1155009A2 (en) 1999-02-19 2001-11-21 Oklahoma Medical Research Foundation Protease inhibitors that overcome drug resistance
HN2002000136A (en) 2001-06-11 2003-07-31 Basf Ag INHIBITORS OF THE PROTEASE OF HIV VIRUS, COMPOUNDS CONTAINING THEMSELVES, THEIR PHARMACEUTICAL USES AND THE MATERIALS FOR SYNTHESIS
WO2003035650A1 (en) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
JP2003119137A (en) 2001-10-10 2003-04-23 Japan Tobacco Inc Hiv inhibitor
DE60218511T2 (en) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. DIHYDROXYPYRIMIDINE CARBOXYLAMIDE INHIBITORS OF THE HIV INTEGRASE
WO2003047564A1 (en) 2001-12-05 2003-06-12 Shionogi & Co., Ltd. Derivative having hiv integrase inhibitory activity
KR20040065251A (en) 2001-12-12 2004-07-21 브리스톨-마이어스 스큅 컴퍼니 Hiv integrase inhibitors
ES2291642T3 (en) 2002-01-17 2008-03-01 MERCK &amp; CO., INC. USEFUL HYDROXINE FTIRIDINON CARBOXAMIDS AS INHIBITORS OF HIV INTEGRESS.
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
BRPI0417248A (en) * 2003-12-04 2007-03-06 Pfizer methods of preparing compounds usable as protease inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
US6329502B1 (en) * 1990-12-11 2001-12-11 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
US5644028A (en) * 1992-05-13 1997-07-01 Japan Energy Corporation Process for producing peptide derivatives and salts therefor
US5629406A (en) * 1992-08-07 1997-05-13 Sankyo Company, Limited Inhibitors of HIV protease
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US5962640A (en) * 1995-06-30 1999-10-05 Japan Energy Corporation Methods for preparing novel dipeptide compounds or pharmacuetically acceptable salts thereof
US6222043B1 (en) * 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103748059A (en) * 2011-05-13 2014-04-23 弗特克斯药品有限公司 Process for the preparation of protease inhibitors

Also Published As

Publication number Publication date
PL366622A1 (en) 2005-02-07
IS7049A (en) 2003-11-21
OA12697A (en) 2006-06-21
IS7050A (en) 2003-11-21
PE20040479A1 (en) 2004-09-20
OA12696A (en) 2006-06-22
WO2002100844A2 (en) 2002-12-19
MA27347A1 (en) 2005-06-01
AU2002345644B2 (en) 2006-08-10
US20030153507A1 (en) 2003-08-14
IL159022A0 (en) 2004-05-12
US20030225071A1 (en) 2003-12-04
MXPA03011336A (en) 2004-12-06
GEP20063890B (en) 2006-08-10
US20070021354A1 (en) 2007-01-25
US6953858B2 (en) 2005-10-11
AP2003002915A0 (en) 2003-12-31
CN100338044C (en) 2007-09-19
EP1739082A1 (en) 2007-01-03
BR0210358A (en) 2004-06-22
HRP20031014A2 (en) 2005-10-31
WO2002100844A3 (en) 2003-03-06
NO20035489D0 (en) 2003-12-10
AR036046A1 (en) 2004-08-04
BR0210344A (en) 2004-07-13
EP1409466A2 (en) 2004-04-21
PA8547601A1 (en) 2003-12-30
MA27348A1 (en) 2005-06-01
US7179918B2 (en) 2007-02-20
NO20035488D0 (en) 2003-12-10
CA2450265A1 (en) 2002-12-19
HN2002000136A (en) 2003-07-31
EA008169B1 (en) 2007-04-27
PE20040241A1 (en) 2004-04-26
JP2005508867A (en) 2005-04-07
WO2002100845A1 (en) 2002-12-19
TNSN03130A1 (en) 2005-12-23
MXPA03011397A (en) 2005-03-07
AP2003002916A0 (en) 2003-12-31
JP2004534061A (en) 2004-11-11
KR20040035601A (en) 2004-04-29
TW200538447A (en) 2005-12-01
PA8547501A1 (en) 2003-02-14
CA2450269A1 (en) 2002-12-19
EA200400023A1 (en) 2004-06-24
AU2002345644C1 (en) 2002-12-23
NZ530024A (en) 2005-10-28
KR20040023616A (en) 2004-03-18
CN1599729A (en) 2005-03-23
HRP20031015A2 (en) 2005-10-31
AR036093A1 (en) 2004-08-11
EA200400026A1 (en) 2004-04-29
EP1448539A1 (en) 2004-08-25
WO2002100845A8 (en) 2003-03-20
AU2002345644A2 (en) 2002-12-23
NZ530023A (en) 2005-10-28
AP1770A (en) 2007-08-22
CN1622942A (en) 2005-06-01
IL159076A0 (en) 2004-05-12
AU2002316235A2 (en) 2002-12-23

Similar Documents

Publication Publication Date Title
US6953858B2 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
AU2002345644A1 (en) HV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
JP2001278886A (en) Benzoxazine derivative and medicament containing the same
JP2023513373A (en) P2X3 modulators
US20070066664A1 (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses, materials for their synthesis
US7094909B2 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
JP6987125B2 (en) New 2,4,6-trisubstituted s-triazine compound and its production method and use
US20080207683A1 (en) Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
CA2603030C (en) Benzyloxypropylamine derivative
CANON-KOCH et al. Patent 2450265 Summary
AU2006235964A1 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US20160326125A1 (en) Sulfone amide linked benzothiazole inhibitors of endothelial lipase
US20050080121A1 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
KR20220005549A (en) Amide derivatives useful for the treatment of HBV infection or HBV-induced disease

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION